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ABSTRACT OF DISSERTATION 
 
RNA AS A UNIQUE POLYMER TO BUILD CONTROLLABLE 
NANOSTRUCTURES FOR NANOMEDICINE AND NANOTECHNOLOGY 
 
RNA nanotechnology is an emerging field that involves the design, construction 
and functionalization of nanostructures composed mainly of RNA for applications in 
biomedical and material sciences. RNA is a unique polymer with structural simplicity 
like DNA and functional diversity like proteins. A variety of RNA nanostructures have 
been reported with different geometrical structures and functionalities. This dissertation 
describes the design and construction of novel two-dimensional and three-dimensional 
self-assembled RNA nanostructures with applications in therapeutics delivery, cancer 
targeting and immunomodulation. Firstly, by using the ultra-stable pRNA three-way 
junction motif with controllable angles and arm lengths, tetrahedral architectures 
composed purely of RNA were successfully assembled via one-pot bottom-up assembly 
with high efficiency and thermal stability. By introducing arm sizes of 22 bp and 55 bp, 
two RNA tetrahedrons with similar global contour structure but with different sizes of 8 
nm and 17 nm were successfully assembled. The RNA tetrahedrons were also highly 
amenable to functionalization. Fluorogenic RNA aptamers, ribozyme, siRNA, and 
protein-binding RNA aptamers were integrated into the tetrahedrons by simply fusing the 
respective sequences with the tetrahedral core modules. Secondly, I reported the design 
and construction of molecularly defined RNA cages with cube and dodecahedron shapes 
based on the stable pRNA 3WJ. The RNA cages can be easily self-assembled by single-
step annealing. The RNA cages were further characterized by gel electrophoresis, cryo-
electron microscopy and atomic force microscopy, confirming the spontaneous formation 
of the RNA cages. I also demonstrated that the constructed RNA cages could be used to 
deliver model drugs such as immunomodulatory CpG DNA into cells and elicit enhanced 
immune responses. Thirdly, by using the modular multi-domain strategy, molecular 
defined RNA nanowires can be successfully self-assembled via a bottom-up approach. 
Only four different 44-nucleotide single-stranded RNAs were used to assemble the RNA 
nanowire. The reported RNA nanowire has the potential to be explored in the future as 
the carrier for drug delivery or matrix for tissue engineering. Fourthly, the construction of 
RNA polygons for delivering immunoactive CpG oligonucleotides will be presented. 
When CpG oligonucleotides were incorporated into the RNA polygons, their 
immunomodulation effect for cytokine TNF-α and IL-6 induction was greatly enhanced, 
while RNA polygon controls induced unnoticeable cytokine induction. Moreover, the 
RNA polygons were delivered to macrophages specifically and the degree of 
immunostimulation greatly depended on the size, shape, and the number of payload per 
RNA polygon. Collectively, these findings demonstrated RNA nanotechnology can 
produce controllable nanostructures with different functionalities and result in potential 
applications in nanomedicine and nanotechnology. 
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Chapter 1: Introduction and Literature Review 
 The literature review section of this chapter was reproduced (with some 
modification) with permission from Hui Li, Taek Lee, Thomas Dziubla, Fengmei Pi, 
Sijin Guo, Jing Xu, Chan Li, Farzin Haque, Xing-Jie Liang, Peixuan Guo. “RNA as a 
stable polymer to build controllable and defined nanostructures for material and 
biomedical applications.” Nano Today. Volume 10, Issue 5, October 2015, Pages 631–
655. Special thanks to Dr. Taek Lee for help in preparing Figure 1.7, 1.8 and Table 1.2, 
and Sijin Guo for help in preparing Table 1.1. 
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1. Brief Summary 
Chapter 1 begins this dissertation with an overview of the hypothesis and 
summarizes the research progress and current state of ribonucleic acid (RNA) 
nanotechnology and RNA nanomedicine. The unique properties of RNA as a polymer are 
introduced. The current methods for the construction of various RNA nanostructures and 
the applications of these RNA nanostructures in nanotechnology and nanomedicine are 
also reviewed. 
Chapter 2 studies the design and self-assembly of multifunctional 3D RNA 
tetrahedrons based on the pRNA-Three Way Junction (3WJ) motif. The 3D structures of 
the assembled RNA tetrahedrons are examined by both atomic force microscopy (AFM) 
and cryo-electron microscopy (EM). The sizes of the RNA tetrahedrons are tuned by 
changing the number of RNA base pairs per edge. Several functional modules including 
aptamers, ribozyme and small interfering RNA (siRNA) are incorporated into the RNA 
tetrahedron and their biological functions are examined. In vitro cell binding and in vivo 
biodistribution studies are performed to show that the RNA tetrahedron functionalized 
with EGFR-aptamer can target to xenograft breast cancer. These results indicated that 3D 
RNA nanoparticles have the potential to deliver imaging modules and therapeutics for 
cancer diagnosis and therapy. 
Chapter 3 reports the design and self-assembly of RNA cube and dodecahedron 
cages with defined shapes and sizes by using the pRNA 3WJ as the basic building block. 
The 3D structures of the assembled RNA cages are examined by cryo-EM and AFM. In 
addition, the designed RNA cube cages are applied to deliver immunoactive cytosine-
phosphate-guanine (CpG) DNA to macrophage cells and induce immune responses.  
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Chapter 4 studies the design and bottom-up self-assembly of RNA nanowire with 
length in the micrometer scale. The constructed RNA nanowire is examined by cryo-EM, 
negative staining transmission electron microscopy (TEM), fluorescent microscopy and 
AFM. This study showcased an example of the expansion of RNA nanostructures to 
RNA microstructures.  
Chapter 5 reports the design, construction and characterization of RNA polygons 
as multivalent nanocarriers of vaccine adjuvants such as CpG DNA for immune 
modulation. It was found that the sizes and shapes of the RNA nanostructures played 
important roles in the induction of immune responses. This study illustrated that RNA 
nanoparticles have the potential to be developed as potent immunomodulators or vaccine 
adjuvants. 
 Chapter 6 briefly summarizes the main conclusions of this dissertation and 
discusses the future directions and prospects in RNA nanotechnology and RNA 
nanomedicine. 
 
2. Hypothesis 
 The central hypothesis of this dissertation is that RNA is a unique polymer that can 
be used to build controllable and defined nanostructures for applications in nanomedicine 
and nanotechnology. 
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3. Literature Review 
Introduction 
 Polymers have been extensively used by humans since the earliest recorded history. 
Tree saps, tar and plant fibers, all represent the earliest natural polymeric materials used 
by humans [1]. Since the 1950s, through continued synthesis and manufacturing 
improvements, synthetic polymers have dramatically improved in quality and strength to 
the point where they, in many cases, can have mechanical properties that better match 
desired use, as compared to alternative natural counterparts. Synthetic polymers have the 
manufacturing advantages of rapid production rates and synthetic simplicity. However, 
owing to the inherently random nature of most polymerization mechanisms, chain 
polydispersity and controlled shaping remain two of the key limiting hurdles that have 
led to increased variable performance and overall reduced control of the final properties 
[2-4]. As such, there has been much effort towards developing synthetic building blocks 
and schemes that can create monodisperse polymer systems [5-7]. These, however, are 
typically very expensive, time consuming and difficult to control. 
 As a result of these developments, we are at another unique turning point in the 
evolution and design of polymers. We once again turn towards nature as our inspiration 
for the development of advanced biomaterials. By applying what we have learned about 
the complexity and versatility of nucleic acid structures, it is now possible to create 
materials with revolutionary properties previously considered unattainable through 
synthetic strategies. Recent advances in RNA chemistry, RNA biology and RNA 
nanotechnology have shown that RNA as a biopolymer not only shares the common 
characteristics of other polymers, but also possesses a range of unique properties 
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advantageous for applications in nanotechnology as well as biomedical and material 
sciences [8-14]. 
 Herein, we will (1) delineate the physiochemical properties of polymers that can be 
applied to RNA, (2) introduce the unique properties of RNA as a polymer, (3) review the 
current methods for constructing RNA nanostructures for diverse applications, and (4) 
discuss the future prospects including challenges, solutions and new directions of this 
nascent field. 
 
Physical and chemical properties of polymers in relationship to RNA 
nanotechnology 
 The word (poly)-(mer) means (many)-(parts) and refers to macromolecules 
consisting of a large number of repeating elementary units covalently joined together. 
These ‘mers’ control the inter-chain interactions and dictate the final polymer 
characteristics. Given the large variations in polymer morphologies, multiple ways are 
used to describe polymer structure. Polymers can be formed from one type of monomer 
(homopolymers) or of various monomers (heteropolymers). Heteropolymers can be 
further described by the arrangement of the monomers along the backbone, including 
alternating, random, and block formations. Heteropolymers also adopt more elaborate 
structures, including star, ring, branched, dendrimeric, crosslinked, ladder, and others 
[15-23]. These large arrays of potential structures and chemical diversity offer a rich 
repertoire of available properties from which one can custom-design a polymer for a 
desired application. 
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 Biological macromolecules, as natural building blocks, are critical for the 
functioning of living organisms. RNA is one of the five most important biological 
macromolecules in addition to DNA, proteins, lipids and carbohydrates. With some 
aspects similar to DNA, RNA, which is composed of four nucleotides including 
adenosine (A), cytosine (C), guanosine (G) and uridine (U), is special in its homogeneity. 
RNA is a homopolymer of nucleotide, but is also a heteropolymer of A, U, G, and C. 
Each nucleotide contains a ribose sugar, a nucleobase, and a phosphate group. The 
nucleotides are covalently linked together through 3’ → 5’ phosphodiester bonds 
between adjacent ribose units, giving the directionality to the sugar-phosphate backbone 
that defines RNA as a polynucleic acid. The phosphate moieties in the backbone are 
negatively charged, making RNA a polyanionic macromolecule at physiological pH. 
RNA molecules are typically single-stranded. However, Watson-Crick (canonical) base-
pair interactions (A:U and G:C), wobble base pairing (such as G:U) [24] or other non-
canonical base pairing such as twelve basic geometric families of edge-to-edge 
interaction (Watson-Crick, Hoogsteen/CH or sugar edge) with the orientation of 
glycosidic bonds relative to the hydrogen bonds (cis or trans) [25-28], all together give 
rise to various structural conformations. Unique RNA structures include loops, hairpins, 
bulges, stems, pseudoknots, junctions, etc., which are essential elements to guide and 
drive RNA molecules to assemble into desired structures [12, 29-32]. On the contrary, 
synthetic polymers are usually formed via a polymerization reaction, a chemical process 
through which many monomers form covalent bonds between each other and finally form 
a long chain or network, imparting them with their desired structural properties. 
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 Generally, the properties of polymers are strongly dependent on their monomer 
chemistry. Moreover, the molecular weight and 2D structure (e.g., linear chain-shaped 
structure or branch-shaped structure) also play important roles in determining the 
characteristics and properties of a specific polymer. Important properties of chemical 
polymers include [1]: (1) rheological properties, (2) solubility, (3) volumetric and 
viscometric properties, (4) stress-strain relationships, (5) electrical properties, (6) thermal 
properties, (7) optical properties, (8) stiffness, (9) flex life, (10) hardness, and (11) 
chemical resistance. Various physical or chemical tests can be readily performed to 
characterize these properties for RNA polymers. 
 Traditional synthetic polymers are heterogeneous and have typical polydispersity 
index greater than 1 [33, 34]. In contrast, RNA is synthesized by either in vitro 
transcription or solid phase chemistry. Both approaches are based on stepwise reactions 
and will generate RNA polymers with defined sequences, structures, and molecular 
weights. This leads to a polydispersity index of 1 of a specific RNA. Structurally, the 
average molecular weight determines the mechanical property of the polymer. However, 
as polydispersity increases, the increased lower molecular weight chains can act as a 
lubricating/solvating system, reducing its mechanical strength and integrity. As increases 
in temperature result in increased molecular motion, these weak associations begin to 
destabilize and reduce mechanical integrity. Such polymers are classically referred to as 
thermoplastics [35], as their mechanical strength weakens with increased temperature. 
However, this property also means they can be intentionally deformed at higher 
temperatures and then regain their structural properties once cooled. Thermodynamically, 
the RNA molecule is relatively more stable at lower temperature and intends to dissociate 
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or misfold at higher temperatures. Thus, RNA displays the typical thermoplasticity of 
polymers. Boiling-resistant RNA has been discovered and constructed [36], suggesting a 
potential application of RNA in molding technology. 
 Chemical polymers have a wide range of applications in biomedical and material 
sciences. Specific applications include, but are not limited to [1, 37-50]: (1) sutures for 
surgery, (2) dental devices, (3) orthopedic fixation devices, (4) scaffolds for tissue 
engineering, (5) drug formulation (e.g., controlled release of drugs, excipients for drug 
stabilization or solubilization), (6) biodegradable vascular stents, (7) biodegradable soft 
tissue anchors, (8) implantable biomedical devices, (9) flexible transparent displays, (10) 
field effect transistors, (11) solar cell panels, (12) printing electronic circuits, (13) organic 
light-emitting diodes, and (14) supercapacitors. Usually, an ideal chemical polymer for 
biomedical and industrial applications should exhibit the majority of the following 
properties: (1) non-toxic, (2) no or low immunogenicity (if applicable, for in vivo use), (3) 
biodegradable and metabolizable, (4) mechanical features that fit the needs of the specific 
application, (5) easily sterilizable, (6) processability, (7) scalability, (8) electrical 
conductivity, and (9) thermostability. RNA as a polymer favorably displays many of 
these properties, as described below. 
 
Unique properties of RNA as a polymer to build nanostructures 
The 2’-hydroxyl group makes RNA dramatically different from DNA 
 The characteristic of RNA that defines and differentiates it from DNA is the 2’-
hydroxyl on each ribose sugar of the backbone. The 2′-OH group offers RNA a special 
property, which can be either an advantage or a disadvantage. From a structural point of 
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view, the advantage of this additional hydroxyl group is that it locks the ribose sugar into 
a 3’-endo chair conformation. As a result, it is structurally favorable for the RNA double 
helix to adopt the A-form which is ∼20% shorter and wider rather than the B-form that is 
typically present in the DNA double helix. Moreover, the 2’-OH group in RNA is 
chemically active and is able to initiate a nucleophilic attack on the adjacent 3’ 
phosphodiester bond in an SN2 reaction. This cleaves the RNA sugar-phosphate backbone 
and this chemical mechanism underlies the basis of catalytic self-cleavage observed in 
ribozymes [51]. The disadvantage is that the 2’-OH group makes the RNA susceptible to 
nuclease digestion since many ribonuclease (RNases) recognize the structure of RNAs 
including the 2’-OH group as specific binding sites. However, such enzymatic instability 
has been overcome by applying chemical modification to the 2’-OH group (see the 
sections Enzymatic stability of RNA and Methodology II: Chemical modification of 
RNA). 
 
Thermodynamic stability of RNA 
 From a thermodynamic point of view, the stability of the double helix of RNA can 
be evaluated by measuring the Gibbs free energy (ΔG0) required for double helix 
formation, or conversely, double helix unwinding (ΔG0 = −ΔG0helix formation = 
ΔG0helix unwinding). Remarkably, the RNA double helix is more thermodynamically 
stable than the DNA double helix considering ΔG0 for RNA double helix formation is, 
on the average, −3.6 to −8.5 kJ/mol per base pair stacked and ΔG0 for DNA double helix 
formation is −1.4 kJ/mol per base pair stacked [52]. Moreover, the presence of special 
motifs such as bends, stacks, junctions and loops in the tertiary structure of RNA may 
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also further improve its stability [8]. In addition, various proteins, such as RNA 
chaperone proteins, and metal ions, such as Mg2+ may also interact or coordinate with 
RNA and significantly contribute to the stability of RNA [53, 54]. 
 
Enzymatic stability of RNA 
 In biological systems, the instability of RNA is mainly the result of enzymatic 
degradation by RNases. The presence of RNases in living organisms is universal, 
suggesting that RNase-mediated RNA degradation is a vital process for normal biological 
function. Several important roles of RNases have been revealed, including degrading 
surplus cellular RNA [55, 56], editing messenger RNA, processing microRNA and other 
non-coding RNA during their maturation [57, 58], defending against the invasion of viral 
RNA [59], and providing crucial machinery for RNA interference (RNAi) [60, 61]. 
RNases can be divided into two major categories: (1) endo-ribonucleases that cleave 
phosphodiester bonds within the RNA backbone [62]. Examples include RNase A, 
RNase H, RNase I, RNase III, RNase L, RNase P, RNase PhyM, RNase T1, RNase T2, 
RNase U2, RNase V; (2) exo-ribonucleases that cleave phosphodiester bonds at either the 
5’ or the 3’ end of an RNA chain [63]. Examples include polynucleotide phosphorylase 
(PNPase), RNase PH, RNase II, RNase R, RNase D, RNase T, oligoribonuclease, 
exoribonuclease I, exoribonuclease II. RNA is indeed very sensitive to degradation by 
RNases, which confers a very short half-life and thus a poor pharmacokinetic profile to 
most RNA molecules. This degradation limits the in vivo application of RNA molecules 
as therapeutics. However, chemical modifications of RNA can overcome this 
shortcoming. For example, the substitution of the 2’ hydroxyl group with a Fluorine (2’-
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F), O-methyl (2’-O-Me) or Amine (2’-NH2) dramatically increases the stability of RNA 
in vivo by preventing degradation by RNases [64-66]. Recent studies also showed that the 
stability of siRNA in serum is also highly depended on the specific RNA sequences and 
the degradation of both short and long RNA duplexes mostly occurred at UA/UA or 
CA/UG sites [67]. 
 Synthetic polymers always show good stability against various enzymes. However, 
biodegradable polymers that can be degraded by enzymes such as proteases, 
oxidoreductases and phospholipases are more beneficial for therapeutic applications [68]. 
Nanocarriers composed of enzyme sensitive polymers can control the site of cellular 
uptake of carriers and drug release to improve drug efficacy [69-71]. Synthetic polymers 
can also be designed to be non-degradable or degradable under certain physiological 
conditions. For example, Poly(lactic-co-glycolic acid) (PLGA) (which is generally 
regarded as safe) is approved by the Food and Drug Administration (FDA), as it can be 
degraded in the body by hydrolysis and has now been widely used to fabricate 
nanoparticles for drug delivery. Poly (beta-amino ester) is another class of degradable 
biomaterial developed by the Langer group [72], which can bind negatively-charged 
RNA or DNA and facilitate gene transfections. Although biodegradable polymers are 
highly attractive for drug delivery purposes, their degradation rate is very hard to control 
and the pharmacokinetic and biodistribution profiles of the nanocarriers can be elusive. 
Synthetic polymers usually are composed of repeated same subunit, while RNA is the 
repetition of four subunits A, U, G and C in a specific sequence order. Therefore, RNA 
polymers might be advantageous concerning controllable biodegradability [73, 74] 
simply by tuning the ratio and location of 2′-modified nucleotides in the RNA sequence. 
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The versatile and plastic properties of RNA 
 The versatility of RNA is highly evident given the diversity of structural 
repertoires available in nature, which include simple structures such as helical stems and 
single stranded hairpin loops to more complicated structures such as multi-way junctions 
and pseudoknots [75-84]. Persistence length is a basic mechanical property used in 
polymer science to measure the flexibility and stiffness of a polymer. If a polymer is 
shorter than the persistence length, the molecule will basically be a rigid rod. From a 
mechanical perspective, the persistence length of dsRNA (62–63 nm) is slightly longer 
than dsDNA (45–50 nm) in an aqueous solution [85, 86]. The stretch modulus of short 
dsRNA (<150 bp) is ∼100 pN, which is 3 times lower than dsDNA of similar length, is 
based on AFM and tweezer studies [87]. Interestingly, RNA was observed to shorten 
upon twisting with two-orders of magnitude slower timescale compared to DNA, which 
in contrast lengthened with a faster timescale. More recently, single molecule force 
spectroscopy was used to study ∼10 nm long dsDNA containing ribonucleoside 
monophosphates (rNMPs) located at specific positions within the DNA strands [88]. The 
results demonstrated that the perturbation of stiffness and the plastic properties by 
guanosine 5’-monophosphate (rG) intrusions is location and sequence dependent, and can 
either soften or stiffen the DNA complex. Molecular dynamics (MD) simulations 
indicated that the perturbations are from local structural distortions arising from hydrogen 
bonding between the OH group of rG and electronegative sites of either the phosphate 
backbone or vicinal base. However, many factors such as sequence, local structural 
environment, and metal ion concentrations [89, 90] can significantly influence RNA 
versatility, stiffness and plasticity at the molecular level [91]. The balance of the ion-
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mediated electrostatic force and the non-electrostatic (chemical) forces determine the 
equilibrium structure of the RNA. It is common to find that one RNA molecule can exist 
in more than one conformation, and one kind of RNA molecule can display multiple 
bands in native gel electrophoresis due to the redistribution of modular motif and local 
thermal energy. The versatile and plastic properties of RNA as a polymer have been 
applied to the construction of RNA polygons by stretching the internal angle of the three-
way junction (3WJ) of phi29 DNA packaging motor from 60 ° to 90 ° to 108 ° to transit 
from triangle, square, and pentagon structures, respectively [92]. 
 
RNA can form complex 3D structures in nanoscale 
 While most biologically active DNAs are double-stranded, in contrast, most RNAs 
in living organisms are single-stranded. However, RNA molecules contain self-
complementary sequences which facilitate the self-folding of these RNAs. In addition to 
Watson-Crick base pairing, non-Watson–Crick base pairs and coaxial stacking of helices 
also play important roles in promoting RNAs folding into complex 3D structures [12, 53]. 
This remarkable folding capability not only provides the structural basis for the diverse 
biochemical functions of different RNA molecules, but also provides huge opportunities 
for designing novel RNA nanostructures. For example, the subdomain IIa-1 RNA of the 
internal ribosome entry site (IRES) from hepatitis C virus (HCV) has a unique 90 ° bend 
L-shaped structure. Molecular modeling using this L-shaped motif showed that a planar 
square shaped 3D nanoparticle can be formed with four repeating L-shaped motifs, as 
verified by gel shift assay and fluorescence resonance energy transfer (FRET) assay [93] 
(Figure 1.1I). Moreover, it has been found that proteins, small molecule ligands (such as 
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thiamine pyrophosphate (TPP) and flavin mononucleotide (FMN)) as well as monovalent 
and/or divalent metal ions are also important mediators of RNA folding, which could add 
another layer of complexity to the assembly of RNA nanostructures [53, 94]. 
 
Toolkits and methodologies for the construction of RNA nanostructures 
 The diverse function of RNA molecules in cells such as ribozymes, riboswitches, 
microRNAs, long non-coding RNAs and aptamers had attracted increasing attention in 
the scientific community. All these properties of RNA originated from nature that RNA 
can adapt different structures and spatial conformations. The laws of how nature 
manipulates RNA structures can also be explored to construct artificial RNA 
nanostructures. Besides the template-guided folding of RNA nanostructures that is 
similar to the tactics in DNA nanotechnology, self-assembly of RNA building blocks is 
another leading approach for bottom-up RNA nanotechnology. A wide variety of RNA 
nanostructures has been successfully constructed based on different assembly principles 
and approaches (Figure 1.1). In this section, I will review several toolkits and 
methodologies that have shown great success for constructing multifunctional RNA 
nanostructures. 
 
Toolkit I: Hand-in-hand interactions involving RNA loops 
 Taking the construction of a wooden table as an analogy, external dowels are used 
to link variety of wood blocks into a structure. One of the unique properties of RNA is its 
folding into loops and hairpin structures. RNA loops can serve as inter-RNA mounting 
dovetails, thus external dowels are not necessary for self-assembly into a unique structure. 
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 The packaging RNA (pRNA) in the phi29 DNA packaging motor [95-103] forms a 
hexameric ring structure through interlocking of two looped regions in each pRNA 
molecule, named the right- and left-hand loops (Figure 1.1A). The loop close to the 5’-
end of the pRNA is defined as the right-hand loop, while the loop close to the 3’-end of 
the pRNA is defined as the left-hand loop. The left-hand and right-hand were brought 
together from interlocking interaction among four nucleotide sequences in the loops. 
Single pRNA molecule with self-complimentary sequences in the loops can be used to 
construct homodimer nanoparticles, or several pRNAs with the right-hand loop matching 
the sequence of the left-hand loop in another pRNA can be used to construct heterodimer 
nanoparticles. Through the interlocking loop interactions between different pRNA, dimer, 
trimer, and hexamer RNA nanoparticles have been created [104-113]. The interlocking 
loop sequences were further extended to increase the thermodynamic stability of 
generated RNA nanoparticles [114]. A toolkit with a set of hand-in-hand loop sequences 
has been designed and tested for constructing stable RNA polygonal nanoparticles. Loop 
extended RNA pairs with confirmed dimer formation capability were used as building 
blocks for higher order RNA oligomer nanoparticles (Figure 1.1B). Using a reengineered 
loop extended pRNA toolkit, pRNA dimer, trimer, tetramer, pentamer, hexamer, and 
heptamer were constructed with highly efficient self-assembly, as shown by gel shift 
assays and AFM imaging [114]. 
 Other loop–loop interactions have also been reported to build various RNA 
nanostructures. For example, noncovalent loop–loop contacts based on RNAI/IIi kissing-
loop complex have been used to build RNA nanorings which are thermostable, 
ribonuclease resistant and capable of delivering RNA interference modules [85, 115, 116] 
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(Figure 1.1E). Moreover, RNA kiss-loops were also used to build square-shaped 
tetrameric RNA nanoparticles and three-dimensional polyhedrons based on rationally 
designed RNAs [117-119] (Figure 1.1D and F). In addition, micrometer-scale RNA 
filaments have also been constructed by the rational design of tectoRNAs incorporating 
4-way junction (4WJ) motifs, hairpin loops and their cognate loop–receptors [120, 121]. 
 
Toolkit II: Foot-to-foot interactions involving palindrome sequence and sticky ends 
 pRNA nanoparticles can also be constructed through the foot to foot interaction 
between pRNA monomers. While hand-in-hand interaction involves the “left” and “right” 
hand and the interaction is “multiple” and “intermolecular”, foot-to-foot interaction 
includes only one foot that is the one unique palindrome sequence by self-dimerization 
interaction of the identical RNA molecule. The foot domain is located in the helical 5′/3′ 
open region of pRNA. Extending this region with helical sequences does not compromise 
the entire pRNA molecule folding. A palindrome sequence reads the same whether from 
5’ → 3’ direction on one strand or from 5’ → 3’ direction on the complementary strand. 
Extending the 3’ end of pRNA monomer with a palindrome sequence can serve as a 
sticky end for linking two pRNA monomers, and is denoted as a foot-to-foot interaction 
[113]. The foot-to-foot interaction by palindrome sequences can also be utilized to bridge 
RNA nanostructures, motifs, or scaffolds for constructing RNA hexamers, octamers, 
decamers, and dodecamers (Figure 1.1K). A pRNA array was constructed by combining 
hand in hand-loop-interactions and foot-to-foot palindrome sequence interactions [113] 
(Figure 1.1C). Recently, strategies involving both loop–loop interaction and sticky-end 
17	
	
cohesion were also reported to assemble three-dimensional and structurally well-defined 
RNA nanoprisms by re-engineering pRNA [122]. 
 
Toolkit III: Grafts of motifs from naturally-occurring RNA molecules 
 Synthetic RNA nanoarchitectures can be designed with the known naturally-
occurring three-dimensional RNA motifs. Particularly, some RNA motifs in nature 
exhibit extraordinary stability, which could provide advantages in the assembly of RNA 
nanostructures. For example, the phi29 motor pRNA [54, 111, 123], tRNA [119], 5S 
RNA [124], and RNAI/II inverse kissing complexes [116] have been used to create 
synthetic RNA nanostructures [36, 93, 119, 125, 126]. The central domain of the pRNA 
molecule contains a 3WJ core structure [54]. This 3WJ can be assembled from three 
individual RNA fragments with high efficiency in the absence of metal ions [124]. The 
3WJ motif itself creates a branched structure that allows for constructing multifunctional 
RNA nanoparticles with different functional moieties at each end of the branches. Since 
the 3WJ motif has three branches, RNA nanoparticles can also be designed and fabricated 
via branch extension [114] of the 3WJ motif (Figure 1.1L). The 3WJ core retained its 
original folding and the conjugated RNA module on the branches can fold into their 
authentic structure and remain functional [124, 127]. For example, after incorporation 
into the 3WJ motif, hepatitis B Virus (HBV) ribozyme retain its capacity to cleave its 
RNA substrate and generate smaller cleavage products, and malachite green (MG) 
binding aptamer was also able to bind MG to emit fluorescence as shown in the 
fluorescent spectra (Figure 1.2A and B). This property makes the pRNA 3WJ structure 
an extraordinary nanocarrier for targeted gene delivery [124]. Moreover, an X-shaped 
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motif from the central domain of the pRNA was discovered through extending the right-
hand loop with a double-stranded sequence [73]. The X-shaped pRNA motif can be self-
assembled from four RNA oligos and it creates a scaffold that allows for the conjugation 
of four RNA functional moieties at the same time. Functional RNA modules such as 
survivin siRNA preserved their target gene knock-down effect after being fused to the X-
shaped structure (Figure 1.2C). Branched hexavalent RNA nanoparticles were further 
constructed from three 3WJ motifs, integrated by one 3WJ core motif structure or by 
palindrome sequence mediated linking of two pRNA-X cores [114]. 
 Recently, Khisamutdinov et al. reported using RNA as an anionic polymer to build 
programmable self-assembling boiling-resistant RNA nanostructures based on pRNA-
3WJ [36] (Figure 1.1N). A triangular shaped RNA nanoparticle was designed and 
prepared by carefully joining extended helices to the thermodynamically stable pRNA-
3WJ motif of the bacteriophage phi29 DNA packaging motor. The step-wise self-
assembly of the triangle RNA nanoparticles was confirmed by native polyacrylamide gel 
electrophoresis (PAGE) analysis, and AFM imaging revealed the triangular shape of the 
nanoparticles as expected. The constructed nanoparticles are thermodynamically 
ultrastable and robust. Functional motifs including siRNA, ribozyme, folate and 
fluorogenic RNA aptamers retained their activities after conjugation to the RNA 
nanoparticles. Moreover, these RNA triangles could be used as building blocks to 
construct supramolecular complexes, such as RNA hexagons and patterned hexagonal 
arrays. The pRNA-3WJ is also highly tunable [92]; the naturally preserved angle between 
the helices H1 and H2 of pRNA-3WJ is ∼60° and this angle can be stretched to form 
square-shaped (90° angle) and pentagon-shaped (108° angle) nanoparticles with pre-
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designed sequences (Figure 1.3A). The polygons were formed in an one-step self-
assembly manner with efficiency >90%, as demonstrated by gel shift assays. The 
different sizes and shapes of the polygons were also confirmed by dynamic light 
scattering (DLS) and AFM. The equilibrium dissociation constants (KD) for triangle, 
square and pentagon are 18.8 nM, 20.3 nM and 22.5 nM, and the melting temperature 
(Tm) values are 56 °C, 53 °C and 50 °C, respectively, revealing structure and shape-
dependent thermodynamic features. In a recent paper by Jasinski et al, the authors 
showed that square-shaped RNA nanoparticles with fluorogenic and ribozymatic 
properties as well as different sizes can be successfully constructed by utilizing the 
pRNA-3WJ at each corner and different length RNA duplexes at each edge of the square 
RNA nanoparticles [126] (Figure 1.3B). DLS and AFM determined the sizes of the small, 
medium, and large square RNA nanoparticles are 4.0, 11.2, and 24.9 nm, respectively. 
The physiochemical properties of the nanoparticles can be easily tuned, as the utilization 
of 2′-F RNA as the core strand significantly increased the melting temperature as well as 
the nanoparticle's resistance to serum-mediated degradation. 
 Naturally occurring stable RNA-protein complexes were also explored as building 
blocks for nanostructures. For example, the assembly of archaeal box C/D small 
ribonucleoproteins (sRNPs) comprising the L7Ae protein from Archaeoglobus fulgidus 
and a box C/D RNA has been utilized to build an equilateral triangle shaped synthetic 
RNA protein complex [128] (Figure 1.1H). The construction relies on the interaction 
between ribosomal protein L7Ae and the Kink-turn motif in box C/D RNA. L7Ae can 
bind to the box C/D K-turn motif through hydrogen bonding with high specificity and 
affinity [129]. It was reported that using RNA-protein complex as building block for 
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nanostructures enhanced its stability in serum comparing to pure unmodified RNA based 
nanoparticles [130]. The ribonucleoprotein (RNP) nanostructure could serve as a scaffold 
for protein or RNA functionalities. For example, an affibody peptide, which can 
recognize human epidermal growth factor receptor 2 (HER2), was connected to a RNP 
triangle through fusing to a L7Ae protein, and the functionality of the affibody peptide 
was still retained. siRNA targeting to GFP gene can be conjugated to the RNP triangle 
through extending the RNA strand and the GFP siRNA on RNP nanoparticles still can be 
processed by dicer and knock down GFP expression in cells. 
 
Toolkit IV: RNA origami 
 DNA origami, which involves the folding of a long template single stranded DNA 
aided by multiple short staple DNA strands, was reported in 2006 [131]. A wide range of 
2D and 3D nanostructures have been successfully constructed using the DNA origami 
technique [132-136]. In 2014, a similar approach for RNA origami was reported to fold 
single stranded RNA into RNA tiles and further assembled into hexagonal lattices [137] 
(Figure 1.1M). A variety of RNA tertiary motifs, including the 180° kissing loop motif 
of the HIV-1 DIS [138], the 120° loop–loop complex of RNA i/ii inverse loop [115], and 
the tetraloops GNRA and UNCG [139] were used to mediate internal RNA tertiary 
interactions, resulting in organized and scalable RNA crossover tiles. The designed RNA 
origami nanostructures are also robust, which could form by either annealing or co-
transcription on mica. In contrast to DNA origami, this RNA origami approach does not 
need short staple strands to facilitate the folding of the origami structure, but using RNA 
modules such as kissing loops to replace the role of staple strands. Interestingly, a 
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different RNA origami approach which is a direct extension of the DNA origami to RNA 
was also reported in 2014 [140] (Figure 1.1P). In this study, a single-stranded RNA 
scaffold and multiple staple RNA strands were used to assemble defined RNA 
nanostructures including a 7-helix bundled RNA tile and a 6-helix bundled RNA tube. 
The authors also showed that functional modules such as biotin could be introduced into 
the RNA origami structures by chemical modifications of the scaffold strands. 
 
Toolkit V: RNA/DNA hybrid nanostructures 
 RNA/DNA hybrids can also be used to construct functional nanoarchitectures. 
Similar to split-protein systems, RNA/DNA hybrids can be computationally designed for 
activating different split functionalities in the presence of respective equivalent strands 
[141-144] (Figure 1.4A). Toehold interactions were used to trigger disassociation of 
RNA/DNA hybrids and re-association of the double-stranded RNA and DNA. The 
thermodynamics and kinetics of the toehold interactions can be tuned to control the 
dissociation and re-association processes. RNA interference modules as well as other 
functionalities such as fluorophores and RNA aptamers can be successfully triggered 
inside mammalian cells. This RNA/DNA hybrids concept has also been applied to other 
nanostructures such as nanorings and cubes [115, 116, 145-147], and the spilt 
functionalities still retain their authentic functionalities. Because the RNA/DNA hybrid is 
more enzymatically stable than RNA, this approach has the potential to improve the 
pharmacological profiles of RNA-based nanoparticles. Moreover, controlled release of 
the split functionalities opens a new avenue for the development of nucleic acid-based 
switches to modulate cellular functions in vivo. 
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Methodology I: Rolling circle transcription 
 Typically, the design and production of RNA nanoparticles have relied on the 
production of discrete RNA strands that can be assembled in a controlled and predictive 
fashion to generate nanoparticles with a defined structure and stoichiometry. Hammond 
and colleagues have departed from this approach with an innovative strategy that 
generates monodisperse spherulitic RNA particles from extremely high molecular weight 
RNA strands by using a rolling circle transcription (RCT) approach [148, 149] (Figure 
1.1J). They created a circular DNA construct containing a siRNA gene without any 
terminator sequences and proceeded by a T7 promoter. As a result, T7 RNA polymerase 
can continuously transcribe the circular DNA hundreds of times to generate a tremendous 
number of copies of the tandem RNA unit. As the continuous RNA strand is transcribed, 
magnesium pyrophosphate crystals are simultaneously generated, and the RNA strands 
attach to the crystallite surfaces to form composite structures; each structure grows in 
length to become fiber-like, then, forms sheet-like lamellae. The lamellae, typically ∼10 
nm thick, finally condense into spherulites with diameters varying from a few 
micrometers to hundreds of micrometers, referred by the author as RNAi microsponges. 
To achieve efficient cellular uptake, Polyethylenimine (PEI) was introduced to condense 
the RNAi-microsponge from 2 µm to 200 nm, and to protect the RNA from degradation 
by RNase. The PEI introduced a positively charged outer layer to the microsponges to 
facilitate cell binding and entry. It was also demonstrated that the spherulitic RNAi-
microsponges produced ∼21 nucleotides (nt) siRNA fragments after incubation with 
Dicer and could transfect a cancer cell line and silence firefly luciferase expression. Gene 
expression knockdown in vivo by intratumoral injection of the PEI-condensed RNAi-
23	
	
microsponges was also reported. This innovative approach opens new directions to RNA 
nanoparticle self-assembly and siRNA delivery. However, the therapeutic potential and in 
vivo safety of this approach requires further evaluation, as PEI has been shown to cause 
well-known adverse side effects, such as high cytotoxicity [150, 151]. In addition, further 
reduction of the size of the particles is recommended to avoid non-specific healthy organ 
accumulation. 
 In material sciences, polymeric membranes are at the forefront in the chemical and 
biotechnology industry because of their versatile applications such as water purification, 
dehydrogenation of natural gas, dialysis of blood, and removal of cell particles [152]. 
Recently, Lee's group demonstrated rolling circle transcription can also be applied to the 
synthesis of macroscopic RNA membranes that has the potential as a controlled drug-
release system [153] (Figure 1.1O). The RNA membrane was fabricated by T7 RNA 
polymerase transcription system with a combination of complementary rolling circle 
transcription (cRCT) and evaporation-induced self-assembly (EISA). The circular DNA 
template and complementary circular DNA template were prepared with long linear DNA 
and the promoter DNA for starting the rolling circle transcription (RCT). Upon addition 
of T7 polymerase to these two circular DNA templates, thousands of copies of single 
stranded RNA and single stranded complementary RNA were continuously generated. 
The two complementary RNA strands hybridized to each other thereby forming the 
double stranded RNA for the large-area of RNA membrane. After the cRCT process, the 
water in the RNA membrane was evaporated and the dried RNA membrane was 
concentrated by the EISA process. The self-assembled RNA membrane was fabricated 
densely on the tube wall during the evaporation process. The durability of the fabricated 
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RNA membrane was tested under various harsh conditions, including RNase and DNase-
rich environments. In addition, they confirmed the application of the RNA membrane as 
an enzyme-responsive drug-release system with doxorubicin and siRNA. The results 
showed that the RNA membrane can provide a high drug-loading efficiency and can be a 
great candidate for membrane-based drug delivery. 
 
Methodology II: Chemical modification of RNA 
 A great deal of work on chemical modifications aiming to improve the chemical 
stability and in vivo properties of RNA has been reported [154-157]. Common chemical 
modifications of RNA can be categorized into five classes: (1) Modification of inter-
nucleotide phosphodiester backbone. This type of modification is the most classic and 
simplest method to improve the performance of RNA in the biological environment. For 
example, creation of a phosphorothioate (PS) linkage by replacing one non-bridging 
oxygen atom on the phosphate backbone with a sulfur atom substantially increases the 
stability of RNA in vitro and in vivo [158]. Other backbone modifications such as 
boranophosphate, phosphoramidate and methylphosphonate have also been explored to 
enhance the resistance to nuclease-mediated degradation [159-161]. However, cytotoxic 
side-effects were also observed if extensive modifications were applied [162]. (2) 
Substitution of 2′-OH group. This is the most widely used approach since it is well-
tolerated and can enhance nuclease resistance as well as reduce immunogenicity. For 
example, the naturally occurring 2′-O-methyl (OMe) modification is nontoxic and is able 
to prevent immune activation while conferring biological stability simultaneously [162] 
and [163]. Guo's lab also reported that incorporation of 2′-fluoro nucleotides into the 
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pRNA scaffold allows the creation of stable and RNase-resistant RNA nanoparticles with 
correct folding and authentic biological activities. The melting temperature of 2′-F RNA 
was further enhanced compared to unmodified RNA [164]. The chemically modified 
pRNA-based nanoparticles have shown promising applications in cancer therapy [36, 66, 
165-168]. Recent study also showed that 2′-F modified pRNA nanoparticles are resistant 
to 125I and 131Cs radiation with clinically relevant doses, which is a required property for 
applying these RNA nanoparticles as delivery vehicles for targeted radiation therapy 
[169]. Other options for 2′-modification like 2′-fluoro-β-d-arabinonucleotide (FANA) 
have also shown promise in gene silencing applications [170]. (3) Locked nucleic acids 
(LNA) and unlocked nucleic acid (UNA). LNA is another class of 2′-modification in 
which 2′-O and 4′-C is linked via a methylene bridge. This locked linkage constrains the 
ribose ring into the C3′-endo conformation, which confers both significant increase in 
thermostability and enhancement in nuclease resistance [171]. Successful applications of 
LNA such as 2′-amino-LNA have been studied by Astakhova et al. to show great promise 
in the development of biosensor, aptamer and other nanomaterials [172]. Antisense 
oligonucleotides (ASO) containing LNA also has been reported to have higher potency 
and specificity [173] and [174], but would also cause liver toxicity in mouse models if 
LNAs were extensively incorporated into the sequence [175]. In the other hand, UNA is 
an acyclic and structurally flexible-RNA analogue in which the C2′–C3′ bond is absent. 
As a result, the binding affinity of UNA towards its complementary strand is decreased 
[176]. (4) Modification of ribonucleotide base. This approach is less commonly used than 
other modification approaches described thus far. However, recently RNA tube 
nanostructures have been reported to be constructed successfully by using RNA scaffolds 
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with 5-biotinylated modified and 5-aminoallyl modified uracil [140]. Other common 
modified bases such as 2-thio-, 4-thio, 5-iodo-, 5-bromo-, dihydro-, pseudo-uracil and 
diamino-purine also have been demonstrated to confer enhancement in stability as well as 
specificity of base-pairing interactions [156, 177, 178]. (5) Modification of ribose moiety. 
This modification strategy, for example, altritol nucleic acid (ANA) and hexitol nucleic 
acid (HNA), is mainly applied in siRNA design to enhance potency and nuclease 
resistance [179]. Besides these classes, other novel methods such as photocaging 
modification have been used to control RNAi induction [180]. The particular effect of 
various chemical modifications on RNA are summarized in Table 1.1. It is expected that 
the rational choice of precise chemical modifications will greatly contribute to the 
development of RNA nanostructures for applications in biomedical sciences and material 
sciences. Moreover, the strategy of combining different modification approaches also has 
the potential to improve the properties of RNA more dramatically. 
 
Methodology III: Computational approach 
 The first step in RNA nanoparticle construction is the consideration of the 
blueprint [181]. This requires an understanding of the assembly and folding mechanism 
in the bottom-up assembly. Designing the sequence of the building block is critical for 
successful RNA nanostructure assembly, which can be achieved by experience and 
brainstorming taking into consideration RNA folding, complementation, hand-in-hand 
interaction, foot-to-foot interaction, and the use of thermostable motifs, kissing loops, 
sticky ends, helices and stem loops. All RNA nanoparticles constructed based on phi29 
motor pRNA were achieved via experience and brainstorming without computer 
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algorithm other than the traditional RNA folding program developed by Zuker 30 years 
ago [182]. It is expected that computer algorithms will facilitate RNA nanoparticle 
construction. A variety of computer programs such as NanoFolder, NanoTiler and 
RNA2D3D are available to facilitate the in silico design of RNA sequences (these 
sequences may contain inter-strand and intra-strand pseudoknot-like interactions) capable 
of self-assembly into multi-sequence RNA nanostructures and the 3D modeling of such 
structures [183-185]. For example, by utilizing computational modeling and sequence 
optimization, three-dimensional cubic RNA-based scaffolds can be successfully designed 
and engineered with precise control over their shape, size and composition [145]. 
Moreover, online RNA structure databases such as RNAJunction database also provide 
useful RNA structures for designing RNA nanostructures [186]. 
 
Application of RNA as a polymer in biomedical sciences 
 RNA as a natural and biocompatible polymer has many advantages for biomedical 
applications. It carries a negative charge at physiological conditions, which disallows 
nonspecific passing through negatively charged cell membrane. With the conjugation of 
chemical ligands and/or RNA aptamers, RNA nanoparticles can be designed for specific 
cell targeting. It is less toxic compared with protein-based nanoparticles since it can avoid 
antibody induction (protein-free nanoparticle), allowing repeated treatment of chronic 
diseases. It also does not induce an interferon response nor cytokine production [92, 187]. 
RNA nanoparticles designed with a size range 10–40 nm display favorable 
pharmacokinetic properties [187], such as extended half-life in vivo (5–12 h compared to 
0.25–0.75 h for siRNA), clearance: < 0.13 L/kg/h, volume of distribution: 1.2 L/kg.  
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 As a building block for nanoparticles, RNA can be synthesized with defined 
structure and stoichiometry. Multivalent RNA nanoparticles can be constructed using 
special RNA motifs as building blocks that combine therapy, targeting, and detection, all 
functionalities in one particle. 
 
RNA as a biocompatible nanomaterial for tissue engineering 
 Tissue engineering is a new area with large amounts of active research and some 
recent success. Biocompatible nanomaterials are needed for various applications in tissue 
engineering, such as scaffolds or arrays that can function as temporary matrices and/or 
niches for the controlled deposition, infiltration, proliferation, and differentiation of cells. 
It would also be advantageous if these nanomaterials could be highly biocompatible and 
mimic the natural tissue microenvironment in vivo. 
 Shu et al. reported that nanometer scale 3D RNA arrays can be assembled by using 
pRNA as building blocks [113] (Figure 1.1C). By rational design, the authors 
incorporated palindrome sequences (nucleotide sequences that read the same 5′ → 3′ on 
one strand and 3′ → 5′ on the complementary strand) into the 3′-end of the pRNA. The 
palindrome sequences served as links for bridging two pRNAs via foot-on-foot 
interactions. Loop–loop interactions were further used to link pRNA molecules into a 
chain. The formation of pRNA arrays was analyzed by PAGE and it was found that the 
arrays were too large to run into the gel and got trapped in the gel wells.  The shape of the 
pRNA arrays was further characterized by AFM. Under AFM imaging, the pRNA arrays 
presented as bundles with micron scale. These RNA arrays are unusually stable and 
resistant to a wide range of temperatures, salt concentrations, and pH environments. The 
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microstructures of the RNA assays are also tailorable by changing the RNA nucleotide 
sequences. Since RNA molecules are highly biocompatible and not toxic, these RNA 
arrays have the potential to be good tissue engineering scaffolds. 
 
RNA nanoparticles for targeted therapeutic delivery 
 Targeted delivery is a major challenge that nucleic acid therapeutics is facing. 
RNA nanoparticles with chemical ligand and nucleic acid aptamers have shown great 
promise in this regard. The utilization of RNA nanostructures as a platform for targeted 
therapeutics delivery has been successfully demonstrated by a series of studies using the 
phi29 pRNA system. In 2003, Hoeprich et al. constructed a pRNA-based carrier to 
deliver hammerhead ribozymes [188]. Upon conjugation to the pRNA 5′/3′ ends, the 
HBV ribozymes were able to fold correctly and almost completely cleaved the polyA 
signal of HBV mRNA in vitro. Targeted therapeutics delivery to specific cancer cells can 
be achieved by using ligand-conjugated RNA nanoparticles as carriers. Furthermore, the 
cargo in vivo release profile from RNA nanoparticles can also be controlled through the 
rational design of RNA nanoparticles. In 2005, Guo et al. reported the construction of 
chimeric pRNA dimer with one subunit harboring folate and the other subunit harboring 
a gene silencing siRNA targeting survivin [109]. Incubation of these pRNA dimers with 
cancer cells resulted in receptor-mediated binding and entry to cells and induced efficient 
gene silencing. Animal trials showed that ex vivo delivery of the pRNA dimer harboring 
both folate and survivin siRNA could suppress tumor development. Khaled et al. studied 
the fabrication of a protein-free 20–40 nm pRNA trimer which could harbor three 
functional modules including siRNA, CD4 aptamer or folate ligands and a fluorescent 
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dye per nanoparticle [112]. They showed that the pRNA trimer could also bind and enter 
into cells and modulate gene expression and apoptosis both in vitro and in vivo. In 2006, 
Guo et al., reported incorporating a folate-AMP into the 5′-end of phi29 pRNA and 
showed that folate conjugated pRNA dimer nanoparticles were able to deliver survivin 
siRNA into nasopharyngeal epidermal carcinoma cells and silence the target gene [189]. 
The pRNA system can also be used to deliver anti-virus siRNAs. Zhang et al., developed 
a folate-linked pRNA conjugated with the siRNA targeting the Coxsackievirus B3 
(CVB3) protease 2A (siRNA/2A) [190]. They observed that the modified pRNA could 
achieve a similar antiviral effect to that of siRNA/2A alone and also strongly inhibited 
CVB3 replication. 
 The latest advance in the utilization of phi29 pRNA for therapeutics delivery is the 
discovery of a phi29 pRNA 3WJ motif with unusual thermodynamic stability. The slope 
of the melting temperature curve of the three-fragment RNA complex is close to 90°, 
indicating extremely low ΔG of the phi29 pRNA-3WJ complex [124]. The pRNA 3WJ 
motif was used as a RNA scaffold to construct bi-, tri-, and tetra-valent RNA 
nanoparticles with very high chemical and thermodynamic stability [73, 124, 181]. The 
resulting RNA nanoparticles are resistant to denaturation in 8 M urea and do not 
dissociate at ultra-low concentrations. Each arm of the 3WJ or X-motif can harbor one 
siRNA, ribozyme, miRNA, or aptamer without affecting the folding of the central core, 
and each daughter RNA molecule within the nanoparticle folds into respective correct 
structure with authentic biological function. The effects of gene silencing progressively 
increased with increasing number of siRNA modules in the RNA nanoparticle [73]. 
These RNA nanoparticles can specifically target subcutaneous tumor xenografts [73, 124, 
31	
	
168], as well as orthotopic breast cancer [174] and intracranial glioma tumors [165] 
without detectable accumulation in liver, lung or other healthy organs or tissues (Figure 
1.5A–C). A recent study also showed that the pRNA-3WJ nanoparticle conjugated with 
folate can specifically target colorectal cancer metastasis in the liver, lungs and lymph 
node simultaneously in vivo, without accumulation in normal liver or lung parenchyma 
[166] (Figure 1.5D). Pharmacological analysis in mice indicated that the pRNA 
nanoparticles display favorable pharmacokinetic (PK) and pharmacodynamic (PD) 
profiles, with in vivo half-life extended 10-fold compared to siRNA alone and did not 
induce adverse immune response including cytokine, interferon, antibody, and other toxic 
effects [187]. The regression of gastric cancer and breast cancer by RNA nanoparticles 
harboring siRNA [73, 124, 168] or anti-miRNA [174] has also been reported recently. 
 A recent paper also reported the development of novel immunomodulators by 
engineering rationally designed RNA polygonal nanoparticles [92]. When immunological 
adjuvants CpG DNA were incorporated into the RNA polygons, potent 
immunostimulation (cytokine TNF-α and IL-6 induction) was observed both in vitro and 
in vivo, compared to controls. Moreover, the RNA nanoparticles could deliver CpG DNA 
to macrophages specifically and the degree of immunostimulation significantly depended 
on the size, shape, and the number of payload per RNA nanoparticle. This finding 
demonstrates that RNA nanotechnology, such as developing RNA nanoparticles based on 
pRNA, has great potential to develop novel immunomodulators. 
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RNA nanoparticles for controlled drug delivery 
 Many pre-clinical studies are evaluating RNAi as novel therapeutics for different 
diseases. However, one concern is that single gene targeted therapy might eventually fail 
due to mutations over time or development of alternative signaling cascades or escape 
pathways. Multivalent RNA nanoparticles can be a very promising vehicle for delivery of 
multiple siRNAs to suppress multiple genes simultaneously. A recent publication by 
Afonin et al. showed that several RNA and RNA/DNA nanocubes could be 
functionalized with multiple double stranded RNAs and the siRNAs can be conditionally 
released through ssDNA toehold-mediated interactions. Furthermore the RNA nanocubes 
can be tracked intracellularly through FRET (fluorescence resonance energy transfer) 
studies using fluorophores [191]. In addition, spherical nucleic acid (SNA) nanoparticle 
conjugates developed by the Mirkin group have also shown promise for systemic siRNA 
delivery for treating diseases such as glioblastoma [192, 193] (Figure 1.4D). Spherical 
nucleic acids are densely packed and highly oriented nucleic acids covalently conjugated 
to the surface of a spherical nanoparticle core. In vivo studies on glioma-bearing mice 
showed that SNA nanoparticle conjugates targeting the oncoprotein Bcl2Like12 
effectively increased intratumoral apoptosis, and reduced tumor burden and progression 
without adverse side effects [193]. 
 DNA origamis have been exploited as a carrier for the chemical drug doxorubicin 
through noncovalent intercalation interactions. The DNA origami/doxorubicin 
nanoparticles were able to enter into doxorubicin-resistant cancer cells and circumvent 
their drug resistance [194]. Furthermore, the DNA origami/doxorubicin nanoparticles 
showed a slow drug release profile at pH 7.4 under physiological conditions but showed 
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enhanced release capability in pH 5.5 which is similar to the pH of acidic subcellular 
organelles in tumors [195]. As we discussed in previous section (Toolkit IV: RNA 
origami), RNA origami structures have been reported [137, 140]. With favorable 
thermodynamic stability and excellent serum stability after chemical modifications, RNA 
origami is expected to be more favorable than its counterpart DNA origami as a drug 
carrier for achieving controlled drug release. 
 
RNA nanoparticles for vascular targeting 
 A critical feature to drug delivery is the transportation of therapeutics to their 
intended target sites. As almost all cells in the body are within ∼100 µm of the 
vasculature, the vascular delivery route represents a promising mean for site specific 
therapeutics delivery [196]. Owing to the significant heterogeneity in endothelial cells, 
both temporally and regionally, it has been observed that the vascular endothelium has 
unique expression of surface markers that are highly regionally variant. In other words, it 
is potentially possible to target unique endothelial zip codes to locally accumulate 
nanocarriers [197]. 
 Current strategies for vascular targeting of nanocarriers have primarily focused on 
antibody and peptide based strategies, targeting to surface markers CD31 (PECAM-1) 
[198] and [199], inflammatory markers (ICAM-1, VCAM-1) [200-205], and 
thrombomodulin [206]. Targeting of CD31, ICAM-1 and VCAM represents a unique 
opportunity as the binding of nanoparticles to their sites highlights a novel endocytic 
mechanism termed as CAM mediated endocytosis [199, 207]. The use of antibodies as 
targeting agents is technically challenging owing to their size, cost of production and 
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potential immune responses. RNA aptamers have already shown exciting advantages in 
vasculature targeting. High affinity aptamers (56 pM) against P-selectin have been 
developed [208]. Microbubbles coated with a low density (1000 copies/µm2) of P-selectin 
aptamers demonstrated high adhesion even under shear rates as high as 1700 L/s. The 
real promise of vascular-targeted RNA nanoparticles comes from the combination of the 
high binding affinity to carrier sizes below 70 nm. The capillary bed represents the 
greatest promise of vascular targeting, where there already exists a highly active 
transcytosis mechanism, with approximately ten thousand times more caveolae than other 
endothelial cells [209]. These 70 nm endocytic vesicles are an exciting target for drug 
delivery [210] yet require a carrier system like RNA nanoparticles that are 
simultaneously small and have high affinity to permit transcytosis and tissue bed delivery. 
 
RNA nanoparticles as non-invasive medical detection reagents 
 Functional RNA structures such as aptamers can be used for developing non-
invasive molecular and cellular imaging reagents which may have applications in the 
diagnosis of various diseases including cancer, cardiovascular diseases, and infectious 
diseases. Considering it is relatively easy to conjugate a fluorophore, radionuclide, 
quantum dot (QD), gold nanoparticle, or other imaging functional groups to RNA, RNA 
molecules with high binding affinity to their targets hold great potential as a platform to 
construct imaging probes which can specifically detect their targets in vitro and in vivo. 
 Fluorescent RNA nanoparticles conjugated with aptamer have been widely 
explored for cancer detection. For example, Bagalkot et al. [211] developed a QD-
aptamer-doxorubicin conjugate nanoparticle as a cancer-targeted imaging, sensing and 
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treatment platform (Figure 1.4B). A10 RNA aptamer, which specifically binds to the 
extracellular domain of the prostate specific membrane antigen (PSMA), was conjugated 
to the surface of fluorescent quantum dots and the anticancer drug doxorubicin was 
intercalated into the double-stranded stem of the A10 aptamer. In the conjugate 
nanoparticle, fluorescence of doxorubicin was quenched by the aptamer through donor-
quencher FRET, and the fluorescence of QD was quenched by doxorubicin through 
donor-acceptor FRET mechanism. When the nanoparticle enters the prostate cancer cell 
and doxorubicin is released, the fluorescence of QD and doxorubicin is re-activated. 
Other RNA aptamers conjugated with fluorescent dye chemicals have also been utilized 
for breast cancer diagnosis, such as EpCAM aptamer labeled with DY647, TYE665 or 
FITC [212]. 
 Conjugating RNA aptamer with radioactive material can also be applied as 
diagnostic radiopharmaceuticals to detect cancer cell markers. In a recent study reported 
by Gomes et al. [213] a 36 nucleotide long truncated RNA aptamer with 2′F pyrimidine 
and 2′-O-methyl purine modification was constructed for targeting to the human matrix 
metalloprotease 9 (hMMP-9), which promotes tumor metastasis and is an important 
marker of malignant tumors. The 5′-end amine modified RNA aptamer was conjugated to 
N-hydroxysuccinimidyl mercaptoacetyltriglycinate (MAG3-NHS), which served as a 
chelator for Technetium-99m (99mTc). The 99mTc labeled modified RNA aptamer was 
able to specifically detect its target in human brain tumors with autoradiography. 
 With the conjugation of the PSMA RNA aptamer to the surface of gold 
nanoparticles (GNPs) [214], a targeted computed tomography (CT) imaging and therapy 
system for prostate cancer can also be established (Figure 1.4C). The CT imaging study 
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revealed that the PSMA aptamer-conjugated GNPs could generate more than four-fold 
greater CT intensity for a PSMA-expressing cell line than a non-PSMA-expressing cell 
line, suggesting good specificity in detection of the targeted cancer cells. 
 
RNA nanoparticles for intracellular imaging and detection 
 An interesting example of applying RNA in intracellular imaging is the Spinach 
RNA aptamer, which is the RNA mimic of Green fluorescent protein (GFP). GFP has 
been extensively utilized as a reporter protein in cell and molecular biology. Similarly, 
the RNA mimics of GFP should also have remarkable applications in biomedical research, 
especially for intracellular imaging of RNA. By using the method of systematic evolution 
of ligands by exponential enrichment (SELEX), Paige et al. developed a novel class of 
RNA aptamers, termed Spinach that bind to fluorophores resembling the fluorophore in 
GFP [215] (Figure 1.6A). Upon binding of the targeted fluorophores, these RNA 
aptamers were capable of emitting tunable fluorescence with comparable brightness to 
enhanced GFP (EGFP) and many other fluorescent proteins. Moreover, the RNA-
fluorophore complex is resistant to photobleaching. Interestingly, the Spinach RNA 
aptamer can be expressed in vivo by fusing to other cellular RNAs, for example, 5S RNA, 
to enable live-cell imaging and monitoring of these cellular RNAs. Furthermore, 
fluorescent sensors for detecting a variety of small molecules and cellular metabolites, 
including adenosine 5′-diphosphate (ADP) and S-adenosylmethionine (SAM), in vitro 
and in living cells could also be generated by combining the Spinach aptamer, a 
transducer, and a target-binding aptamer [216] (Figure 1.6B). 
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 Reif et al. [217] recently reported another novel method to enable real-time 
monitoring of RNA folding and degradation in living cells based on the pRNA-3WJ. The 
authors designed and constructed RNA nanoparticles by incorporating an RNA aptamer 
capable of binding to malachite green (MG), the hepatitis B virus ribozyme and the 
luciferase siRNA into the pRNA 3WJ. When MG aptamer binds to MG dye, it will emit 
fluorescent light only if the aptamer folds correctly. The MG aptamer system can then be 
used to monitor the degradation of the constructed RNA nanoparticles by fluorescent 
microscopy and fluorescence spectroscopy. By using this novel design, the authors 
determined the half-life (t1/2) of the MG aptamer containing pRNA-3WJ inside living 
cells to be ∼4.3 h. 
 
RNA as a polymer for biosensor systems 
 The biomolecular-based detection system has been widely investigated in many 
applications including clinical diagnosis, food industry, environmental monitoring 
industry, and security industry [218, 219]. Conventionally, biosensors can detect proteins, 
nucleic acids such as DNA or RNA sequences, and small organic molecules [219-221]. 
RNA molecules are well suited to serve as detection tools for small molecules, antibiotics, 
peptides, metal ions, and ligands [222, 223] because of their unique folding structures, 
functional conformation, predictable base pairing, and high fidelity. These characteristics 
of RNA allow for the development of ribozyme or aptamer, and aptazyme-based 
biosensors [224-226]. Also, as the target, RNA can be used to develop the biosensor for 
the detection of messenger RNA or micro RNA [227-230]. Various detection methods of 
RNA-based biosensors were proposed such as electrochemical type, fluorescence type, 
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optical type, and electrical type. Also, there are various detection platforms for RNA-
based biosensors (Figure 1.7) [231-236]. In this section, we briefly introduce RNA-based 
biosensors for biomedical and environmental monitoring applications. 
 The first proof of concept of using RNA in a biosensor was developed by Breaker 
Group [222]. Self-cleaving hammerhead-ribozymes were created with seven different 
RNA switches and these immobilized each pixel that responded allosterically to six types 
of analytes (Co2+, cGMP, cCMP, cAMP, FMN and theophylline). The platform of 
biosensor array was prepared on a polystyrene cell culture plate which was coated with 
gold by physical vapor deposition. The ribozyme was immobilized onto gold surface via 
a 5′-thiotriphosphate-terminated RNA moiety. When individual analyte was added, the 
corresponding RNA biosensor captured the analyte and induced the self-cleavage and 
release of the 3′ fragment of the ribozyme. They also showed the quantitative and 
qualitative measurement of cAMP in culture media from E. coli strand. 
 RNA can also serve as the detection analyte to detect viable E. coli as an indicator 
organism in drinking water, which was proposed by the Baeumner group [229, 230]. This 
RNA-based biosensor was generated with the extraction and amplification of mRNA 
molecules from E. coli in 20 min. Viable E. coli in the water were identified and 
quantified using a 200 nt target sequence from mRNA. The detection limit of the 
biosensor system could detect around 40 viable E. coli in water (5 fmol per sample) using 
the electrochemiluminescence (ECL) detection method. They introduced the isothermal 
amplification technique, a nucleic acid sequence-based amplification (NASBA) for 
mRNA amplification. 
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 RNA was also applied to develop medical diagnosis biosensors. Theophylline (1, 
3-dimethylxanthine) is a common agent in the bronchodilators and used for acute and 
chronic asthma. Gothelf group developed a RNA-based electrochemical biosensor for 
theophylline in serum with a ferrocence (Fc) redox probe [226, 234]. In this study, the 
thiol group-modified and amino group-modified RNA aptamer were immobilized onto 
gold substrate via covalent bonding between thiol group and gold substrate. Then, the Fc 
redox probe was covalently attached to the 3′-amino group of RNA aptamer through Fc-	
carboxylic acid NHS reaction. Usually, the RNA aptamer stays on the open conformation 
in absence of theophylline. However, when the theophylline added to RNA aptamer-
modified electrode, the aptamer folds into the conformationally restricted hairpin 
structure. As a result, this phenomenon changed the electron transfer that was monitored 
by cyclic and differential pulse voltammetry. Moreover, specific recognition of dopamine 
by the RNA aptamer allows selective amperometric detection of dopamine from 100 nM 
to 5 µM range in the presence of competitive neurotransmitters such as catechol, 
epinephrine, norepinephrine, and others [233]. 
 In an alternative approach, the Hammond group used a RNA-based fluorescent 
biosensor for detecting cyclic di-GMP and cyclic AMP-GMP [227]. The c-di-GMP was 
generated by a GEMM (Genes for the Environment, Membranes, and Motility)-I 
riboswitch aptamer and the riboswitch ligand mutation can recognize the c-AMP-GMP, 
c-di-GMP. The fluorescence turn-on was activated by the 3, 5-difluoro-4-
hydroxybenzylidene imidazolinone (DFHBI) fluorescent molecule for cell imaging. This 
system provided selective and sensitive detection for each cyclic dinucleotide. Thus, 
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there are many examples demonstrating that RNA molecules are promising candidates 
for biosensor applications. 
 
Application of RNA as a polymer in material sciences 
RNA as a polymer for biocomputation systems 
 Silicon-based computer systems are ubiquitous [237] but new processors to 
implement computation, communication, and controls are needed to meet the demands of 
various applications. Gordon Moore's Law suggested that due to the increasing demand 
of the memory, computer electronic devices on the microprocessor will be doubled every 
18 months. Scientists and engineers are wondering whether current computer technology 
growth can be continued in the next ten years. They raised the concern that silicon 
microprocessor speed and miniaturization will eventually reach limits by current 
technology. Thus, molecular-scale computing has been explored since 1994 due to the 
predictable ending of Moore's Law for silicon-based computer devices. 
 In the last few decades, biotechnology has been integrated with nanotechnology 
and electrical engineering [238-240]. As a result, the field of bioelectronics has been 
created [241] and [242]. Bioelectronics has led to the development of the nanoscale 
biochip, biosensor, and biocomputation devices such as information storage devices, 
logic gates, field-effect transistors and computation systems (Table 1.2) [243-246]. 
Typically, bioelectronic devices are composed of a biological actuation portion, and an 
electronic signal transduction portion. So far, the biological component is usually 
composed of biomolecules, such as protein and DNA [240], [243] and [245]. Recently, 
some pioneering groups have suggested that RNA-based bioelectronic devices also 
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exhibited the logic gate behavior, processing functions, and biocomputational functions 
[181, 247-251]. The advantages of RNA-based computation are summarized in Figure 
1.8. Biocomputation approaches for information control, storage, and processing using 
RNA-based devices brings new possibilities that embody multiple functions in biological 
systems. The development of biological computers composed of artificial RNA 
molecules to operate inside living cells or tissues would provide a new avenue. A 
combination of these results will pave the way to develop the new-concept of 
biocomputer development in the future such as tissue-mimicked computations. 
 
RNA as a polymer for logic gates 
 In computer science, the ‘logic’ term is defined as circuits which gives an output 
corresponding to a set of two input values (True ‘1’, High voltage and False ‘0’, Low 
voltage). The logic gate is required to have two input values for performing Boolean 
function [242]. Thereby, it gives the logical output to perform the next function. Usually, 
man-made computers consist of millions of combinational logic gates. Thus, logic gates 
are essential components of the computer. As mentioned in the last section (RNA as a 
polymer for biocomputation systems), in the last few decades, the concept of a 
biomolecule-based computation system has been proposed or explored to solve the 
current limitation of silicon-based computations [247, 252-256]. The first attempt of 
molecular-scale computation was developed by Adleman's group in 1994 [252]. They 
introduced the encoded DNA molecule to solve the Hamiltonian path problem. This 
research established a milestone for the field of biomolecule-based computations. Since 
then, several groups proposed the DNA polymer-based logic systems [253, 255, 256]. 
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The basic operation mechanism of DNA-based logic gate is combinational DNA 
hybridization that undergoes conformational change or chemical reaction and includes 
pH, temperature, light, electrical, or electrochemical signals [252-256]. The function of 
logic gate gives the discrete state change such as structure, fluorescence, absorbance, and 
electrochemical or electrical current as the output. Like this, the various types of DNA-
based computations have been proposed. DNA, however, is hard to use to perform the 
complex functions because of its simple functionality. To develop the new-concept of 
biocomputation systems, RNA is a candidate owing to its intriguing characteristics. The 
folding and assembly of RNA molecules drive themselves into secondary and tertiary 
structures using the formation of hairpin loops, dovetails, bulges, and internal loops [10]. 
Thereby, RNA has functionality such as aptamer, ribozyme, siRNA, non-coding RNA, 
and circular RNA [181]. These various functional groups can be easily applied to the new 
concept of logic gate behavior, information storage, information processing, and 
computations as the novel elements [257-265]. 
 An autonomous biomolecular-based computer has been proposed to regulate the 
gene expression “logically” [249]. The basic computation rule is governed by ‘diagnostic 
rule’ for prostate cancer stage detection. If the specific genes relating to prostate cancer 
are overexpressed, then ssDNAs will bind to their mRNA and inhibit the protein 
synthesis. The level of specific RNA and the concentration of specific molecule which 
regulates the point mutations were regarded as an input. The release of short ssDNA 
modulated the levels of gene expression for anticancer activity, as the output logically. 
The computation module has two states, “positive” and “negative”, in response to the 
level of specific gene expression. This biocomputation concept is related with the 
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identification of mRNAs of disease-related genes. Thereby, it can be applied to cancer 
diagnosis systems based on logic analysis. 
 A RNAi-based logic evaluator has also been reported to perform Boolean logic 
corresponding to input molecules in the human kidney cells [250]. The reported 
biological circuit is composed of several mRNA species that encode the same protein but 
have different non-coding regions. This protein served as the output. As an input, siRNAs 
were used to control the degradation of the target mRNA and the expression of the output 
protein. Expressions with up to five logic variables were directly evaluated by this system. 
 
RNA as a polymer for information processor 
 In computer sciences, the information processor is a unit that receives the input 
information and processes it into another form based on programmed functions. RNA-
based information processing devices that operate logic gates, signal filtering, and 
cooperativity functions have been reported [251, 260, 266]. RNA devices composed of 
ribozymes and RNA aptamers received, processed and transmitted the molecular inputs 
to express the green fluorescent protein as output. As a sensor part, the RNA aptamer was 
introduced and a hammerhead ribozyme was used to process the cleaving of the aptamer. 
Also, the transmitter part was composed of sequences that bind to the aptamer and 
ribozymes. It was suggested that the RNA aptamer and ribozyme combination can be 
used as actuating elements for multi-functional information processor development [251, 
266]. 
 An intracellular RNA computation device in a single mammalian cell has also 
been reported [260]. Trigger-controlled transcription factors were used to regulate the 
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gene expression individually and the RNA-binding protein was used to inhibit the 
translation of transcripts on target RNA motifs. This computation biosynthetic circuit can 
provide the NOT, AND, NAND, and N-IMPLY expression functions in individual cells. 
Moreover, two N-IMPLY expression functions can combine with other cells to operate 
XOR gate functions and three logic gates can perform the half-adder and half-subtractor 
functions for arithmetic calculation. 
 
RNA as a polymer for resistive biomolecular memory 
 RNA can also provide several advantages such as ease of construction, well 
defined structure and thermodynamic stability for the development of biomolecular 
memory devices. Based on the discovery of the ultra-high thermostable pRNA-3WJ, a 
pRNA-3WJ/QD hybrid nanoparticle for resistive biomolecular memory application has 
been constructed [267]. The QD was used as a semiconducting part for storage of the 
electrons and pRNA-3WJ was used as an insulating part and serves as the bridge between 
QD and metal substrate. The electrical measurement (I–V) was conducted to this hybrid 
structure for resistive memory performances. This study showed the RNA polymer 
conjugates can be used directly for molecular memory device fabrication. 
 
Hybrid RNA polymers as semiconductors 
 Biomolecular hybrids of a conducting polymer [poly (O-methoxy aniline) (POMA)] 
and dsRNA have been investigated as semiconductors by Routh et al. in 2009 [268]. 
Fourier transform infrared (FTIR) spectroscopy indicated that three types of 
supramolecular interactions including electrostatic, H-bonding, and pi–pi interactions 
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were involved in these hybrid polymers. The circular dichroism spectra of the hybrid 
polymers indicated that the dsRNA underwent a small distortion in conformation from 
the canonical A-form RNA towards the B-form RNA during the formation of the hybrid 
polymers. Ultraviolet–visible spectroscopy revealed that the interaction of POMA on 
RNA occurred much faster than that on DNA. Morphological study by TEM further 
revealed that these POMA-RNA hybrids exhibited a fibrillar network structure in the 
nanometer scale. Conductivity studies revealed that the conductivity values of the 
POMA-RNA hybrids were three orders of magnitude higher than that of RNA alone. 
Moreover, when RNA concentrations increased in the hybrids, the conductivity values of 
the POMA-RNA hybrids also decreased. The I–V curves of the POMA-RNA hybrid 
polymers also clearly exhibited a hysteresis loop and demonstrated a semiconducting 
nature. Based on these interesting physical and electronic characteristics, the POMA-
RNA hybrids have the potential to be candidates for fabricating biosensors for other 
applications. 
 
Conjugation of RNA to graphene 
 Graphene is a one-atom thick, two-dimensional honeycomb lattice composed of 
sp2-bonded carbon atoms. It can be used as a fundamental building block for constructing 
other graphite-based structures such as fullerenes and nanotubes [269, 270]. This newly 
discovered carbon-based material has been a popular subject in material science and 
nanotechnology. It has been used for the sensing of a toxin Microcystin-LR in water 
[271-274]. RNA aptamer has been covalently immobilized on graphene oxide and a 
polydispersed stable RNA-graphene oxide nanosheet has been constructed [275]. The 
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RNA attached to these nanosheets was resistant to nuclease degradation and the 
nanosheets competitively absorbed trace amounts of the peptide toxin microcystin-LR 
from drinking water. PEI-grafted graphene oxide was also used to deliver siRNA as well 
as anticancer drug doxorubicin to cancer cells [276]. RNA has also been used as a 
surfactant to exfoliate flakes of graphene from nanocrystalline graphite to produce 
transparent and conducting RNA-graphene-based thin films [277], which has a potential 
for a variety of electronic applications. Further research in RNA-graphene 
nanocomposites may open a new avenue towards many applications of graphene-based 
conductive materials. 
 
Conjugation of RNA with other nanoparticles 
 The conjugation of RNA with nanoparticles such as quantum dot, iron oxide 
nanoparticle or gold nanoparticle has been successfully demonstrated by a series of 
studies for nanosized imaging, therapy and diagnosis [278-283]. For example, siRNA and 
tumor-homing peptides (F3) were conjugated to the PEGylated QD core as a scaffold 
[279, 280]. The complex was efficiently delivered to HeLa cells, released from the 
endosomal compartment, and triggered knockdown of EGFP signal. This leads to dual 
purpose of treatment and imaging. In another case, siRNA was also conjugated to the iron 
oxide nanoparticle [281, 283] for dual purpose: (1) in vivo transfer of siRNA and (2) 
imaging the accumulation of siRNA in tumor through magnetic resonance imaging (MRI) 
and near-infrared in vivo optical imaging (NIRF) using near-infrared Cy5.5 dye. Another 
report showed that the conjugation of gold nanoparticle and RNA also increased the 
availability of the tethered RNA splicing enhancer [284]. 
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 In 2007, the pRNA of the phage phi29 DNA-packaging motor was conjugated to 
the gold nanoparticles via a thiol group for single particle quantification in bacterial virus 
assembly [282]. The pRNA-gold nanoparticle conjugates were bound to procapsid by in 
vitro phage assembly. The results demonstrated the feasibility in using RNA-gold 
nanoparticle for single molecule imaging and counting of biological machines. 
 
Prospects 
 RNA is a polymer by nature. Recent technological advances to make RNA 
chemically and enzymatically stable [65, 66] and the discovery of unusual thermostability 
of some RNA motifs, as well as important biomedical applications [124, 125, 132, 133, 
285] have propelled the concept of RNA as a polymeric building block [36] into a new 
horizon. The concern of yield and production costs has been and will be addressed 
continually by industry scale production and fermentation. It is expected that applications 
of RNA as a polymer and as building blocks will appear more and more in therapeutics, 
detection, sensing, nanoelectronic devices, and other polymer industries. The anion 
nature, the thermodynamic stability, the insulating property, the self-assembly capability 
and other novel features such as versatility, molecular-level plasticity, as well as the 
potential semiconductor behavior will make RNA unique for exploring new scientific 
territories. RNA has been shown to be major components of cells and leading 
functionality of life, and it is expected that RNA will also be the momentous material of 
daily life in the future. 
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Table 1.1. Summary of chemical modifications of RNA. 
Chemical Modifications Advantages Disadvantages References 
Phosphate backbone 
·Phosphorothioate (PS) 
·Boranophosphate (BO) 
·Phosphonoacetate 
(PACE) 
·Phosphoramidate 
·Methylphosphonate 
·Improve nuclease resistance. 
·Combine with other modifications 
to dramatically improve RNA 
property 
·Destabilize 
siRNA duplexes 
(e.g. decreases 
Tm by 0.5 °C per 
PS linkage). 
·Extensive 
modification 
causes cytotoxic 
effect. 
[158-163] 
2’-OH group 
·Small 2’-substituents 
(e.g. 2’-O-methyl (2’-
OMe), 2’-fluoro (2’-F), 2’-
aminoethyl, 2’-deoxy-2’-
fluoroarabinonu-cleic acid 
(2’-F-ANA)) 
·Bulky 2’-modifications 
(e.g. 2’-O-MOE, 2’-O-
allyl) 
·Significantly improve nuclease 
resistance.  
·Greatly thermo-stabilizes dsRNA 
duplex (e.g. increase Tm 0.5-0.7 °C 
per 2’-OMe and 1 °C per 2’-F). 
·Particularly, 2’-OMe is nontoxic 
and prevents immune activation. 
·Bulky 2’-modifications can 
modulate thermos-stability and 
duplex asymmetry, and also give 
higher binding affinity. 
·Extensive or full 
modification will 
reduce or fully 
deactivate siRNA 
potency. 
·Bulky 2’-
modifications are 
only tolerated at 
limited position 
owing to their 
distortion of RNA 
helix structure. 
[36, 66, 
162-170, 
174] 
Locked nucleic acid 
(LNA) 
Unlock nucleic acid 
(UNA) 
·LNA enhances the complementary 
binding affinity and greatly 
improves thermostability by 2-
10 °C per incorporation, as well as 
improves nuclease resistance and 
reduces RNA immunogenicity. 
·Each UNA destabilizes duplex by 
5-8 °C to improve local 
destabilization of siRNA duplex, 
and enhance biostability in vivo. 
·LNA would 
probably cause 
liver toxicity. 
·Extensive 
modification with 
LNA and UNA 
generally results 
in decreased 
activity of siRNA 
and failure in 
annealing of 
dsRNA, 
respectively. 
[171-176] 
Ribose moiety 
·Altritol nucleic acid 
(ANA)  
·Hexitol nucleic acid 
(HNA) 
·2’-deoxy-2’-
fluoroarabino-nucleic acid 
(2’-F-ANA)  
·Cyclohexenyl nucleic 
acid 
·Enhance thermostability (e.g. 2’-
F-ANA increases Tm of RNA 
duplex by 0.5-0.8 °C per 
modification).  
·Improve nuclease resistance. 
·Modification at 
seed region would 
slightly reduce 
siRNA potency. 
[179] 
Ribonucleotide base 
(5-bromo-, 5-iodo-, 2-thio-
, 4-thio-uracil, dihydro-, 
pseudo, 5-biotinylated, 5-
aminoallyl-uracil, 
diamino-purine) 
·Stabilize base-pairing and to 
enhance binding specificity.  
·Particularly, 2-thio- and pseudo-
uracil reduce cellular immune 
response. 
·Some base 
modifications 
(e.g. 5-bromo- 
and 5-iodo-uracil) 
will affect siRNA 
potency. 
[140, 178] 
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Table 1.2. Classification of RNA polymer-based bioelectronics. 
RNA-based bioelectronics References 
Biocomputation devices 
Biologic gate [239, 244] 
Biomemory [239, 244, 267] 
Bioinformation processor 
[243, 244, 246, 248, 249, 
251] 
Biosensors 
Biomedical sensor 
[216, 218, 222, 223, 226-
228] 
Environmental sensor [229, 230] 
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Figure 1.1. Design and construction of RNA nanostructures. (A) Phi 29 DNA packaging 
motor pRNA hexamer [111]. The loop close to the 5’-end of the pRNA is defined as the 
right-hand loop, while the loop close to the 3’-end of the pRNA is defined as the left-
hand loop. Reprinted with permission from Ref. [111]. Copyright 1998 Elsevier. (B) 
pRNA dimer and trimer [107]. Adapted with permission from Ref. [107]. Copyright 2003 
American Scientific Publishers. (C) pRNA arrays [113]. Reprinted with permission from 
Ref. [113]. Copyright 2004 American Chemical Society. (D) RNA tecto squares [117]. 
Reprinted with permission from Ref. [117]. Copyright 2004 The American Association 
for the Advancement of Science. (E) The RNA nanoring [115]. Reprinted with 
permission from Ref. [115]. Copyright 2007 American Chemical Society. (F) The tRNA-
based polyhedron [119]. Reprinted with permission from Ref. [119]. Copyright 2010 
Nature Publishing Group. (G) Cubic RNA-based scaffolds designed in silico [145]. 
Reprinted with permission from Ref. [145]. Copyright 2010 Nature Publishing Group. (H) 
Triangular RNA–protein complex [128]. Reprinted with permission from Ref. [128]. 
Copyright 2011 Nature Publishing Group. (I) The self-assembling RNA square [93]. 
Both the 2D sequence and the crystal structure of the RNA square are shown in the figure. 
Reprinted with permission from Ref. [93]. Copyright 2011 The National Academy of 
Sciences of the United States of America. (J) RNA microsponges for siRNA delivery 
[148]. Reprinted with permission from Ref. [148]. Copyright 2012 Nature Publishing 
Group. (K) pRNA nanoparticles fabricated via both toolkit I: hand-in-hand interactions 
involving RNA loops and toolkit II: foot-to-foot interactions involving palindrome 
sequence and sticky ends [114]. Reprinted with permission from Ref. [114]. Copyright 
2013 RNA Society. (L) pRNA nanoparticles fabricated via branch extension tool kit 
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[114]. Reprinted with permission from Ref. [114]. Copyright 2013 RNA Society. (M) 
Single stranded RNA origami [137]. Reprinted with permission from Ref. [137]. 
Copyright 2014 The American Association for the Advancement of Science. (N) Boiling-
resistant RNA triangles and the array based on RNA triangles [36]. Reprinted with 
permission from Ref. [36]. Copyright 2014 American Chemical Society. (O) The self-
assembled RNA membrane [153]. Reprinted with permission from Ref. [153]. Copyright 
2014 Nature Publishing Group. (P) RNA origami tile and tube [140]. Reprinted with 
permission from Ref. [140]. Copyright 2014 John Wiley and Sons. 
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Figure 1.2. Construction and functional assays of thermodynamically stable pRNA 3WJ 
or pRNA-X nanoparticles. (A) HBV ribozyme cleavage assay showing the catalytic 
activity of the HBV ribozyme is retained after its incorporation into pRNA-3WJ 
nanoparticles. Cleave products are highlighted in the red box. Representative results from 
at least three independent experiments are shown. (B) MG aptamer fluorescence assay 
showing the function of the MG aptamer is retained after its incorporation into pRNA-
3WJ nanoparticles [124]. Representative results from at least three independent 
experiments are shown. Adapted with permission from Ref. [124]. Copyright 2011 
Nature Publishing Group. (C) Survivin gene knockdown assay showing the gene 
silencing activity of the surviving siRNA is retained after its incorporation into pRNA-X 
nanoparticles [73]. Representative results from at least three independent experiments are 
shown. Reprinted with permission from Ref. [73]. Copyright 2012 Elsevier. 
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Figure 1.3. Construction of RNA polygons based on pRNA-3WJ. (A) Construction of 
RNA triangle, square and pentagon by tuning the interior pRNA-3WJ angle [92]. 
Representative results from thirty-nine raw AFM images are shown. Reprinted with 
permission from Ref. [92]. Copyright 2014 Oxford University Press. (B) Construction of 
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RNA squares with tunable sizes [126]. Representative results from fifty-eight raw AFM 
images are shown. Reprinted with permission from Ref. [126]. Copyright 2014 American 
Chemical Society. 
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Figure 1.4. Functional RNA nanostructures for therapeutics delivery and medical 
detection. (A) Schematic illustration shows triggered siRNA delivery based on 
RNA/DNA hybrid nanostructures [141]. Control DNA duplexes fluorescently labeled 
with Alexa 488 and Alexa 546 were unable to recombine (upper part) and fluorescently 
labeled RNA/DNA hybrids were programmed for re-association and FRET occurred 
when the siRNA was released (lower part) [141]. Reprinted with permission from Ref. 
[141]. Copyright 2013 Nature Publishing Group. (B) QD-aptamer-doxorubicin conjugate 
nanoparticles as a cancer-targeted imaging, sensing and treatment platform [211]. 
Reprinted with permission from Ref. [211]. Copyright 2007 American Chemical Society. 
(C) PSMA aptamer-conjugated gold nanoparticles for targeted molecular CT imaging and 
therapy of prostate cancer [214]. Reprinted with permission from Ref. [214]. Copyright 
2010 American Chemical Society. (D) Spherical nucleic acid scaffold for loading RNA 
therapeutics [192]. Spherical nucleic acids are densely packed and highly oriented nucleic 
acids covalently conjugated to the surface of a spherical nanoparticle core. Reprinted 
with permission from Ref. [192]. Copyright 2014 American Chemical Society. 
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Figure 1.5. pRNA nanoparticles for cancer targeting. (A) pRNA-3WJ nanoparticles 
target folate-receptor positive tumor xenografts [124]. Upper panel: whole body; lower 
panel: organ imaging (Lv, liver; K, kidney; H, heart; L, lung; S, spleen; I, intestine; M, 
muscle; T, tumor). Reprinted with permission from Ref. [124]. Copyright 2011 Nature 
Publishing Group. (B) pRNA-3WJ nanoparticles target glioma [165]. Folate conjugated-
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pRNA nanoparticles with Alexa 647 labeling (FA-Alexa647-pRNA-3WJ) showed 
stronger binding to glioma compared with folate-free pRNA nanoparticles (Alexa647-
pRNA-3WJ). Reprinted with permission from Ref. [165]. Copyright 2015 Impact 
Journals, LLC. (C) pRNA-X nanoparticles target folate-receptor positive tumor 
xenografts [73]. Reprinted with permission from Ref. [73]. Copyright 2012 Elsevier. (D) 
Folate conjugated-pRNA nanoparticles with Alexa 647 labeling (FA-pRNA-Alexa647) 
target colorectal cancer metastases [166]. pRNA nanoparticles with Alexa 647 labeling 
but without folate (pRNA-Alexa647) was used as a control. Reprinted with permission 
from Ref. [166]. Copyright 2015 American Chemical Society. 
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Figure 1.6. Spinach RNA aptamer for intracellular imaging and sensing. (A) Live-cell 
imaging of Spinach-tagged 5S RNA [215]. Fluorescence and phase images showed the 
comparison of HEK293T cells expressing 5S RNA tagged with either Spinach RNA (5S-
Spinach) or negative control Lambda RNA (5S-Lambda). Fluorescence was detected in 
5S-Spinach-expressing cells in the presence of 20 µM DFHBI (+DFHBI), and granule 
formation was detected in cells treated with 600 mM sucrose for 30 min (↑Suc). Nuclear 
borders assessed by Hoechst 33342 staining were highlighted by white dashed lines [215]. 
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Representative results from at least three experimental replicates are shown. Reprinted 
with permission from Ref. [215]. Copyright 2011 The American Association for the 
Advancement of Science. (B) Imaging cellular metabolites in E. coli with sensor RNA 
[216]. Upper panel: the sensor RNA comprises Spinach (black), a transducer (orange), 
and a target-binding aptamer (blue). Target binding to the aptamer promotes stabilization 
of the transducer stem, enabling Spinach to fold and activate DFHBI fluorescence. Lower 
left panel: emission spectra of the SAM sensor in the presence or absence of SAM. 
Lower right panel: patterns of SAM accumulation after adding methionine to E. coli 
expressing the SAM sensor RNA were observed under a fluorescent microscope [216]. 
Scale bar, 5 µm. Representative results from at least three experimental replicates are 
shown. Reprinted with permission from Ref. [216]. Copyright 2012 The American 
Association for the Advancement of Science.  
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Figure 1.7. The basic constitution of RNA-based biosensor. 
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Figure 1.8. Advantages of RNA-based biocomputation. 
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Chapter 2: Controllable Self-assembly of RNA Tetrahedrons with 
Precise Shape and Size for Cancer Targeting 
 This chapter was reproduced (with some modification) with permission from Hui 
Li†, Kaiming Zhang†, Fengmei Pi, Sijin Guo, Luda Shlyakhtenko, Wah Chiu, Dan Shu 
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experiments, analyzed all the data and drafted the manuscript. Dr. Peixuan Guo led and 
supervised the whole study and provided financial support. All the authors revised and 
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Abstract 
Since RNA shows an integer of 11 nucleotides per helix turn of 360°, in 
comparison to DNA that shows a non-integer of 10.5 nucleotides per helix turn, I propose 
that different sizes of RNA 3D structures can be constructed with precise control and the 
size of the particle will increase linearly by increasing the nucleotide number as multiples 
of eleven. I used the ultra-stable pRNA-3WJ motif with controllable angles and arm 
lengths to construct tetrahedral architectures composed purely of RNA via one-pot 
bottom-up assembly with high efficiency and thermal stability. By introducing arm sizes 
of 22 bp and 55 bp, respectively, I constructed two RNA tetrahedrons with similar global 
contour structure, but with different sizes of 8 nm and 17 nm, respectively. AFM and 
cryo-EM imaging clearly demonstrated the 3D shapes of RNA tetrahedrons that were 
consistent with the designs. The RNA tetrahedrons were also highly amenable to 
functionalization. Fluorogenic RNA aptamers, ribozyme, siRNA, and protein-binding 
RNA aptamers were integrated into the tetrahedrons by simply fusing the respective 
sequences with the tetrahedral core modules. Upon systemic injection, 2'-F modified 
RNase resistant RNA tetrahedrons harboring EGFR aptamers specifically targeted 
orthotopic breast tumors without getting trapped in healthy organs. The favorable 
biodistribution highlight their potentials as safe and specific drug delivery vectors. The 
reported design principles can be extended to construct higher order polyhedral RNA 
architectures for various applications.  
Keywords: RNA nanotechnology; RNA nanoparticle; Phi29 packaging RNA; Three-way 
junction; Tetrahedron 
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Introduction 
The Watson-Crick base pairing properties of DNA and RNA have led to their 
development as excellent building blocks for the construction of nanomaterials by bottom 
up self-assembly [74, 133-135, 181, 286]. For constructing larger architectures by 
directional or angular extension, it is necessary to extend the building blocks with a 
defined angle or orientation. This has been challenging for DNA since one helix turn of 
360° is 10.5 nucleotides for B-form DNA. A non-integer per helix turn will result in the 
twisting of the extension angle or the restriction in orientation control. In RNA, the 
number of nucleotides per helix turn is an integer of 11 for A-form RNA, which is a 
common structure for most RNA sequences (Appendix 1 Supplementary Figure 1). I 
propose that this unique property of RNA will enable RNA structural growth with precise 
one directional control, which will facilitate the construction of large size architectures 
for materials science, computer device, and biomedical applications.  
RNA nanotechnology is an emerging field that involves the design, construction 
and functionalization of nanometer-scale particles composed mainly of RNA for 
applications in biomedical and material sciences [181]. Previous reports have shown that 
a variety of RNA nanostructures can be constructed with defined sizes, shapes and 
stoichiometry, including triangles [36], squares [93, 118, 126], bundles [113, 121], 2D 
arrays [36, 117], hexamers [54, 111, 116] and 3D cages [119, 122, 145] by bottom-up 
self-assembly based on intra- and inter-RNA interactions. We have extensively utilized 
the structural features of bacteriophage phi29 packaging RNA [123] to construct varieties 
of RNA nanoparticles via loop-loop interactions [111, 113, 114, 125], palindrome 
sequence mediated foot-to-foot interactions [113, 114], and three-way junction (3WJ) 
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motif [36, 74, 92, 114, 124]. More recently, we constructed 2D polygons such as triangle, 
square and pentagon [92] using the pRNA-3WJ as core scaffold at the vertices.  Here I 
extended our previous 2D work to design and construct 3D RNA nanoparticles with 
controllable shape and size.  
Tetrahedral geometry is attractive because of its intrinsic mechanical rigidity and 
structural stability. It is a pyramid-like structure with four triangular faces and six edges. 
Several methods have been used to construct DNA based tetrahedrons, such as an 
origami approach based on a long single DNA strand [287], complementary hybridization 
of strands using sticky ends [288, 289], and hierarchical assembly of tiles [290]. RNA is 
an attractive alternative building block due to its high thermal stability [164, 52] and 
versatility in structures [181, 291], well beyond the simplistic canonical Watson-Crick 
base pairing in DNA nanostructures. Herein, the well-characterized ultrastable 3WJ motif 
[54, 124] was used as the core scaffold to construct tetrahedral architectures. The RNA 
tetrahedrons have defined 3D structure as revealed by atomic force microscope (AFM), 
as well as by single particle cryo-electron microscopy (cryo-EM) that has long been 
found to be very challenging in imaging pure RNA structures without forming complex 
with proteins [292]. Moreover, for the functionalization of the RNA tetrahedrons, 
aptamers, ribozyme and siRNA were placed at the edges of the RNA tetrahedrons with 
high precision without disrupting the overall structure. Importantly, the functional 
modules were incorporated prior to the assembly of the RNA tetrahedrons to ensure the 
production of homogeneous nanoparticles with high yield. Biodistribution studies 
revealed that RNA tetrahedrons functionalized with EGFR targeting RNA aptamer 
specifically targeted orthotopic breast tumors without detectable accumulation in healthy 
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vital organs. The RNA tetrahedrons are envisioned to have a broad impact in 
nanotechnology arena, such as for organizing nanoscale materials with high precision, 
encapsulation of functional materials within its hollow cavity, targeted therapy to 
diseased cells and as image-guided delivery vectors.  
 
Materials and Methods 
RNA tetrahedron design, synthesis, and self-assembly  
The crystal structure of the pRNA 3WJ motif (PDB ID: 4KZ2) was used for 
designing RNA tetrahedrons utilizing computational programs UCSF Chimera, Swiss 
PDB Viewer and the PyMOL Molecular Graphics System. RNA strands were 
synthesized by in vitro T7 transcription using corresponding DNA templates generated 
by polymerase chain reactions (PCR) following previously reported procedures [125]. 
DNA oligos for PCR and for the assembly of DNA tetrahedrons were ordered from 
Integrated DNA Technologies, Inc. (Coralville, IA). For a 50 µl transcription reaction, 10 
µl of DNA template with 10 µl of 5× transcription buffer, 10 µl of 25 mM NTPs solution, 
5 µl of 100 mM DTT, 10 µl of T7 RNA polymerase and 5 µl 0.05% (vol/vol) DEPC 
water were mixed together and incubated at 37 °C for 4 h. The transcription reaction was 
stopped by adding 1 µl of DNase I and incubating at 37 °C for another 30 min to digest 
the DNA template. For generating 2’-F modified RNA tetrahedrons, Y693F mutant T7 
polymerase and 2’-F modified cytosine (C) and uracil (U) nucleotides were used to 
synthesize the corresponding RNA strands. For a 50 µl 2’F transcription reaction, 2.5 µg 
of DNA template diluted in 15 µl 0.05% (vol/vol) DEPC water, 5 µl of 10× 2’-F 
transcription buffer, 5 µl of 100 mM DTT, 5 µl of 50 mM 2’-F CTP, 5 µl of 50 mM 2’-F 
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UTP, 5 µl of 50 mM ATP, 5 µl of 50 mM GTP, and 5 µl of Y639F mutant T7 RNA 
polymerase were mixed together and incubated at 37 °C overnight.  All synthesized RNA 
strands were purified by 8 M urea, 8% denaturing PAGE. RNA tetrahedrons were 
assembled in a one-pot manner by mixing the four RNA strands in equimolar 
concentrations (100 nM) in 1× Tris buffer (100 mM NaCl, 50 mM Tris, pH 8.0), and 
heated to 95 °C for 5 minutes and slowly cooled to 4 °C over 45 minutes using a PCR 
machine. The step-wise assembly of the RNA tetrahedrons were verified by native PAGE 
gels run in 1× TBM (89 mM Tris, 200 mM boric acid, and 2.5 mM MgCl2) buffer at 90 V, 
4 °C. The gels were stained with ethidium bromide (EB) and imaged by Typhoon FLA 
7000 (GE Healthcare, Marlborough, MA). For AFM imaging and cryo-EM imaging, the 
assembled RNA tetrahedrons were further purified by native PAGE. 
The detailed sequences for assembling the designed RNA tetrahedrons are listed 
below: 
a. RNA sequences of the 8 nm RNA tetrahedron. 
Strand 1 
5’- GGACUGAUACGAAUCAUCGUGUAGCACCAGCUGUAAUCG 
AUGUGUACGGGAAGAGCCUAUGCCCAUCCUACUUUGUU 
CUACUAUGGCG -3’ 
Strand 2 
5’– GGUGCUACACGAUGUGUAGCCAGACUUAGCGGAAUGUU 
CGUACUUUGUUCAUGCGAGGCCGUCCAAUACCGAAUCAU 
CGAUUACAGCU -3’ 
Strand 3 
5’- GGGCAGUUGAGAUGUGUACGAACAUUCCGCUAAGUCUG 
GCUACUUUGUUCGUAUCAGUCCCGCCAUAGUAGAAUCAU 
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CGUAUCACCAU -3’ 
Strand 4 
5’- GGCCUCGCAUGAAUCAUCUCAACUGCCCAUGGUGAUACG 
AUGUGUAGGAUGGGCAUAGGCUCUUCCCGUACUUUGUU 
CGGUAUUGGAC -3’ 
 
b. RNA sequences of the 17 nm RNA tetrahedron. 
Strand 1 
5’- GGAUGACAGGUGUCAAUGCACUGAUACGAAUCAUCGUG 
UAGCAGAUUCGAUUGUACUCGUCCUCAGGUUCUACAGACGA
GCUGUAAUCGAUGUGUACGGGAAGAGAGUCACUUGCGUGG
CUCCCCUCUACUGCAGUAGUGUAUGCCCAUCCUACUUUGUU
CUACUAUGGCGGCAAGUAUGAUCCAUG -3’ 
Strand 2 
5’- GGACGAGUACAAUCGAAUCUGCUACACGAUGUGUAGCCA 
GACUUAGUGUCGUGACCGUACGACCGACUCGAGUCGACGAC
GGAAUGUUCGUACUUUGUUCAUGCGAGGGCGAUAGCGCCU
AGCUGCCUCUGACUGGACCUAGUGUCCAAUACCGAAUCAUC
GAUUACAGCUCGUCUGUAGAACCUGA -3’ 
Strand 3 
5’- GGAGAGCGUAGUCCUGUACGCAGUUGAGAUGUGUACGA 
ACAUUCCGUCGUCGACUCGAGUCGGUCGUACGGUCACGACA
CUAAGUCUGGCUACUUUGUUCGUAUCAGUGCAUUGACACCU
GUCAUCCCAUGGAUCAUACUUGCCGCCAUAGUAGAAUCAUC
GUAUCACCAUGAACAUCAUCACAGAC -3’ 
Strand 4 5’- GGCAGCUAGGCGCUAUCGCCCUCGCAUGAAUCAUCUCAA 
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CUGCGUACAGGACUACGCUCUCCGUCUGUGAUGAUGUUCAU
GGUGAUACGAUGUGUAGGAUGGGCAUACACUACUGCAGUA
GAGGGGAGCCACGCAAGUGACUCUCUUCCCGUACUUUGUUC
GGUAUUGGAC ACUAGGUCCAGUCAGA -3’ 
 
c. RNA sequences of the different functional modules. 
MG Aptamer 
5’- GGAUCCCGACUGGCGAGAGCCAGGUAACGAAUGGAU 
CC -3’ 
Spinach Aptamer 
5’- GGACGCAACUGAAUGAAAUGGUGAAGGACGGGUCC 
AGGUGUGGCUGCUUCGGCAGUGCAGCUUGUUGAGUAGA
GUGUGAGCUCCGUAACUAGUCGCGUCC -3’ 
HBV Ribozyme 
5’- GGGACGAAAAAAAACAAAUUCUUUACUGAUGAGUCC 
GUGAGGACGAAACGGGUCAAAAAAAACGUCCC -3’ 
Streptavidin 
Aptamer 
5’- GGAUGCGGCCGCCGACCAGAAUCAUGCAAGUGCGUA 
AGAUAGUCGCGGGUCGGCGGCCGCAUCC -3’ 
EGFR Aptamer 
5’-GCCUUAGUAACGUGCUUUGAUGUCGAUUCGACAGGA 
GGC -3’ 
Luciferase siRNA 
Sense Strand 
5’- AACUUACGCUGAGUACUUCGAUU -3’ 
Luciferase siRNA 
Antisense Strand 
5’- UCGAAGUACUCAGCGUAAGUU -3’ 
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Atomic force microscopy  
Both 8 nm and 17 nm RNA tetrahedrons were imaged by AFM, following 
previously reported procedures [293]. Briefly, RNA tetrahedrons (5-10 µL at 3-5 nM) 
were deposited on the aminopropyl silatrane (APS)-modified mica surface and excess 
samples were washed with diethylpyrocarbonate (DEPC)-treated water and dried before 
imaging. AFM imaging was conducted using the MultiMode AFM NanoScope IV system 
(Veeco, Plainview, NY) operated in tapping mode.  
 
Dynamic light scattering measurements  
The apparent hydrodynamic sizes and zeta potential of the assembled RNA 
tetrahedrons were measured by Zetasizer nano-ZS (Malvern Instruments, Ltd, Malvern, 
United Kingdom) at 25 °C, respectively. For size measurements, 500 µl 100 nM RNA 
tetrahedron in 1× Tris buffer was used. For zeta potential measurements, 800 µl 100 nM 
RNA tetrahedron in 1× Tris buffer was used. The laser wavelength used for the 
experiments was 633 nm. The data were obtained from at least three independent 
measurements. The intensity distribution was used to calculate the sizes of the 
nanoparticles. 
 
Melting temperature measurements  
The melting temperature of RNA, 2’-F RNA and DNA tetrahedrons were 
measured by the Roche Lightcycler 480 real-time PCR machine, following previously 
reported procedures [124, 125]. Briefly, all tetrahedrons were assembled in 20 µl 1× Tris 
buffer in the presence of 1× SYBR Green II dye (Invitrogen, Carlsbad, CA) with final 
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nanoparticle concentration of 250 nM. The samples were heated to 95 °C for 5 min and 
then slowly cooled down to room temperature at a rate of 0.11 °C/s using the Roche 
Lightcycler 480 real-time PCR machine. The melting temperature was obtained from at 
least three independent measurements. 
 
Cryo-electron microscopy (cryo-EM)  
RNA tetrahedron nanoparticles solution (2 µl at 0.3 mg/ml) was applied onto a 
glow-discharged 200-mesh R1.2/1.3 Quantifoil grid. The grids were blotted for 3 s and 
rapidly frozen in liquid ethane using a Vitrobot Mark IV (FEI, Hillsboro, OR). Then the 
girds were transferred to JEM2200FS cryo-electron microscope (JEOL, Tokyo, Japan) 
operated at 200 kV with in-column energy filter with a slit of 20 eV for screening. 
Micrographs of 17 nm tetrahedron were recorded with a direct detection device (DDD) 
(DE-12 3k × 4k camera, Direct Electron, LP, San Diego, CA) operating in movie mode at 
a recording rate of 25 raw frames per second at 20,000× microscope magnification 
(corresponding to a calibrated sampling of 2.5 Å per pixel) and a dose rate of ~25 
electrons/sec/Å2 with a total exposure time of 3 s. Micrographs of 8 nm tetrahedron were 
recorded on a 4k × 4k CCD camera (Gatan, Pleasanton, CA) at 60,000× microscope 
magnification (corresponding to a calibrated sampling of 1.8 Å per pixel) and a dose rate 
of ~30 electrons/sec/Å2 with a total exposure time of 1.5 s. A total 131 images of 17 nm 
tetrahedron and 52 images of 8 nm tetrahedron were collected with a defocus range of 
2~4 µm. 
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Single particle image processing and 3D reconstruction  
The image processing software package EMAN2.1, was used for the micrograph 
evaluation, particle picking, contrast transfer function correction, 2-D reference-free class 
averaging, initial model building and 3-D refinement of the cryo-EM data. Particle 
images recorded on DE-20 detector used the averaged sum of 72 raw frames per 
specimen area. The final frame average was computed from averages of every three 
consecutive frames to correct for the specimen movement (Courtesy of B. Bammes).  For 
the 17 nm tetrahedron, a total of 1662 particles were boxed to generate the 2D class 
averages for building the initial models. At last, 1582 particles were used for final 
refinement, applying the tetrahedral symmetry.  For the 8 nm tetrahedron, a total of 1346 
particles were boxed to generate the 2D class averages for building the initial models. In 
total, 1254 particles were used for final refinement, applying the tetrahedral symmetry. 
The resolution for the final maps were estimated by the 0.143 criterion of FSC curve 
without any mask. 23 Å and 19 Å Gauss low-pass filter were applied to the final 3D maps 
displayed in the Chimera software package. 
 
Tilt-pair validation for cryo-EM map  
Tilt-pair validation data were collected at two goniometer angles, 0 ° and −10 °, 
for each region of the grid. A particle set of 50 particles from two tilt pairs of 17 nm RNA 
tetrahedron was used for the validation test. The test was performed using 
e2tiltvalidate.py program in EMAN2. More details about the tilt-pair validation are listed 
in Table 2.1.  
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HBV ribozyme activity assay  
HBV ribozyme activity assay was performed according to previously reported 
procedures [124, 188]. Briefly, HBV RNA substrate was labeled by Cy5 using Cy5 Label 
IT® Kit (Mirus Bio LLC, Madison, WI) and incubated with 50 µL 200 nM RNA 
tetrahedrons harboring HBV ribozyme at 37 °C for 1 hour at 4:1 molar ratio. pRNA 
conjugated with HBV ribozyme was used as the positive control, while RNA tetrahedron 
only and pRNA conjugated with disabled HBV ribozyme (G→A mutation) were used as 
negative controls. The cleavage products of the HBV RNA substrate were further 
analyzed by 8% denaturing PAGE and imaged by Typhoon FLA 7000 (GE Healthcare, 
Marlborough, MA) under the Cy5 channel. 
 
Malachite green (MG) and Spinach aptamer fluorescence assays  
Measurements of MG and Spinach aptamer fluorescence emissions in solution 
were performed according to previously reported methods [36, 124]. Briefly, 100 µl at 
100 nM multifunctional RNA tetrahedrons harboring MG and Spinach aptamers were 
incubated with 2 µM MG dye and 2 µM DFHBI (Lucerna, Inc., New York, NY) at room 
temperature. pRNA-3WJ harboring MG and Spinach aptamers were used as the positive 
control. RNA tetrahedron only and dye only were used as negative controls. Fluorescence 
emission spectrum was recorded using a fluorospectrophotometer (Horiba Jobin Yvon, 
Edison, NJ), excited at 450 nm (465-750 nm scanning for emission) for Spinach aptamer 
and 615 nm (625-750 nm scanning for emission) for MG aptamer. 
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Streptavidin (STV) aptamer binding assay  
Multifunctional RNA tetrahedrons harboring STV aptamer (50 µL at 400 nM) 
were incubated with STV agarose resin (Thermo Scientific, Waltham, MA) in binding 
buffer (1× PBS with 10 mM Mg2+) at room temperature for 1 hr. Then the resin was spun 
at 500× g for 1 min and the supernatant was collected. Binding buffer (50 µL) was added 
to the resin to wash the resin for three times. The wash fractions were also collected. 
After washing, biotin (50 µL at 5 mM in 1× PBS with 10 mM Mg2+) was added to the 
resin three times to elute the RNA. All the collected supernatant, washing, and elution 
fractions were measured by Nanodrop (Thermo Scientific, Waltham, MA) for absorbance 
at 260 nm and further analyzed by PAGE. RNA tetrahedrons without STV aptamer were 
used as negative control. 
 
Transfection assay for tetrahedron harboring siRNAs  
5×104 MCF-7 cells (human breast adenocarcinoma cell line) were grown on 24 
well plate (TPP tech, Switzerland) with Eagle's Minimum Essential Medium (EMEM) 
(ATCC, Manassas, VA) supplemented with 10% fetal bovine serum  (FBS) (Sigma, St. 
Louis, MO) and 0.01 mg/ml of bovine insulin (Cell Applications, San Diego, CA) at 
37 °C in humidified air containing 5% CO2 overnight. The cells were co-transfected with 
1 nM RNA tetrahedrons and both plasmid DNA pGL3 encoding firefly luciferase and 
pRT-LK (Promega, Madison, WI) encoding renilla luciferase by lipofectamine2000 (Life 
technologies, Carlsbad, CA) following manufacturer’s instructions. Luciferase siRNA (4 
nM) was used as the positive control, while 5 nM scramble siRNA was used as the 
negative control. Dual luciferase assay (Promega, Madison, WI) was performed to 
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evaluate the siRNA silencing effects 48 h post transfection. Briefly, cells were washed 
with PBS once, then lysed with 100 µl of passive lysis buffer per well. Luciferase assay 
reagent (LARII) (50 µl) was added to 20 µl of cell lysate in a 96 well plate, and the 
firefly luciferase activity was measured. Then 50 µl of Stop and Glow buffer was added 
to measure the control renilla luciferase activity on a microplate reader (Synergy 4, Bio 
Tek Instruments, Inc, Winooski, VT). The firefly luciferase activity was then normalized 
with renilla luciferase activity to determine whether luciferase siRNA are still functional 
after incorporation into RNA tetrahedrons. At least four independent wells were tested 
for each sample. 
 
In vitro binding of RNA tetrahedrons harboring EGFR aptamers  
5×104 EGFR-positive MDA-MB-231 cells (human breast adenocarcinoma cell 
line) were grown on glass cover slides in 24-well plates in a 1:1 mixture of Dulbecco's 
modified Eagle's medium (DME) and Ham's F-12 nutrient mixture (DME/F-12 (1:1) 
medium) with 10% FBS at 37 °C in humidified air containing 5% CO2 overnight. RNA 
tetrahedrons harboring EGFR aptamers and labeled by Alexa 647 were diluted in 300 µl 
Opti-MEM medium to final concentration at 100 nM and incubated with the cells for 1 h 
at 37 °C. RNA tetrahedrons without EGFR aptamer at 100 nM in 300 µl Opti-MEM 
medium were used as the negative control. After the incubation, the cells were washed 
with PBS and then fixed by 4% paraformaldehyde. Cellular actin were stained by Alexa 
488 Phalloidin (Life Technologies, Carlsbad, CA) and the Prolong Gold antifade reagent 
with DAPI (Life Technologies, Carlsbad, CA) were used to stain the nuclei and mount 
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the cells. The images were obtained by the FluoView FV1000-Filter Confocal 
Microscope System (Olympus, Tokyo, Japan). 
 
In vivo targeting of RNA tetrahedrons to tumor-bearing mice  
All protocols and procedures involved in the animal experiments were approved 
by the University of Kentucky Institutional Animal Care and Use Committee (IACUC). 
Female athymic nu/nu mice (4-8 weeks old) were purchased from Taconic Biosciences, 
Inc. To generate the orthotopic triple-negative breast cancer (TNBC) xenograft tumors, 
2×106 MDA-MB-231 cells were re-suspended in PBS and injected into the mammary fat 
pad of the mice. To generate the KB cells (human cervix carcinoma cell line) xenograft, 
2×106 KB cells were re-suspended in PBS and injected subcutaneously to nude mice. The 
xenograft tumors were apparent within 2 weeks after the implantation. RNA tetrahedrons 
harboring EGFR aptamers and Alexa 647 in 1× PBS (100 µL at 2.4 µM) were then 
injected into the tumor bearing mice. PBS injected mice were used as negative control. 
For the animal trial on the mice bearing KB cells xenograft, RNA tetrahedrons without 
EGFR aptamer were also included as control. The mice were sacrificed and dissected 8 
hours after injection. The major organs including heart, lung, liver, spleen, kidney as well 
as tumors were collected and subjected to biodistribution analysis via fluorescence 
imaging using IVIS Spectrum station (Caliper Life Sciences, Waltham, MA) with 
excitation at 640 nm and emission at 680 nm.  
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Statistical analysis 
The results were presented as mean ± standard deviation. Statistical differences 
were evaluated using unpaired Student’s t-test, and p<0.05 was considered significant. 
 
Results and Discussion 
Design and self-assembly of RNA tetrahedrons 
 In this study, the pRNA-3WJ motif [54, 124] (Figure 2.1a) was used as a core 
module and placed at each of the four vertices to build RNA tetrahedrons (Figure 2.1b). 
A total of four RNA strands were designed consisting of four pRNA 3WJ core sequences 
and six linking RNA sequences. A 3D model of the RNA tetrahedron (Figure 2.1c) was 
then generated using computational modeling software UCSF Chimera [294], Swiss PDB 
Viewer (http://www.expasy.org/spdbv/) and PyMOL Molecular Graphics System 
(https://www.pymol.org/). The resulting computational model exhibited authentic 
tetrahedral conformation. For assembling the RNA tetrahedrons, the four RNA strands 
were synthesized by in vitro transcription and then mixed in stoichiometric ratio and 
annealed in 1×Tris buffer in a one-pot manner. Step-wise assembly of the complex was 
observed by native polyacrylamide gel electrophoresis (PAGE) (Figure 2.1d).  
 
Physicochemical characterization of RNA tetrahedrons 
 For 3D RNA tetrahedrons, the most convincing structural characterization in their 
native state comes from single particle cryo-EM studies. We first analyzed the 3D 
structure of the 8 nm RNA tetrahedrons with 2-helix turn per edge (Figure 2.1f). Single 
particle 3D reconstruction was applied by analyzing a total of 1254 particles collected 
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from cryo-EM images and achieved a final resolution of 19 Å (gold standard criterion, 
0.143 Fourier shell correlation, Figure 2.2). The 3D reconstruction data revealed that the 
RNA tetrahedron has a clear overall shape consistent with the computational 3D model 
(Figure 2.1c), which agrees with the predicted size of 8 nm. The 2D computed 
projections of the reconstructed RNA tetrahedron 3D model showed clear match to the 
2D class averages of the raw particles, suggesting the reconstructed 3D model truly 
represented the native structure and conformation of the designed RNA tetrahedron. The 
images from cryo-EM accord with the global images obtained by AFM imaging (Figure 
2.1e). However, the central cavity of each tetrahedron was too small to be resolved by 
AFM. The observed size discrepancy is due to limitations in the diameter of the AFM tip. 
To further characterize the size of the RNA tetrahedrons, dynamic light scattering (DLS) 
was performed. DLS assumes that the particles have an average globular geometry in 
solution. The apparent hydrodynamic size of the RNA tetrahedron was determined to be 
8.5 ± 2.4 nm (Figure 2.3a).  
 The surface charge of RNA tetrahedrons, measured as zeta potential, was also 
evaluated by DLS. As expected, due to the phosphate backbone of nucleotides, RNA 
tetrahedrons have a negative surface charge with a single peak at ‒14.9 ± 1.0 mV (Figure 
2.3b). This negative surface charge is advantageous for the overall colloid stability of 
RNA nanoparticles and prevents forming aggregation in solution. Moreover, negative 
surface charge could also reduce the non-specific interaction of the nanoparticles with the 
reticuloendothelial system (RES) and minimize non-specific cell entry, which is 
attractive for in vivo targeted drug delivery and theranostic applications [295]. 
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 To assess the thermodynamic stability of RNA tetrahedrons, I investigated their 
melting temperatures (Tm) by measuring their fluorescence intensities in the presence of 
SYBR Green II dye with the change of temperature on a real-time PCR machine. Melting 
experiments revealed that the assembled RNA tetrahedron had a very smooth, high-slope 
temperature dependent melting curve with a Tm of 71.3 ± 1.8 °C (Figure 2.3c). The high 
slope indicates cooperative assembly of the tetrahedron from its four component strands. 
Moreover, I compared the melting curve of RNA, 2'-F RNA and DNA tetrahedrons. The 
results showed that 2’-F RNA tetrahedrons was the most stable with a Tm of 77.7 ± 
2.4 °C, followed by RNA tetrahedron with a Tm of 71.3 ± 1.8 °C, and finally DNA 
tetrahedron with a much lower Tm of 58.3 ± 0.5 °C (Figure 2.3d).  These results were in 
agreement with previously reported thermodynamic stability of nucleic acids with the 
order of stability: 2’-F RNA > RNA > DNA [52, 164].  
 To investigate their enzymatic stability, unmodified and 2’-F modified (U and C 
nucleotides) RNA tetrahedrons were incubated in cell culture medium with 10% fetal 
bovine serum (FBS) (Figure 2.4). At specific time points, aliquots were extracted and 
evaluated by native PAGE. The unmodified RNA tetrahedrons were degraded within 15 
minutes, while 2’-F counterparts were stable over an extended period of time, well 
beyond 24 hrs. The resistance to serum-mediated degradation combined with the high 
thermodynamic stability is particularly attractive for the in vivo application of these RNA 
nanoparticles. 
 To demonstrate the precise tunable sizes of the RNA tetrahedrons, I designed a 
larger 17 nm RNA tetrahedron in which every edge of the tetrahedron was extended to 55 
bp equal to 5 helix turns (Figure 2.5). This larger nanoparticle has the same overall 
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tetrahedral geometry in our design (Figure 2.6a). Upon annealing the four component 
strands in one pot self-assembly, the larger RNA tetrahedron assembled with high 
efficiency, as revealed by native PAGE analysis (Figure 2.6b). DLS experiments 
revealed that the hydrodynamic diameter of the larger RNA tetrahedron was 16.9 ± 1.6 
nm, which is in agreement with the designed dimensions (Figure 2.6c). Moreover, AFM 
imaging was clearly able to resolve the tetrahedral morphology along with the inner 
cavities (Figure 2.6d). Since the RNA tetrahedrons were dried on the APS-modified 
mica surface before imaging in air, flattened tetrahedral shapes were observed. The RNA 
nanoparticles were also highly homogenous in shape and structure, demonstrating the 
robustness of the self-assembly of RNA tetrahedrons. Cryo-EM image further showed the 
very clear RNA tetrahedron nanoparticles (indicated by red circles) with the expected 
sizes and geometries (Figure 2.6e). Single particle 3D reconstruction of a total of 1582 
particles collected from 131 cryo-EM images achieved a resolution of 23 Å (gold 
standard criterion, 0.143 Fourier shell correlation, Figure 2.7). 
 
In vitro and in vivo functional assessments of multifunctional RNA tetrahedrons 
 To evaluate the application of tetrahedrons, four different functional modules 
including a hepatitis B virus (HBV) ribozyme, fluorogenic aptamers for Malachite Green 
(MG) or Spinach, and a streptavidin-binding aptamer (Figure 2.8a) were incorporated 
into the tetrahedron structure. The sequences of the functional modules were simply 
fused with the sequences of the 3WJ core, and then synthesized by in vitro transcription. 
After annealing the strands, the step-wise self-assembly was evaluated by native PAGE 
analysis to confirm the successful assembly of the RNA tetrahedrons (Figure 2.8b). 
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Functional assays were then conducted to determine whether the modules retained their 
authentic folding and functionalities upon incorporation into the RNA tetrahedrons.  
Retention of the HBV ribozyme catalytic activity: The HBV ribozyme is a 
hammerhead ribozyme that can target and cleavage the 135-nt HBV genomic RNA 
substrate [188]. The HBV ribozyme was fused to the RNA tetrahedron by extending one 
of the strands of the nanoparticle. After incubation with the RNA tetrahedron harboring 
the HBV ribozyme, the HBV substrate was cleaved into fragments with smaller 
molecular weights, as revealed by PAGE analysis (Figure 2.8c). The yield of the 
cleavage reaction was comparable with the positive control (pRNA harboring HBV 
ribozyme). In contrast, RNA tetrahedron by itself or harboring disabled HBV ribozyme 
(G→A mutation in catalytic site) had no catalytic effects. The result confirmed that the 
designed multifunctional RNA tetrahedron successfully escorted the HBV ribozyme, and 
the catalytic activity was retained after ribozyme sequence was fused to the tetrahedron. 
Assessment of the fluorogenic properties of MG and Spinach aptamers: Both MG 
[296, 297] and Spinach [215, 216] aptamers are well-characterized for their fluorogenic 
properties, which emit fluorescence upon binding of their respective dye targets, 
triphenylmethane and DFHBI. To verify that the MG and spinach aptamers incorporated 
into the multifunctional RNA tetrahedron are still functional and folded correctly, 
fluorescence studies were performed using a fluorospectrophotometer. The fluorescence 
emission spectrums showed that both aptamers retained their ability to bind their 
respective dyes and emitted strong fluorescence at a similar level to the positive control, 
indicating the retention of the correct folding and functionalities of these fluorogenic 
89	
	
aptamers (Figure 2.8d-e). The fluorogenic modules fused with tetrahedron nanoparticles 
can have potential applications for imaging these nanoparticles in cells. 
Assay for streptavidin (STV) binding: Upon incubation with STV agarose resins, 
the multifunctional RNA tetrahedrons harboring STV aptamer [298] successfully bound 
to the resin with high affinity and were eluted by biotin (Figure 2.8f). In contrast, the 
negative control tetrahedron did not bind to the resin and also did not show up in the 
elution fractions. The results indicated that the fusion with RNA tetrahedron did not 
interfere with the native structure and function of the STV aptamer. Moreover, in PAGE 
analysis of the eluted multifunctional nanoparticles harboring MG and Spinach aptamer, 
they still retained their fluorogenic properties, indicating that the RNA tetrahedron 
structure promoted the correct folding of the two aptamers after fusion into the RNA 
nanoparticle (Figure 2.9). The results demonstrated that the fused STV aptamer could be 
potentially employed as a handle to specifically purify the assembled multifunctional 
RNA tetrahedrons by using STV agarose resins. 
Assay for luciferase gene silencing: Dual-luciferase reporter assay was utilized to 
study the gene silencing effects of the RNA tetrahedron harboring four siRNAs targeting 
the same region of the Firefly luciferase gene (Figure 2.10). The Renilla luciferase, 
which was not the target of the luciferase siRNA, served as an internal control. The 
relative ratio of the expression level of the firefly luciferase to the Renilla luciferase was 
used to evaluate the targeted gene silencing effect in MCF-7 cells upon transfection. The 
results revealed that the tetrahedron harboring four luciferase siRNAs with 1 nM 
concentration achieved ~90% gene silencing, which is similar to the positive control of 
luciferase siRNA only at 4 nM concentration. In contrast, the tetrahedron only and 
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scrambled control did not show any noticeable gene silencing effects (Figure 2.11b). 
These results demonstrated that luciferase siRNA still retained their gene silencing ability 
after incorporation into the RNA tetrahedrons, suggesting that RNA tetrahedrons could 
serve as a vehicle for intracellular siRNA delivery.  
Cellular binding and entry of RNA tetrahedrons harboring EGFR aptamers: For 
effective cancer therapy, it is critical to guide therapeutics to specific cancer cells. The 
Epidermal Growth Factor Receptor (EGFR) family of Receptor Tyrosine Kinases (RTK) 
are highly prevalent in both primary tumors and metastatic breast cancer cells, making 
them an ideal candidate for targeted therapies [299]. RNA aptamers have been developed 
to bind to EGFR receptors [300-303] with high selectivity and sensitivity. Here I 
incorporated EGFR targeting RNA aptamers into RNA tetrahedrons (Figure 2.12) and 
evaluated their cellular binding by confocal microscopy (Figure 2.11a). Alexa 647 (red) 
labeled RNA strand was incorporated into tetrahedrons for fluorescence imaging. 
Tetrahedrons without EGFR aptamer were used as negative control.  Confocal imaging 
showed that tetrahedron nanoparticles with EGFR aptamers strongly bound to EGFR (+) 
MDA-MB-231 cells (Figure 2.11a), as revealed by the co-localization of the Alexa 647-
labeled RNA (red) and cellular actin (green) (Figure 2.11a). In contrast, negative control 
“naked” tetrahedrons without the EFGR aptamer showed negligible cellular binding. The 
results suggest that the EFGR aptamer could facilitate the binding of RNA tetrahedrons 
to EGFR-expressing cancer cells. 
 In vivo targeting in xenograft cancer mouse models: For studying the in vivo 
cancer-targeting properties of the RNA tetrahedrons, we generated orthotopic breast 
cancer mouse models by injecting MDA-MB-231 cells directly into the mammary fat pad 
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of athymic nude mice [174] to generate xenografts. Nuclease-resistant 2’-F RNA 
tetrahedrons harboring EGFR aptamers and Alexa 647 were systemically injected into 
mice and biodistribution monitored by whole body imaging. The mice were sacrificed 8 
hours post injection and their organs were collected for ex vivo imaging (Figure 2.11c). 
RNA tetrahedrons were not detected in any other organs except the breast tumor, 
indicating that the nanoparticles were cleared from normal organs quickly and did not 
accumulate in the liver, lung, spleen or kidney after systemic injection. In another 
confirmatory animal trial by using EGFR-expressing KB cells xenograft mouse model, 
the similar cancer-targeting ability of the RNA tetrahedrons was also observed (Figure 
2.13). Previous biodistribution experiment of pRNA 3WJ RNA nanoparticles harboring 
EGFR aptamer also showed similar results [174]. The cancer-targeting ability of the 
RNA tetrahedrons would make this delivery system an attractive candidate for future 
targeted cancer imaging studies and/or cancer therapy.  
 
Conclusion 
In conclusion, here I report the design and self-assembly of multifunctional 3D 
RNA tetrahedrons based on the ultrastable pRNA-3WJ motif. The constructed RNA 
tetrahedrons have defined 3D structures as revealed by both AFM and single particle 
cryo-EM. The size of the RNA tetrahedrons can be easily tuned by changing the number 
of RNA base pairs per edge. Melting experiments revealed its high thermodynamic 
stability. Aptamers, ribozyme and siRNA were successfully incorporated into the RNA 
tetrahedron with their correct folding and optimal functionality. Cellular binding and 
biodistribution study showed that the RNA tetrahedron functionalized with EGFR-
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aptamer targeted orthotopic breast tumors without detectable accumulation in other 
healthy organs. These results suggest that 3D RNA tetrahedron nanoparticles have the 
potential to escort imaging modules and therapeutics for in vivo cancer diagnosis and 
therapy. Moreover, since the current study only used in vivo fluorescent imaging to study 
the biodistribution, it should be note that it is difficult to accurately quantify the exact 
percentage of nanoparticles distributed into the tumor. In the future, radiolabeled RNA 
nanoparticles should be used to accurately quantify the biodistribution profile and also 
get a clear picture regarding how the RNA nanoparticles was metabolized and cleared 
from the body. 
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Figure 2.1. Design and assembly of 8 nm RNA tetrahedrons. (a) 2D sequence of pRNA 
monomer showing the central pRNA-3WJ motif. The 22-nucleotide core sequence (with 
red color) of pRNA-3WJ are used to construct RNA tetrahedrons. (b) 2D sequences and 
(c) 3D computational model of RNA tetrahedrons. (d) 7% native PAGE gel showing 
step-wise assembly of RNA tetrahedrons. '+' indicates the presence of the strands. M: 
ultra low range DNA Ladder. Representative results from at least three independent 
experiments are shown. (e) AFM images of 8 nm RNA tetrahedrons. Representative 
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results from twenty-one raw AFM images are shown. (f) Single particle cryo-EM 3D 
reconstruction of 8 nm RNA tetrahedrons. A total of 1346 particles were used to generate 
the 2D class averages for building the initial models. A total of 1254 particles were used 
for the final refinement of the model by applying the tetrahedral symmetry. 
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Figure 2.2. (a) Cryo-EM raw images of the 8 nm RNA tetrahedrons. A representative 
image from 52 raw images of 8 nm RNA tetrahedron was shown. (b) Reference free 2D 
class averages of the 8 nm RNA tetrahedrons. (c) 0.143 Fourier shell correlation. A total 
of 1346 particles were used to generate the 2D class averages for building the initial 
models. A total of 1254 particles were used for the final refinement of the model by 
applying the tetrahedral symmetry.   
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Figure 2.3. Physiochemical characterization of RNA tetrahedrons. Dynamic Light 
Scattering (DLS) assay showing (a) the hydrodynamic size and (b) the zeta potential of 
RNA tetrahedrons. Representative results from three independent measurements are 
shown. (c) Melting curve of RNA tetrahedron complex and each of the four component 
strands. Representative results from three independent measurements are shown. (d) 
Comparison of melting curves for RNA, 2'-F and DNA tetrahedrons. Representative 
results from three independent measurements are shown.
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Figure 2.4. Serum stability assay of 2’-F RNA tetrahedron and unmodified RNA 
tetrahedron. (a) 2’-F RNA tetrahedrons and (b) unmodified RNA tetrahedrons were 
incubated in 10% FBS for different time points. (c) Quantification of intact particles in 
panels A and B using Image J. Data was from one experiment. Similar serum stability 
assays have been performed for other 2’F-modified RNA nanoparticles for numerous 
times, and similar results were observed and published previously [124, 125, 174].  
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Figure 2.5. 2D sequence of the larger RNA tetrahedron with 55 bp per edge. The 22-
nucleotide core sequence of pRNA-3WJ was highlighted in red color. 
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Figure 2.6. Design, assembly and characterization of 17 nm RNA tetrahedrons. (a) 
Schematic showing tunable size conversion (from 22 bp per edge to 55 bp per edge) of 
RNA tetrahedrons. (b) 6% native PAGE gel showing step-wise assembly of larger RNA 
tetrahedrons. '+' indicates the presence of the strands. M: 100 bp DNA ladder. 
Representative results from at least three independent experiments are shown. (c) DLS 
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assay showing the hydrodynamic size of larger RNA tetrahedrons. Representative results 
from three independent measurements are shown. (d) AFM images of 17 nm RNA 
tetrahedrons. Representative results from sixteen raw AFM images are shown. (e) Cryo-
EM images and 3D reconstruction of 17 nm RNA tetrahedrons. A representative image 
(left) from 131 raw images of 17 nm RNA tetrahedron was shown. A total of 1662 
particles were used to generate the 2D class averages for building the initial models. A 
total of 1582 particles were used for final refinement by applying the tetrahedral 
symmetry.   
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Figure 2.7. (a) Reference free 2D class averages of the raw 17 nm RNA tetrahedrons. (b) 
0.143 Fourier shell correlation of the 17 nm RNA tetrahedron. (c) Tilt-pair validation of 
3D structure of the 17 nm RNA tetrahedron. A total of 1662 particles were used to 
generate the 2D class averages for building the initial models. A total of 1582 particles 
were used for final refinement by applying the tetrahedral symmetry.  A particle set of 50 
particles from two tilt pairs of 17 nm RNA tetrahedron was used for the validation test. 
The test was performed using e2tiltvalidate.py program in EMAN2. 
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Figure 2.8. Functional characterization of multifunctional RNA tetrahedrons. (a) 
Schematic showing multifunctional RNA tetrahedrons harboring HBV ribozyme, MG 
aptamer, Spinach aptamer and STV aptamer. (b) 7% native PAGE gel showing step-wise 
assembly of multifunctional RNA tetrahedrons. '+' indicates the presence of the strands. 
Representative results from at least two independent experiments are shown. (c) 
Ribozyme activity assay showing cleavage of 135 nt substrate. Representative results 
from at least three independent experiments are shown. Fluorogenic assay demonstrating 
fluorescence emission of (d) MG aptamer and (e) Spinach aptamer. Data was from one 
experiment, and the fluorogenic properties of MG aptamer and Spinach aptamer were 
further confirmed by PAGE (Figure 2.9). (f) Streptavidin (STV) aptamer binding assay 
using STV affinity column. The error bars represent standard deviation from three 
independent measurements. The binding property of STV aptamer was further confirmed 
by PAGE (Figure 2.9). ***: p < 0.001 versus corresponding control value, unpaired 
Student's t-test. 
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Figure 2.9. 7% native PAGE assay of multifunctional RNA tetrahedrons with (top) and 
without (bottom) Streptavidin aptamer after binding, washing and elution from the STV 
column. The gels were visualized by ethidium bromide staining (left), Spinach aptamer 
fluorescence (middle) and MG aptamer fluorescence (right). Data was from one 
experiment, and the purpose of this experiment is to confirm the previous studies of the 
fluorogenic properties of MG aptamer (Figure 2.8D) and Spinach aptamer (Figure 2.8E) 
as well as the binding properties of Streptavidin aptamer (Figure 2.8F). 
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Figure 2.10. 2D sequence of the RNA tetrahedron harboring luciferase siRNAs. Total 
four luciferase siRNAs were incorporated into one RNA tetrahedron. 
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Figure 2.11. In vitro and in vivo evaluation of RNA tetrahedrons harboring siRNA and 
cancer-targeting aptamers. (a) Confocal images showing RNA tetrahedron (with and 
without EGFR aptamers) binding to MDA-MB-231 cells. Representative results from at 
least three technical repeats are shown. Similar cell binding experiment of pRNA 3WJ 
RNA nanoparticles harboring EGFR aptamer was conducted by Dr. Dan Shu, and similar 
results were observed and published previously [174]. (b) Luciferase siRNA silencing 
effects assayed by dual luciferase assay. The error bars represent standard deviations 
from at least four independent wells. Representative results from at least two independent 
experiments are shown. ****: p < 0.0001 versus plasmid only control, unpaired Student's 
t-test. (c) Biodistribution assay in orthotopic MDA-MB-231 tumor-bearing mice after 
systemic tail vein injection of RNA tetrahedrons harboring EGFR aptamers. Data was 
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from one experiment, and the biodistribution experiment was repeated and further 
confirmed in KB xenograft mouse model (Figure 2.13). Similar biodistribution 
experiment of pRNA 3WJ RNA nanoparticles harboring EGFR aptamer was also 
conducted by Dr. Dan Shu, and similar results were observed and published previously 
[174]. 
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Figure 2.12. 2D sequence of the RNA tetrahedron harboring EGFR aptamers 
(highlighted in the purple boxes) and Alexa 647 fluorescent probe (highlighted in the red 
box). 
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Figure 2.13. Biodistribution of tetrahedron nanoparticles with EGFR aptamer in KB 
xenograft mouse model. PBS saline and tetrahedron without EGFR aptamer treated mice 
were used as control. Data was from one experiment, and the purpose of this experiment 
is to confirm the previous biodistribution study on MDA-MB-231 xenograft mouse 
model (Figure 2.11c). 
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Table 2.1. (Related to Figure 2.7) Tilt geometry computed for tilt pair of images, using 
the final 3D model of the17 nm RNA Tetrahedron.   
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
  
 Image Pair 
Total Particle Pairs 50 
Particle Pairs in Cluster 24 
Fraction in Cluster 48% 
Mean Tilt Angle 14.8 
RMSD Tilt Angle 5.73 
Mean Tilt Axis -168.8 
RMSD Tilt Axis 50.33 
Tilt Angle via Microscope 15 
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Chapter 3: Controllable Self-assembly of Molecularly Defined RNA 
Cages with Cube and Dodecahedron Shapes based on Stable pRNA 
Three-way Junction for Therapeutics Delivery 
 This chapter is adapted from a manuscript entitled “Controllable Self-assembly of 
Molecularly Defined RNA Cages based on Stable pRNA Three-way Junction for 
Therapeutics Delivery” by Hui Li, Sijin Guo, Kaiming Zhang, Luda Shlyakhtenko, Wah 
Chiu and Peixuan Guo. The manuscript is in preparation for submission to Advanced 
Materials. Special thanks to Dr. Kaiming Zhang for help in preparing Figure 3.1, 3.6 and 
3.11, Sijin Guo for help in preparing Figure 3.12, Dr. Luda Shlyakhtenko for help in 
preparing Figure 3.5 and 3.9. Author contribution: Sijin Guo performed the ELISA 
experiments. Dr. Kaiming Zhang performed the cryo-EM imaging and single particle 
reconstruction based on the cryo-EM raw data under the supervision of Dr. Wah Chiu. Dr. 
Luda Shlyakhtenko performed the AFM studies. Hui Li conceived the idea of building 
RNA cube and dodecahedron nanoparticles based on pRNA-3WJ, designed the 2D 
sequence and 3D computational model of RNA cube and dodecahedron nanoparticles, 
performed all the other experiments, analyzed all the data and drafted the manuscript. Dr. 
Peixuan Guo led and supervised the whole study and provided financial support.  
 
 
 
 
Copyright © Hui Li 2016 
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Abstract 
Over the past decade, RNA has been shown to be a unique and programmable 
biopolymer that can be exploited to self-assemble nanoscale objects with sophisticated 
structures and rich functionalities. Herein, I report the design and construction of 
molecularly defined RNA cages with cube and dodecahedron shapes based on the stable 
pRNA 3WJ. The RNA cages can be easily self-assembled by single-step annealing. The 
RNA cages were further characterized by gel electrophoresis, cryo-electron microscopy 
and atomic force microscopy, confirming the spontaneous formation of the RNA cages. I 
also demonstrated that the constructed RNA cages could be used to deliver model drugs 
such as immunomodulatory CpG DNA into cells and elicit enhanced immune responses. 
The RNA cages can be further explored to be a new generation of molecularly defined 
nanocarriers for drug delivery. 
 
Keywords: RNA nanotechnology; RNA nanostructures; Cage; Cube; Dodecahedron 
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Introduction 
RNA nanotechnology is an emerging research field that focuses on utilizing RNA 
as a unique and programmable biopolymer to self-assemble nanoscale objects with 
sophisticated structures and rich functionalities [181]. Similar to DNA, most of RNA-
RNA interactions are based on Watson-Crick base pairings and these base pairings are 
largely predictable. However, in contrast to DNA, RNA-RNA interactions also involves 
many non-canonical base pairings, and RNA can form complicated secondary structures 
such as single-stranded loops, bugles, hairpins, pseudoknots and junctions [12, 29-31]. In 
addition, RNA is one of the most important biomolecules in a cell and plays a critical role 
in normal physiology as well as various diseases. Previous research has shown that a 
variety of 2D and 3D RNA nanostructures including triangles [36], squares [93, 118, 126], 
pentagons [92], tetrahedrons [304], polyhedrons [119] and prisms [122] can be 
successfully constructed based on utilizing naturally-occurring RNA structures and 
motifs as basic building blocks. These RNA nanostructures can also be easily 
functionalized by incorporating functional groups such as aptamers, siRNAs and 
ribozymes [36, 126, 304]. These functionalized RNA nanostructures have the potential 
for many applications in biomedical and material sciences such as drug delivery, disease 
diagnosis and tissue engineering [181, 286]. Here I report the design and construction of 
molecularly defined RNA cages with cube and dodecahedron shapes based on the stable 
pRNA 3WJ [54]. To demonstrate the versatility of the stable pRNA 3WJ as a basic 
building block for RNA nanostructures, I designed and constructed an extended pRNA 
3WJ and then cryo-EM was used to characterize the extended pRNA 3WJ. The core 
motif of the pRNA 3WJ was then used to construct RNA cages with cube and 
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dodecahedron shapes. The assembled RNA cages have defined 3D structures as revealed 
by AFM and cryo-EM. I also demonstrated that the constructed RNA cages could be used 
to deliver model drugs such as immunomodulatory CpG DNA [305] into cells and elicit 
enhanced immune responses. 
 
Materials and Methods 
RNA design, synthesis, and self-assembly 
The extended pRNA 3WJ was designed by extending the three branches of the 
pRNA 3WJ by sixty perfectly base-paired nucleotides. The NanoEngineer program [306] 
was used to facilitate the design of the RNA cages. Six RNA strands were designed for 
assembling the RNA cube, while twelve RNA strands were designed for assembling the 
RNA dodecahedron. Each RNA strand represents one face of the RNA cube or 
dodecahedron. The nucleotide sequence of the individual RNA strand was designed 
based on the pRNA 3WJ sequence and perfectly base-paired double-stranded RNA 
sequences. RNA strands were synthesized by in vitro T7 transcription following 
previously reported procedures [125]. Briefly, DNA templates for generating the RNA 
strands were made by polymerase chain reactions (PCR). DNA oligo for PCR were 
directly ordered from Integrated DNA Technologies, Inc. (Coralville, IA). For a 50 µl 
transcription reaction, 10 µl of DNA template with 10 µl of 5× transcription buffer, 10 µl 
of 25 mM NTPs solution, 5 µl of 100 mM DTT, 10 µl of T7 RNA polymerase and 5 µl 
0.05% (vol/vol) DEPC water were mixed together and incubated at 37 °C for 4 h. The 
transcription reaction was stopped by adding 1 µl of DNase I and incubating at 37 °C for 
another 30 min to digest the DNA template. For generating 2’-F modified RNA 
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tetrahedrons, Y693F mutant T7 polymerase and 2’-F modified cytosine (C) and uracil (U) 
nucleotides were used to synthesize the corresponding RNA strands. For a 50 µl 2’F 
transcription reaction, 2.5 µg of DNA template diluted in 15 µl 0.05% (vol/vol) DEPC 
water, 5 µl of 10× 2’-F transcription buffer, 5 µl of 100 mM DTT, 5 µl of 50 mM 2’-F 
CTP, 5 µl of 50 mM 2’-F UTP, 5 µl of 50 mM ATP, 5 µl of 50 mM GTP, and 5 µl of 
Y639F mutant T7 RNA polymerase were mixed together and incubated at 37 °C 
overnight. After transcription, the RNA strands were purified by 8 M urea, 8% denaturing 
PAGE, respectively.  
The detailed sequences for assembling the designed structures are listed below: 
a. RNA sequences for assembling the extended pRNA 3WJ: 
Strand 1: Extended 3WJ-a 
5’-GGGACAGCACACAGAGCAGCAGCUUGAGACUCAGCGUACUUCUGGCAA 
GGUACGGUACUUUUGUCAUGUGUAUGUUGGGCGCAGACGGCGAUACCUAG
UAGUCACCUAGUGCUCUAUCGUAGAAGUGUAGCAUGACGCC -3’ 
Strand 2: Extended 3WJ-b 
5’- GGCGUCAUGCUACACUUCUACGAUAGAGCACUAGGUGACUACUAGGUA 
UCGCCGUCUGCGCCCACAUACUUUGUUGAUUGGAUGAGAUCACUUGUGAA
UCUGGUGAUCCAUGUGCCAGCGUGCGACGUAUAGUGAGCC -3’ 
Strand 3: Extended 3WJ-c 
5’- GGCUCACUAUACGUCGCACGCUGGCACAUGGAUCACCAGAUUCACAAG 
UGAUCUCAUCUAGUCAAUCAUGGCAAAAGUGCCGUACUUUGCCAGAAGUA
CGCUGAGUCUCAAGCUGCUGCUCUGUGUGCUGUCCC -3’ 
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The extended pRNA 3WJ was self-assembled in a one-pot manner by mixing the 
corresponding RNA strands in equimolar concentrations (1 µM) in 1× annealing buffer 
(10mM Tris-HCl, 50mM NaCl, 1mM EDTA, pH=8.0) and heated to 95 °C and slowly 
cool down to room temperature. For cryo-EM imaging, the assembled extended pRNA 
3WJ were further purified by native PAGE. 
b. RNA sequences for assembling the RNA cube: 
Strand 1: 
 5’- GGUGCUACACGAUGUGUAGCCAGACUUAGCGGAAUGUUCGAUGUGUAC 
GGGAAGAGCCUAUGCCCAUCCAUGUGUACAUGCGAGGCCGUCCAAUACCG
AUGUGUACGAUUACAGCU -3’  
Strand 2: 
 5’- GGCUCUUCCCGUACUUUGUUCUGUGUCGUCCAAGACUGUCGAAAUCAU 
GUUACAGUGCCCAUACUCGACAUACUAACUCAACUGCCCAUGGUGAUACG
UUGUUUCAUGGAUGGGCAUA -3’  
Strand 3: 
5’- GGGCAGUUGAGUUGUUUCAUGAGUAUACCACGAUCUGCUCGAUACUUU 
GUUCGUACUCCGUCUUCCUCAACCUAAUCAUCGGUAUUGGACGGCCUCGCA
UGUACUAACGUAUCACCAU -3’  
Strand 4: 
 5’- GGAUCAGCUCAUACUAAGACUACGUGUACACUUGCAACUUUGUUUCAU 
CGUGUAGCACCAGCUGUAAUCGUACUUUGUUAGGUUGAGGAAGACGGAGU
ACGAAUCAUCAGUAGCAGGC -3’  
Strand 5: 
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 5’- GGACGACACAGAAUCAUCGAACAUUCCGCUAAGUCUGGCUACUAAAGU 
UGCAAGUGUACACGUAGUCUUGUUUCAUUACCGACGUAUGCGUGAUGCUA
UACUUUGUUUCGACAGUCUU -3’  
Strand 6: 
 5’- GGCACUGUAACAUGUGUAUAGCAUCACGCAUACGUCGGUAAUGUGUAU 
GAGCUGAUCCGCCUGCUACUGAUGUGUAUCGAGCAGAUCGUGGUAUACUC
AUGUGUAUGUCGAGUAUG -3’  
c. RNA sequences for assembling the RNA dodecahedron 
Strand 1: 
5’- GGUGCUACACGAUGUGUAAGUCGCCACGUGAGACACGUGCAUGUGUAC 
UGUGUCGUCCAAGACUGUCGAAUGUGUACGGGAAGAGCCUAUGCCCAUCC
AUGUGUAGCCAGACUUAGCGGAAUGUUCGAUGUGUACGAUUACAGCU -3’ 
Strand 2: 
5’- GGACGACACAGUACUUUGUUUACCGACGUAUGCGUGAUGCUAAAUCAU 
CGUACUCCGUCUUCCUCAACCUAAUCAUGACUACGUGUACACUUGCAACUU
ACUUUGUUAGCUCGUCUAGCACCAUAUGAGAAUCAUUCGACAGUCUU -3’ 
Strand 3: 
5’- GGUAUGAGCUGUUACUUUGUUCAUGCGAGGCCGUCCAAUACCGUACUU 
UGUUUAGCAUCACGCAUACGUCGGUAAAUCAUGCACGUGUCUCACGUGGC
GACUUACUUUGUUUCGUGAGACGGACACGUCUCGAAAUCAUCAAUGUCAC
G -3’ 
Strand 4: 
5’- GGUACGCAUGCUACUUUGUUGCCUAGACAUGAAGACUGACCUUACUUU 
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GUUUCGAGACGUGUCCGUCUCACGAAAUCAUCGUGUAGCACCAGCUGUAA
UCGUACUUUGUUGCACUAACAUCGCGGAUCGACAAAUCAUGACAGAC 
AUGA -3’ 
Strand 5: 
5’- GGGCAGUUGAGUACUUUGUUUGACGCGACCUAACAUGAGCACUACUUU 
GUUUGUCGAUCCGCGAUGUUAGUGCAAUCAUCGAACAUUCCGCUAAGUCU
GGCUACUUUGUUUGCUCUCGGAAGAGUCCAAGAUAAUCAUCGUAUCA 
CCAU -3’ 
Strand 6: 
5’- GGAUCAGCUCAAAUCAUGUGAUCGUGUAACGCACCGAGUUACUUUGUU 
AUCUUGGACUCUUCCGAGAGCAAAUCAUGGAUGGGCAUAGGCUCUUCCCG
UACUUUGUUCUCAUAUGGUGCUAGACGAGCUAAUCAUCAGUAGCAGGC -3’ 
Strand 7: 
5’- GGAUGUACAGAUACUUUGUUAGGUUGAGGAAGACGGAGUACGAUGUGU 
ACGGUAUUGGACGGCCUCGCAUGAAUCAUCACCGACUGUCUGAGAUGACG
UAAUCAUCAGUGACUACCGCAUGCGUCAGUACUUUGUUCAGCUCCAGAU -3’ 
Strand 8: 
5’- GGACUUCGCCUUACUUUGUUACGUCAUCUCAGACAGUCGGUGAUGUGU 
AACAGCUCAUACCCGUGACAUUGAUGUGUAAGGUCAGUCUUCAUGUCUAG
GCAAUCAUGACAGCGAACUGUGGACAGUAGAAUCAUUCGACCUGAGA -3’ 
Strand 9: 
5’- GGUGAGUACUGUACUUUGUUCUACUGUCCACAGUUCGCUGUCAUGUGU 
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AGCAUGCGUACCUCAUGUCUGUCAUGUGUAGUGCUCAUGUUAGGUCGCGU
CAAAUCAUGCUAGUUCACCGACUCGAGUCUAAUCAUGACCGUCAGAU -3’ 
Strand 10: 
5’- GGUGAACUAGCAUGUGUACUCAACUGCCCAUGGUGAUACGAUGUGUAA 
CUCGGUGCGUUACACGAUCACAUGUGUAAUGAUCCAUGCUGAUGACGAGC
AAUCAUCGUUACUAAGCUGAUGCGAGACUACUUUGUUAGACUCGAGUC -3’ 
Strand 11: 
5’- GGCUGUCCUUCUACUUUGUUGCUCGUCAUCAGCAUGGAUCAUUACUUU 
GUUUGAGCUGAUCCGCCUGCUACUGAUGUGUAAGUUGCAAGUGUACACGU
AGUCAUGUGUAUCUGUACAUCCAUCUGGAGCUGAAUCAUCAUCACAGACA 
-3’  
Strand 12: 
5’- GGUAGUCACUGAUGUGUAAGGCGAAGUCCUCUCAGGUCGAAUGUGUAC 
AGUACUCACCAUCUGACGGUCAUGUGUAGUCUCGCAUCAGCUUAGUAACG
AUGUGUAGAAGGACAGCCUGUCUGUGAUGAUGUGUACUGACGCAUGC -3’ 
d. DNA sequences for assembling RNA cube harboring CpG DNA 
CpG DNA strand 1: 
5'- TCCATGACGTTCCTGACGTTTTTTTGGTGCTACACGATGTGTAGCCAGACT 
TAGCGGAATGTTCGATGTGTACGGGAAGAGCC -3’ 
CpG DNA strand 2: 
5'- TCCATGACGTTCCTGACGTTTTTTTTATGCCCATCCATGTGTACATGCGAG 
GCCGTCCAATACCGATGTGTACGATTACAGCT -3’ 
CpG DNA strand 3: 
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5'- TCCATGACGTTCCTGACGTTTTTTTGGCACTGTAACATGTGTATAGCATCA 
CGCATACGTCGGTAATGTGTATGAGCTGATCC -3’ 
CpG DNA strand 4: 
5'- TCCATGACGTTCCTGACGTTTTTTTGCCTGCTACTGATGTGTATCGAGCAG 
ATCGTGGTATACTCATGTGTATGTCGAGTATG -3’ 
The RNA cube or dodecahedron was self-assembled in a one-pot manner by 
mixing the corresponding RNA strands in equimolar concentrations (0.3 µM for RNA 
cube and 0.5 µM for RNA dodecahedron) in 1× Tris buffer and heated to 95 °C and 
slowly cool down to room temperature. The RNA cube harboring CpG DNA was self-
assembled in a one-pot manner by mixing the corresponding RNA and DNA strands in 
equimolar concentrations (5 µM) in 1× annealing buffer (10mM Tris-HCl, 50mM NaCl, 
1mM EDTA, pH=8.0) and heated to 95 °C and slowly cool down to room temperature. 
The step-wise self-assembly of the RNA cages was verified by PAGE or agarose gels. 
The gels were stained with ethidium bromide (EB) and imaged by Typhoon FLA 7000 
(GE Healthcare, Marlborough, MA). For AFM imaging, the assembled RNA cube or 
dodecahedron was further purified by native PAGE. For cryo-EM imaging, the 
assembled RNA cube was further purified by native PAGE, while the RNA 
dodecahedron was further purified by an Amicon Ultra-0.5 mL centrifugal filter (100K 
molecular weight cut-off). 
 
Cryo-electron microscopy of the extended pRNA 3WJ 
2 µl of extended pRNA 3WJ solution (0.3 mg/ml) was applied onto a glow-
discharged 200-mesh R1.2/1.3 Quantifoil grid. The grids were blotted for 1.5 s and 
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rapidly frozen in liquid ethane using a Vitrobot Mark IV (FEI, Hillsboro, OR). Then the 
grid was transferred to JEM2200FS cryo-electron microscope (JEOL, Tokyo, Japan) 
operated at 200 kV with in-column filter for screening. Micrographs were recorded on a 
4k×4k CCD camera (Gatan, Pleasanton, CA) at 50,000× microscope magnification 
(calibrated sampling of 2.16 Å per pixel) and a dose rate of ~13 electrons/sec/Å2 with a 
total exposure time of 4 s.  Ninety-eight images were collected with a defocus range of 
2~4 µm. 
 
Single particle image processing and 3D reconstruction of the extended pRNA 3WJ 
The image processing software package EMAN2 was used for the micrograph 
evaluation, particle picking, contrast transfer function (CTF) correction, 2D reference-
free class averaging, initial model building and 3D refinement of the cryo-electron 
microscopy data. A total of 4702 particles were boxed to generate the 2D class averages 
for building the initial models. In total, 4340 particles were used for final refinement, 
applying the icosahedral symmetry. The resolution for the final maps was estimated by 
the 0.143 criterion of FSC curve without any mask. A 30 Å Gauss low-pass filter was 
applied to the final 3D map displayed in the Chimera software package. 
 
Cryo-electron microscopy of the RNA cube 
For cryo-electron microscopy, 2 µl of RNA cube cage sample (0.45 mg/ml) was 
applied onto a glow-discharged 200-mesh R1.2/1.3 Quantifoil grid. The grid was blotted 
and rapidly frozen in liquid ethane using a Vitrobot IV (FEI, Hillsboro, OR). 
Micrographs were recorded with a direct detection device (DDD) (DE-20 4k×5k camera, 
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Direct Electron, LP, San Diego, CA) operating in movie mode at a recording rate of 25 
raw frames per second at 40,000× microscope magnification (corresponding to a 
calibrated sampling of 1.64 Å per pixel) and a dose rate of ~20 electrons per second per 
Å2 with a total exposure time of 3 s. A total of 149 images of RNA cube were collected 
with a defocus range of 2~4 µm. 
 
Single particle image processing and 3D reconstruction of the RNA cube 
The image processing software package EMAN2 was used for the micrograph 
evaluation, particle picking, CTF correction, 2-D reference-free class averaging, initial 
model building and 3-D refinement of the cryo-electron microscopy data. A total of 5106 
particles were boxed to generate the 2D class averages for building the initial model. 
Finally, 4371 particles were used for final refinement, applying the octahedron symmetry. 
The resolution for the final map was estimated by the 0.143 criterion of FSC curve 
without any mask. Sixteen Å Gauss low-pass filter was applied to the final 3D map 
displayed in the Chimera software package. 
 
Cryo-electron microscopy of the RNA dodecahedron 
RNA dodecahedron nanoparticles solution (2 µl at 1 mg/ml) was applied onto a 
glow-discharged 200-mesh R1.2/1.3 Quantifoil grid. The grids were blotted for 1.5 s and 
rapidly frozen in liquid ethane using a Vitrobot Mark IV (FEI, Hillsboro, OR). Then the 
grid was transferred to JEM2200FS cryo-electron microscope (JEOL, Tokyo, Japan) 
operated at 200 kV with in-column filter for screening. Micrographs were recorded on a 
4k × 4k CCD camera (Gatan, Pleasanton, CA) at 40,000× microscope magnification 
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(calibrated sampling of 2.83 Å per pixel) and a dose rate of ~20 electrons 
electrons/sec/Å2 with a total exposure time of 3 s.  Fifty-five images were collected with 
a defocus range of 2~5 µm. 
 
Single particle image processing and 3D reconstruction of the RNA dodecahedron 
The image processing software package EMAN2 was used for the micrograph 
evaluation, particle picking, CTF correction, 2-D reference-free class averaging, initial 
model building and 3-D refinement of the cryo-electron microscopy data. A total of 1598 
particles were boxed to generate the 2D class averages for building the initial models. At 
last, 991 particles were used for final refinement, applying the icosahedral symmetry. The 
resolution for the final maps was estimated by the 0.143 criterion of FSC curve without 
any mask. A 27 Å Gauss low-pass filter was applied to the final 3D map displayed in the 
Chimera software package. 
 
Atomic force microscopy 
The RNA cube or dodecahedron samples (5-10 µL at 3-5 nM) were deposited on 
the aminopropyl silatrane (APS)-modified mica surface and excess samples were washed 
with DEPC-treated water and dried before imaging. AFM images were obtained by using 
the MultiMode AFM NanoScope IV system (Veeco, Plainview, NY) operated in tapping 
mode following previously published procedures [293]. 
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Determine the level of immunomodulation by RNA cube nanoparticles harboring 
CpG DNA via enzyme-linked immunosorbent assay (ELISA) 
RAW 264.7 cells were plated into 24-well plates with the density of 2.5 × 105 
cells per well and cultured overnight. RNA cube nanoparticles harboring different 
numbers of CpG ODNs (10 µl at 5 µM in 1× annealing buffer (10mM Tris-HCl, 50mM 
NaCl, 1mM EDTA, pH=8.0)) were diluted in 300 µl Opti-MEM medium (Life 
Technologies, Carlsbad, CA) and then incubated with the RAW 264.7 cells for 8 hours at 
37 °C in humidified air containing 5% CO2. Then the cell culture supernatant of each 
well was collected and stored at -80 °C freezer until use. The concentration of TNF-α and 
IL-6 in the supernatant was determined by enzyme-linked immunosorbent assay (ELISA) 
by using Mouse ELISA MAX™ Deluxe sets (BioLegend, Inc., San Diego, CA), 
following protocols provided by the manufacturer. At least three independent wells were 
tested for each nanoparticle and control samples. 
 
Statistical analysis 
The results were presented as mean ± standard deviation. Statistical differences 
were evaluated using unpaired Student’s t-test, and p<0.05 was considered significant. 
 
Results and Discussion 
Design, construction and characterization of extended pRNA three-way junction as 
a flexible building block for RNA nanostructures 
 The pRNA 3WJ has been demonstrated by previous studies as a 
thermodynamically stable RNA motif and has been widely used in constructing RNA 
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nanostructures as a fundamental building block [36, 73, 92, 114, 124, 304]. However, 
because the size of the pRNA 3WJ is relative small (~ 4 nm), it is difficult to directly and 
clearly observe the pRNA 3WJ under electron microscope. In order to better characterize 
the pRNA 3WJ, I extended the three branches of the pRNA 3WJ by sixty perfectly base-
paired nucleotides, respectively, to make a larger RNA 3WJ that is large enough to be 
observed by electron microscope. The designed extended pRNA 3WJ is still composed of 
three RNA strands with length of 139 nucleotides, 138 nucleotides and 134 nucleotides. 
To characterize the extended pRNA 3WJ in detail, cryo-electron microscope was applied 
to directly observe its structure (Figure 3.1). Cryo-EM is a powerful technique for 
imagining three-dimensional (3D) structure of biological macromolecules under their 
native states [292]. Cryo-EM images 2D class averages and single particle reconstruction 
showed very clear extended pRNA 3WJ with expected three-branched shape and 
dimension. Moreover, in the raw images of the cryo-EM results, different conformations 
of the extended pRNA 3WJ with different angles among the three RNA branches were 
observed, suggesting conformational flexibility of the pRNA 3WJ. Importantly, as 
demonstrated in the following sections of this chapter, this conformational flexibility can 
be exploited to build novel 3D RNA nanostructures such as cubes and dodecahedrons by 
adjusting the angles among the three RNA branches. 
 
Design and self-assembly of the RNA cube cages  
A typical cube structure has eight vertexes, six square faces and twelve edges. A 
3D computational model of the RNA cube was first generated using the software 
NanoEngineer (Figure 3.2a). The resulting computational model exhibited authentic 
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cubic conformation and the eight RNA 3WJs can be clearly observed in the model. For 
designing the RNA cages with cube shape, eight pRNA 3WJs (four of them are reverse 
pRNA 3WJs) are positioned into the vertexes and twelve double-stranded RNAs are 
positioned into the edges of the cube to link the individual pRNA 3WJs. A total of six 
RNA strands were designed to construct the RNA cube, while each RNA strand 
represents one square face of the RNA cube (Figure 3.3). For assembling the RNA cube, 
the designed six RNA strands were synthesized by in vitro transcription and then mixed 
in stoichiometric ratio and annealed in 1×TMS buffer in a one-pot manner. Step-wise 
assembly of the RNA cubic cages was observed by a PAGE gel, confirming the 
formation of the high molecular weight RNA cubes (Figure 3.4). 
 
Design and self-assembly of the RNA dodecahedron cages  
A typical dodecahedron structure has twenty vertexes, twelve faces and thirty 
edges. Similar to the RNA cube, a 3D computational model of the RNA dodecahedron 
was generated using the same software NanoEngineer (Figure 3.2b). The resulting 
computational model exhibited authentic dodecahedron conformation and the twenty 
RNA 3WJs can be clearly observed in the model. For designing the RNA cages with 
dodecahedron shape, twenty pRNA 3WJs are positioned into the vertexes and thirty 
double-stranded RNAs are positioned into the edges of the dodecahedron to link the 
individual pRNA 3WJs. A total of twelve RNA strands were designed to construct the 
RNA dodecahedron, while each RNA strand represents one face of the RNA 
dodecahedron (Figure 3.5). For assembling the RNA dodecahedron, the designed twelve 
RNA strands were synthesized by in vitro transcription and then mixed in stoichiometric 
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ratio and annealed in 1×TMS buffer in a one-pot manner. Step-wise self-assembly of the 
RNA dodecahedron cages was clearly observed by running an agarose gel, suggesting the 
formation of the high molecular weight RNA dodecahedron (Figure 3.6).  
 
Imaging of the RNA cube cages by atomic force microscopy  
 Atomic force microscopy (AFM) has been extensively used to characterize a 
variety of nucleic acid nanostructures [293]. AFM was also applied to characterize the 
RNA cube cages. Before AFM imaging, the self-assembled RNA cube was deposited on 
an APS-modified mica surface, washed with water and dried in room temperature. AFM 
studies of the RNA cube clearly revealed the shape of the cube, which was similar to its 
theoretical prediction (Figure 3.7). The height of the RNA cube was found to be around 
7-8 nm, which was consistent to the height of the RNA cube after drying (the RNA cube 
was collapsed on the mica surface after drying, which gave a distorted dimension). 
 
Imaging of the RNA cube cages by cryo-electron microscopy  
To further confirm the formation of the RNA cube cages, cryo-electron 
microscopy (EM) was applied to direct image the RNA cube cages. Cryo-EM images 
showed very clear RNA cubes with expected dimensions. The single particle 3D 
reconstruction data revealed that the RNA cube has a clear overall shape and 
conformation in agreement with the computational 3D model and the predicted size of 10 
nm (Figure 3.8). The six faces of the cube cage can be clearly observed in the 
reconstructed 3D model. The 2D computer projections of the reconstructed RNA cube 
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model showed good match to the 2D class averages of the raw images, suggesting the 
reconstructed 3D model correctly represented the native structure of the RNA cube.  
 
Imaging of the RNA dodecahedron cages by atomic force microscopy  
Similar to the RNA cube cages, AFM was also applied to characterize the RNA 
dodecahedron cages. Before AFM imaging, the self-assembled RNA dodecahedron was 
deposited on an APS-modified mica surface, washed with water and dried in room 
temperature. AFM studies of the RNA dodecahedron clearly revealed the shape of the 
cube, which was in agreement to its theoretical prediction (Figure 3.9). The height of the 
RNA dodecahedron was found to be around 8 nm, which was consistent to the distorted 
dimension of the RNA dodecahedron after drying. Moreover, the nuclease-resistant 2’F-
modified RNA dodecahedrons were also imaged by AFM and similar images were 
observed under AFM (Figure 3.10). It should be noted that a sharper AFM tip was used 
for imaging the 2’F-modified RNA dodecahedron, so the resolution of the image of the 
2’F-modified RNA dodecahedron was higher and more details of the inner cavities were 
observed. Overall, the AFM result suggests that 2’F-modification did not significantly 
change the conformation of the RNA dodecahedron. 
 
Imaging of the RNA dodecahedron cages by cryo-electron microscopy  
To further confirm the successful self-assembly of the RNA dodecahedron cages, 
cryo-electron microscopy (EM) was also applied to direct image the RNA dodecahedron 
cages. Cryo-EM images showed very clear RNA dodecahedrons with expected shapes 
and sizes. The single particle 3D reconstruction data revealed that the assembled RNA 
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dodecahedron has a clear overall 3D conformation in agreement with the computational 
3D model and the predicted size of 20 nm (Figure 3.11). The twelve faces of the 
dodecahedron cage can be clearly observed in the reconstructed 3D model. The 2D 
computer projections of the reconstructed RNA dodecahedron model showed good match 
to the 2D class averages of the raw images, confirming the reconstructed 3D model truly 
represented the native structure of the RNA dodecahedron.  
 
Immunomodulation in macrophage cells by CpG DNA escorted by RNA cages 
 The synthetic CpG ODN are a type of DNA molecule that could induce potent 
immune response both in vitro and in vivo [305, 307]. Herein, based on the hypothesis 
that 3D display of CpG DNA by nanoparticles will create synergistic effect and enhance 
the immune response, I utilized the constructed RNA cube to deliver CpG DNA by 
incorporating 4 CpG DNA oligos to the 4 edges of each RNA cube. RNA cubes 
harboring CpG DNA were then incubated with macrophage-like RAW 264.7 cells, and 
the cell culture supernatant was collected to determine the TNF-alpha and IL-6 cytokine 
level by ELISA. The ELISA assay showed that CpG DNA delivered by the RNA cube 
induced significantly enhanced immune response, and the induced immune response is 
strongly dependent on the number of immunostimulatory molecules per RNA cube 
(Figure 3.12). More CpG DNA molecules incorporated into the RNA cube, stronger 
immune responses were observed, while the RNA cube without CpG DNA induced 
negligible immune response. These results suggested the designed RNA cube has the 
potential to be employed as a novel vehicle for immunoactive CpG DNA delivery. 
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Conclusion 
In this study, I reported the successful bottom-up self-assembly of molecular 
defined RNA cages with cube and dodecahedron shapes by using the stable pRNA 3WJ 
as the basic building block. The constructed RNA cages have defined 3D structures as 
revealed by both cryo-EM and AFM. Comparing with previously reported RNA cages 
[119, 122, 145], the RNA cages reported here has more regular and defined shapes. 
Moreover, since the thermodynamic stable pRNA 3WJ was used as the building block to 
build the RNA cages, it is expected that the constructed cages will also have remarkable 
thermodynamic stability. Furthermore, I also found that the designed RNA cube cages 
could be used to deliver immunostimulatory CpG DNA to macrophage-like RAW 264.7 
cells and elicit enhanced immune response. The extent of the induced immune response is 
also strongly dependent on the number of CpG DNA molecules loaded into the RNA 
cube. This study showcased that the reported RNA cages have the potential to be 
explored in the future as molecularly defined nanocarriers for therapeutics delivery. 
Another appealing future research direction is to develop RNA cages with tunable 3D 
conformation (for example, 3D RNA cube with different length, width and height) and 
investigate the effect of different 3D shapes on the intracellular fate and in vivo behaviors 
of these RNA cages. 
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Figure 3.1. Cryo-EM characterization of the extended pRNA 3WJ nanoparticles. (a) A 
representative raw image showing a typical microscopic view of the extended pRNA 
3WJ nanoparticles under cryo-EM. Scale bar: 50 Å. A total of ninety-eight raw images 
were collected with a defocus range of 2~4 µm. (b) Forty representative raw particles 
extracted from ninety-eight raw cryo-EM images of the extended pRNA 3WJ 
nanoparticles. (c) 2D class averages of the extended pRNA 3WJ nanoparticles based on 
the cryo-EM data. (d) Reconstructed 3D map of the extended pRNA 3WJ nanoparticles 
based on the cryo-EM data. Four views of the 3D map at four different angles (90 ° 
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rotation) are shown in the figure. Scale bar: 260 Å. A total of 4702 particles were used to 
generate the 2D class averages for building the initial models, and 4340 particles were 
used for final refinement by applying the icosahedral symmetry. 
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Figure 3.2. Computation models of (a) RNA cube and (b) RNA dodecahedron designed 
by NanoEngineer program. Two views from two different angles are shown for the RNA 
cube model and RNA dodecahedron model, respectively. The RNA cube was composed 
of six different RNA strands and contains eight 3WJs in its vertexes, while the RNA 
dodecahedron was composed of twelve different RNA strands and contains twenty 3WJs 
in its vertexes.   
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Figure 3.3. 2D sequence design of the RNA cube. The RNA cube was composed of six 
different RNA strands (1-6) highlighted with six different colors. The 5’ and 3’ end of the 
individual RNA strand is labeled in the figure. The pRNA 3WJ motif is highlighted in 
orange color (Rev denotes the reverse pRNA 3WJ sequence).  
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Figure 3.4. 6% native TBM PAGE showing the step-wise self-assembly of the designed 
RNA cube. 100 bp DNA ladder is used as the molecular weight marker. The final product 
(cube 1+2+3+4+5+6) showed a distinct band (highlighted in the red square), 
demonstrating correct assembly of the designed RNA cube. Representative results from 
three independent experiments are shown. 
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Figure 3.5. 2D sequence design of the RNA dodecahedron. The RNA dodecahedron was 
composed of twelve different RNA strands (1-12) highlighted with twelve different 
colors. The 5’ and 3’ end of the individual RNA strand is labeled in the figure. The 
pRNA 3WJ motif is highlighted in orange color. 
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Figure 3.6. 2.5% agarose gel showing the step-wise self-assembly of the RNA 
dodecahedron. 100bp DNA ladder is used as the molecular weight marker. The final 
product (dodecahedron 1-12) showed a distinct band (highlighted in the red square), 
demonstrating correct assembly of the designed RNA dodecahedron. Representative 
results from three independent experiments are shown. 
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Figure 3.7. AFM characterization of the RNA cube. Left panel shows a typical AFM 
view of the RNA cube. Right panel shows the magnified view of individual RNA cube. 
Note that the RNA cube was collapsed on the mica surface after drying, which gave a 
distorted dimension. Representative results from eight raw AFM images are shown. 
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Figure 3.8. Cryo-EM characterization of the RNA cube with single particle 
reconstruction. (a) A representative raw cryo-EM image with box highlighting individual 
RNA cube. Scale bar: 100 Å. A total of 149 raw images of RNA cube were collected 
with a defocus range of 2~4 µm. (b) Classes of the RNA cube as observed by cryo-EM 
with corresponding projections of the reconstructed 3D RNA cube model. (c) 2D class 
averages (top), starting 3D model (middle) and refined 3D model of the RNA cube 
(bottom). Two views of the refined 3D model at two different angles (30 ° rotation) are 
shown in the figure. Scale bar: 100 Å. A total of 5106 particles were used to generate the 
2D class averages for building the initial model, and 4371 particles were used for final 
refinement by applying the octahedron symmetry. 
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Figure 3.9. AFM characterization of the RNA dodecahedron. Left panel shows a typical 
AFM view of the RNA dodecahedron. Right panel shows the magnified view of 
individual RNA dodecahedron. Note that the RNA dodecahedron was collapsed on the 
mica surface after drying, which gave a distorted dimension. Representative results from 
thirty-six raw AFM images are shown. 
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Figure 3.10. AFM characterization of the 2’F-modified RNA dodecahedron. Left panel 
shows a typical AFM view of the 2’F-modified RNA dodecahedron. Right panel shows 
the magnified view of individual 2’F-modified RNA dodecahedron. Note that the 2’F-
modified RNA dodecahedron was collapsed on the mica surface after drying, which gave 
a distorted dimension. It should also be noted that a sharper AFM tip was used for 
imaging the 2’F-modified RNA dodecahedron, so the resolution of the image of the 2’F-
modified RNA dodecahedron was higher and more details of the inner cavities were 
observed. Representative results from fifteen raw AFM images are shown. 
 
  
143	
	
 
Figure 3.11. Cryo-EM characterization of the RNA dodecahedron with single particle 
reconstruction. (a) A representative raw cryo-EM image with box highlighting individual 
RNA dodecahedron. Scale bar: 500 Å. A total of fifty-five raw images were collected 
with a defocus range of 2~5 µm. (b) Reconstructed 3D RNA dodecahedron model. Two 
views of the reconstructed 3D model at two different angles (90 ° rotation) are shown in 
the figure. Scale bar: 200 Å. (c) Classes (denoted as C) of the RNA dodecahedron as 
observed by cryo-EM with corresponding projections (denoted as P) of the reconstructed 
3D RNA dodecahedron model. A total of 1598 particles were used to generate the 2D 
class averages for building the initial models and 991 particles were used for final 
refinement by applying the icosahedral symmetry. 
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Figure 3.12. Determination of the level of immunomodulation by RNA cube 
nanoparticles harboring CpG DNA via ELISA. (a) Determination of the level of TNF-α 
after incubating RNA cube nanoparticles harboring CpG DNA with macrophage RAW 
264.7 cells. The error bars represent standard deviations from three independent wells. 
***: p < 0.001 versus 200 nM DNA CpG only control, unpaired Student's t-test. ****: p 
< 0.0001 versus 200 nM DNA CpG only control, unpaired Student's t-test. The induction 
of TNF-α in RAW 264.7 cells by 50 nM RNA cube harboring 4 CpGs, 50 nM RNA cube 
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only control and 200 nM DNA CpG only control was independently repeated one more 
time with triplicate independent wells for each sample and similar results were observed. 
(b) Determination of the level of IL-6 after incubating RNA cube nanoparticles harboring 
CpG DNA with macrophage RAW 264.7 cells. The error bars represent standard 
deviations from three independent wells. **: p < 0.01 versus 200 nM DNA CpG only 
control, unpaired Student's t-test. ***: p < 0.001 versus 200 nM DNA CpG only control, 
unpaired Student's t-test. ****: p < 0.0001 versus 200 nM DNA CpG only control, 
unpaired Student's t-test. The induction of IL-6 in RAW 264.7 cells by 50 nM RNA cube 
harboring 4 CpGs, 50 nM RNA cube only control and 200 nM DNA CpG only control 
was independently repeated one more time with triplicate independent wells for each 
sample and similar results were observed. 
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Chapter 4: Bottom-up Self-assembly of Molecularly Defined RNA 
Nanowire 
 This chapter is adapted from a manuscript entitled “Bottom-up Self-assembly of 
Molecularly Defined RNA Nanowire” by Hui Li, Kaiming Zhang, Wah Chiu and 
Peixuan Guo. The manuscript is in preparation for submission to Small. Special thanks to 
Dr. Kaiming Zhang for help in preparing Figure 4.2 and 4.3. Author contribution: Dr. 
Kaiming Zhang performed the TEM and cryo-EM imaging under the supervision of Dr. 
Wah Chiu. Hui Li conceived the idea of building RNA nanowire via the modular multi-
domain strategy, designed the 2D sequence and 3D computational model of RNA 
nanowire, performed all the other experiments, analyzed all the data and drafted the 
manuscript. Dr. Peixuan Guo led and supervised the whole study and provided financial 
support.  
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Abstract 
Since the proof-of-concept of RNA nanotechnology in 1998, RNA has been 
shown to be an exceptional and smart biopolymer that can be employed to create 
nanostructures with various conformations and diverse functionalities. In this study, I 
report the design and construction of a molecularly defined RNA nanowire that was only 
assembled from four different 44-nucleotide long single-stranded RNAs by using the 
modular multi-domain strategy. The RNA nanowire can be easily constructed by single-
step annealing. The RNA nanowire was further characterized by cryo-electron 
microscopy, negative staining transmission electron microscopy, atomic force 
microscopy and fluorescent microscopy, confirming the spontaneous self-assembly of the 
RNA nanowire. Interestingly, I also found that the RNA nanowire can self-grow to 
micrometer-scale wire-shaped structure, expanding the horizon of RNA nanostructures to 
RNA microstructures. The reported RNA nanowire can be further explored as the carrier 
for drug delivery or the extracellular matrix for tissue engineering or the conductive 
nanowire after coating with conductive metals. 
 
Keywords: RNA nanotechnology; RNA nanostructures; Nanowire 
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Introduction 
RNA nanotechnology is an emerging research field that utilizes RNA as a unique 
and smart biomaterial to create nanostructures with various conformations and diverse 
functionalities [181]. Previous research has shown that a variety of 2D and 3D RNA 
nanostructures with defined shapes and sizes can be successfully constructed and 
functionalized [36, 54, 93, 111, 113, 116-119, 121, 122, 126, 147]. These RNA 
nanostructures have the potential for many useful applications in biomedical and material 
sciences such as drug delivery and tissue engineering [286]. Here I report the design and 
construction of molecularly defined RNA nanowire with micrometer length by using the 
modular multi-domain strategy [308]. The modular multi-domain strategy has been used 
to assemble DNA tubes and DNA ribbons with tunable width [308]. In my study, I 
applied this modular multi-domain strategy to RNA nanotechnology. Only four different 
44-nucleotide long single-stranded RNAs were designed and used to assemble the RNA 
nanowire. The assembled RNA nanowire has defined 3D structure as revealed by cryo-
EM, negative staining TEM, AFM and fluorescent microscopy. Interestingly, I also found 
that the RNA nanowire can self-grow to micrometer-scale wire-shaped structure based on 
non-covalent RNA base pairing interactions, expanding the horizon of RNA 
nanostructures to RNA microstructures. The reported RNA nanowire can be further 
explored as the carrier for drug delivery, the extracellular matrix for tissue engineering or 
the conductive nanowire after coating with conductive metals. 
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Materials and Methods 
RNA nanowire design, synthesis, and self-assembly 
The NanoEngineer program [306] was used to facilitate the design of the 
molecularly defined RNA nanowire. The modular multi-domain strategy previously 
reported for assembling DNA tubes and DNA ribbons was employed to design the RNA 
nanowire. In addition, different from the DNA double helix, 11 nucleotides per helix turn 
for RNA double helix were used in the design. RNA strands were synthesized by in vitro 
T7 transcription following previously reported procedures. DNA templates for generating 
the RNA strands were made by polymerase chain reactions (PCR). DNA oligo for PCR 
were directly purchased from Integrated DNA Technologies, Inc (Coralville, Iowa, USA). 
For a 50 µl transcription reaction, 10 µl of DNA template with 10 µl of 5× transcription 
buffer, 10 µl of 25 mM NTPs solution, 5 µl of 100 mM DTT, 10 µl of T7 RNA 
polymerase and 5 µl 0.05% (vol/vol) DEPC water were mixed together and incubated at 
37 °C for 4 h. The transcription reaction was stopped by adding 1 µl of DNase I and 
incubating at 37 °C for another 30 min to digest the DNA template. After transcription, 
the RNA strands were purified by 8 M urea and 8% denaturing PAGE. The RNA 
nanowire was self-assembled in a one-pot manner by mixing the four different RNA 
strands in equimolar concentrations (1.4 µM) in 1× TMS buffer and heated to 95 °C and 
slowly cooled down to room temperature. The step-wise self-assembly of the RNA 
nanowire was further verified by a 3% agarose gel.  The gel was stained with ethidium 
bromide (EB) and imaged by Typhoon FLA 7000 (GE Healthcare, Marlborough, MA). 
The detailed sequence for assembling the RNA nanowire are listed below: 
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Nanowire Strand 1: 
5’- GGUGCUACACG CGAUUACAGCU UGUCGAGUAC CGGGCAGUUG AG -3’ 
Nanowire Strand 2: 
5’- GGUUCAGACCG  CGGGAAGAGCC CGUGUAGCAC CAGCUGUAAU CG -3’ 
Nanowire Strand 3: 
5’- GGUGCUGUGUC AGCUGUCAGAA CGGUCUGAAC CGGCUCUUCC CG -3’ 
Nanowire Strand 4: 
5’- GGUACUCGACA  CUCAACUGCCC GACACAGCAC CUUCUGACAG CU -3’ 
 
Atomic force microscopy 
 The RNA nanowire (10 µl at 0.02 mg/ml) was first deposited on a mica surface 
and excess samples were washed with water and dried on room temperature before 
imaging. AFM images were obtained by using a Bruker AXS Dimension Icon 
Atomic/Magnetic Force Microscope with ScanAsyst (Bruker, Billerica, MA) operated in 
tapping mode. 
 
Fluorescent microscopy 
 One RNA strand for assembling the RNA nanowire was labeled by Cy3 by using 
the Label IT® Nucleic Acid Labeling Reagents kit (Mirus Bio LLC, Madison, WI). 
Fluorescent RNA nanowire was assembled by mixing three unlabeled RNA strands with 
one Cy3-labled RNA strand in equimolar concentrations (8 µM) in 1× TMS buffer. The 
mixture was heated to 95 °C and cooled to room temperature. The assembled RNA 
nanowire (1 µL at 8 µM) was further diluted in 1× TMS buffer by 10 times and deposited 
151	
	
on glass slide and observed under 40 × or 20 × objective lens using a fluorescent 
microscope (Olympus Corporation, Tokyo, Japan). 
 
Electron microscopy 
RNA nanowire sample (6 µl at 0.09 mg/ml) was transferred onto the EM grid and 
then the grid was negatively stained with 2% (w/v) uranyl acetate for 10 s. Electron 
micrographs were recorded with a JEOL 2100 transmission electron microscope (JEOL, 
Tokyo, Japan). For cryo-electron microscopy, 2 µl of nanowire sample (0.45 mg/ml) was 
applied onto a glow-discharged 200-mesh R3.5/1 Quantifoil grid. The grid was blotted 
and rapidly frozen in liquid ethane using a Vitrobot IV (FEI, Hillsboro, OR). 
Micrographs were recorded on a 4k × 4k CCD camera (Gatan, Pleasanton, CA) at 
40,000× microscope magnification (corresponding to a calibrated sampling of 2.83 Å per 
pixel) and a dose rate of ~20 e-/s/Å2 with a total exposure time of 3 s. 
 
Results  
Design and self-assembly of the RNA nanowire  
RNA nanowire was designed by adopting the modular multi-domain strategy 
previously reported for assembling DNA tubes and DNA ribbons [308].  However, in 
contrast with DNA that has 10.5 nucleotides per helix turn, the number of nucleotides per 
helix turn is an integer of 11 for A-form RNA. As a result, I have used 11-nucleotide 
sequence as a single domain in our RNA nanowire design. By using the NanoEngineer 
program, I first built the computational model of the RNA nanowire (Figure 4.1a). A 
total of four single-stranded RNA strands were designed consisting of four single 
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domains per RNA strand. The detailed 2D sequence of the RNA nanowire is shown in 
Figure 4.1b. It is expected that these designed RNA domains will base pair with their 
corresponding domains and spontaneously grow in size and finally form RNA nanowire 
with micrometer-scale length. For assembling the RNA nanowire, the four RNA strands 
were synthesized by in vitro transcription and then mixed in stoichiometric ratio and 
annealed in 1×TMS buffer in a one-pot manner. Step-wise assembly of the RNA 
nanowire was observed by a 3% agarose gel, confirming the formation of the high 
molecular weight RNA nanowire (Figure 4.1c). 
 
Imaging of the RNA nanowire by cryo-electron microscopy and negative staining 
transmission electron microscopy 
To further confirm the formation of the RNA nanowire, cryo-electron microscopy 
(EM) was applied to direct image the RNA nanowire. Cryo-EM is a useful technique for 
characterizing the native structure of biological macromolecules including RNA 
molecules [292]. I expected that cryo-EM imaging would provide meaningful data to 
show the native structure of the constructed RNA nanowire. Cryo-EM images indeed 
showed very clear long RNA nanowires with expected width and dimensions (Figure 
4.2). From the cryo-EM images, it could also be observed that two or more RNA 
nanowires could intertwine to from higher order structures. This is plausible since the 
assembly buffer contains magnesium ions, which could shield part of the negative charge 
of the RNA phosphate backbone and induce intertwining of RNA nanowires. 
Moreover, transmission electron microscopy (TEM) was also used to characterize 
the RNA nanowire under negative staining by 2% (w/v) uranyl acetate. Similar to the 
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results obtained by cryo-EM, long RNA nanowires were also observed under negative 
staining TEM as expected (Figure 4.3).  
 
Imaging of the RNA nanowire by fluorescent microscopy 
 Because it was found that the length of the RNA nanowire was in the micrometer 
range as revealed by EM and AFM, I speculated that RNA nanowire could also be 
imaged by fluorescent microscopy. For preparing the fluorescently labeled RNA 
nanowire, one RNA strand was labeled with Cy3 and subsequently mixed with the other 
three non-labeled RNA strands. Under the fluorescent microscope, the RNA nanowire 
can be clearly observed with expected micrometer length, further confirming its 
successful self-assembly (Figure 4.4a). 
 
Imaging of the RNA nanowire by atomic force microscopy  
 Atomic force microscopy (AFM) has been widely used to characterize nucleic 
acid nanostructures [293]. I also applied AFM to characterize the self-assembled RNA 
nanowire. Before AFM imaging, the self-assembled RNA nanowire was deposited on a 
mica surface, washed with water and dried in room temperature. AFM studies of the 
RNA nanowire clearly revealed the shape of the nanowire, which was similar to its 
theoretical prediction (Figure 4.4b). The height of the RNA nanowire was found to be 
around 4 nm, which was consistent with the height of the RNA nanowire under dried 
condition. 
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Discussion and Conclusion 
As a central molecule in molecular biology, RNA not only plays an indispensable 
role in modulating gene expression and maintain the normal flow of genetic information, 
but also can form delicate 3D structures with defined shape and atomic level precision. 
Previous work in RNA nanotechnology has demonstrated that a range of 2D and 3D 
nanostructures can be successfully constructed based on utilizing naturally occurring 
RNA motifs and/or computational design [36, 54, 93, 111, 113, 116-119, 121, 122, 126, 
147]. Specifically, there are some notable previous studies that applied RNA to build 
array- or filament-like structures based on non-covalent RNA-RNA interactions [113, 
121]. For example, Shu et al. reported in 2004 that nanometer scale 3D RNA arrays could 
be constructed by linking pRNA molecules into a chain-like structure via foot-on-foot 
interactions based on palindrome sequences as well as loop–loop interactions [113]. The 
formation of the array was analyzed by PAGE and the structure of the array was further 
confirmed by AFM imaging. Moreover, Nasalean et al. reported in 2006 that micrometer-
scale RNA filaments could be successfully constructed in a controlled manner by using 
H-shaped RNA molecules involving RNA 4WJ, specific hairpin loops and loop–
receptors [121]. Under TEM, the RNA filaments were clearly visualized, confirming the 
successful self-assembly of the designed structure. In this current study, I reported the 
bottom-up self-assembly of molecular defined RNA nanowire by applying the modular 
multi-domain strategy [308] in RNA nanotechnology. The modular multi-domain 
strategy was firstly reported by Yin et al. in DNA nanotechnology to synthesize DNA 
tubes with monodisperse and programmable circumferences [308]. However, comparing 
with DNA, RNA is more structurally diverse and has important biological functionalities 
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that cannot be replaced by DNA. In this regard, I set out to explore the feasibility to 
design and assemble RNA nanowires via the modular multi-domain strategy [308]. 
Notably, since the number of nucleotides per helix turn is 11 for A-form RNA (DNA has 
10.5 nucleotides per helix turn), I designed multiple 11-nucleotide sequences as the 
modular domains for the self-assembly of the RNA nanowire. As revealed in a series of 
characterization experiments including cryo-EM, negative staining TEM, fluorescent 
microscopy and AFM, the constructed RNA nanowire has a defined wire-like 3D 
structure that is in agreement with its theoretical predication. Comparing with previously 
reported RNA array and RNA filaments, this newly designed RNA nanowire was self-
assembled purely based on RNA base pairing and did not involve any naturally occurring 
RNA motifs or junctions. Notably, only four artificially designed short RNA strands were 
used to assembly the RNA nanowire. In summary, this study showcases the expanding of 
the horizon of RNA nanostructures to RNA microstructures by incorporating the modular 
multi-domain strategy previously used in DNA nanotechnology [308]. How to control the 
width and length of the assembled RNA nanowire will be an interesting direction for 
future studies. Moreover, the reported RNA nanowire can be further explored for a 
variety of applications such as the carrier for drug delivery, the extracellular matrix for 
tissue engineering or the conductive nanowire after coating with conductive metals. 
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Figure 4.1. The design and self-assembly of the molecularly defined RNA nanowire. (a) 
The computational model of the RNA nanowire designed by NanoEngineer program. (b) 
2D sequence of the RNA nanowire. The RNA nanowire was assembled from four 
different 44-nucleotide long single-stranded RNAs.  The 5’ and 3’ end of the individual 
single-stranded RNA is labeled in the figure. (c) 3% agarose gel examine the self-
assembly of the RNA nanowire. 100 bp DNA ladder is used as the molecular weight 
marker. The final product (nanowire 1+2+3+4) showed bands with high molecular 
weight (highlighted in the red square), demonstrating successful assembly of the designed 
RNA nanowire. Representative results from three independent experiments are shown. 
158	
	
 
Figure 4.2. Cryo-EM imaging of the RNA nanowire. Left panel shows a typical cryo-EM 
view of the RNA nanowire (scale bar: 100 nm). Right panel shows the magnified view of 
the RNA nanowire (scale bar: 20 nm). Nanowire structures are clearly visible in the 
images. Representative results from a total of seven raw cryo-EM images are shown. 
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Figure 4.3. TEM imaging of the negatively stained RNA nanowire. Two representative 
TEM images from a total of seven raw TEM images are shown. Nanowire structures are 
clearly visible in the images. It is also notable that two or more RNA nanowires could 
intertwine to from higher order structures. Scale bar: 200 nm.  
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Figure 4.4. Fluorescent microscopy and AFM imaging of the RNA nanowire. (a) 
Fluorescent microscopy imaging of the RNA nanowire deposited on a glass slide. Scale 
bar: 50 µm. A representative image from a total of eleven raw fluorescent microscopy 
images is shown. (b) AFM imaging of the RNA nanowire deposited on mica surface. 
Scale bar: 910 nm. A representative image from a total of sixteen raw AFM images is 
shown. Nanowire structures are clearly visible in both fluorescent microscopy and AFM 
images.  
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Chapter 5: Engineering RNA Nanoparticles for Potent 
Immunomodulation 
 Part of this chapter was reproduced (with some modification) with permission 
from Emil F. Khisamutdinov†, Hui Li†, Daniel L. Jasinski†, Jiao Chen, Jian Fu and 
Peixuan Guo. “Enhancing immunomodulation on innate immunity by shape transition 
among RNA triangle, square and pentagon nanovehicles.” Nucleic Acids Res. 2014 Nov 
1; 42(15):9996-10004. †: Joint First Authors. Special thanks to Dr. Emil F. 
Khisamutdinov for help in preparing Figure 5.1 and 5.7, Daniel L. Jasinski in Figure 5.2d, 
5.4 and 5.6a, Dr. Jiao Chen in Figure 5.3b, 5.3c and 5.4, and Dr. Luda Shlyakhtenko in 
Figure 5.2c. Author contribution: Dr. Emil F. Khisamutdinov and Daniel L. Jasinski 
designed and constructed RNA polygon nanoparticles based on the tunable angle of 
pRNA-3WJ. Hui Li conceived the idea of using RNA polygon nanoparticles to deliver 
CpG oligos to immune cells, designed and constructed RNA triangles harboring CpG 
oligos, performed cell and animal testing of RNA polygon nanoparticles harboring CpG 
oligos. Dr. Jiao Chen provided assistance to the ELISA experiments and animal 
experiments under the supervision of Dr. Jian Fu. Dr. Emil F. Khisamutdinov, Hui Li, 
Daniel L. Jasinski and Dr. Peixuan Guo analyzed all the data and drafted the manuscript. 
Dr. Peixuan Guo led and supervised the whole study and provided financial support.  
 
 
 
 
Copyright © Hui Li 2016 
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Abstract 
Modulation of immune response through cytokine induction is a vital process in 
vaccine development and immune therapy. It is desirable to develop potent and non-toxic 
immunomodulators to promote successful cancer immunotherapy. In this study, I report 
the development of novel immunomodulators by engineering rationally designed RNA 
nanoparticles based on the pRNA of the bacteriophage phi29 DNA packaging motor. 
RNA nanoparticles with triangular, square and pentagonal shape could be successfully 
constructed by stretching the angle of the pRNA three-way junction from 60° to 90° or 
108°. When immunoactive CpG oligodeoxynucleotides (ODNs) were incorporated into 
the RNA nanoparticles by DNA-RNA hybridization, their immunomodulation effect for 
cytokine TNF-α and IL-6 induction was greatly enhanced both in vitro and in vivo, while 
RNA nanoparticle controls induced unnoticeable cytokine induction. Moreover, the RNA 
nanoparticles were delivered to macrophages specifically and the degree of 
immunostimulation greatly depended on the size, shape, and the number of payload per 
RNA nanoparticles. Stronger immune response was observed when the number of 
adjuvants per nanoparticle was increased, demonstrating the advantage of shape 
transition of the nanoparticles from triangle into pentagon, which can carry five adjuvants.  
This finding demonstrates that RNA nanotechnology such as developing RNA 
nanoparticles based on pRNA has great potential to develop novel immunomodulators for 
cancer immunotherapy. 
 
Keywords: RNA nanotechnology; pRNA; CpG; Immunomodulator; Immunotherapy 
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Introduction 
Cancer and infectious diseases such as influenza and human immunodeficiency 
virus infection / acquired immunodeficiency syndrome (HIV/AIDS) are still huge threats 
to public health worldwide [309, 310]. Prophylactic and treatment vaccines could offer 
promising opportunities for controlling these diseases [311, 312]. However, despite tens 
of years of extensive research, such vaccines are still far away from completely 
controlling these diseases due to either low effectiveness or safety issues. New strategies 
and approaches in designing and developing new vaccines and adjuvants targeting these 
diseases are urgently needed. CpG oligodeoxynucleotides (ODNs) are a type of 
immunostimulatory DNA molecules containing the CpG motif which is unmethylated 
cytosine-phosphate-guanine dinucleotide with optimized flanking sequence [305]. 
Previous reports have shown that CpG DNA strongly activates mammalian innate 
immune system by interacting with various immune cells via endosomal Toll-like 
receptor 9 (TLR9) [305, 313].  The therapeutic potential of CpG DNA has also been 
explored in a number of clinical applications, including vaccine adjuvants, anticancer 
agents, immunoprotective agents and anti-allergic agents [307, 314]. Recently, several 
groups have reported the utilization of nucleic acid nanostructures to deliver 
immunostimulatory CpG DNA.  However, most of the published reports were using 
DNA nanostructures such as DNA tetrahedron [315], DNA polypod-like structures [316] 
or DNA origami structure [317].  
In this study, I demonstrated that rationally designed RNA nanoparticles, based 
on the pRNA of the bacteriophage phi29 DNA packaging motor [123], have the potential 
to serve as a new generation of delivery system for immunomodulators such as CpG 
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DNA. By stretching the angle of the pRNA three-way junction from 60° to 90° or 108°, 
RNA nanoparticles with triangular, square and pentagonal shapes could be successfully 
constructed. When immunoactive CpG ODNs were further incorporated into the RNA 
triangular, square and pentagonal nanoparticles by DNA-RNA hybridization, their 
immunomodulation effect for cytokine TNF-α and IL-6 induction was greatly enhanced 
both in vitro and in vivo, while RNA nanoparticle controls induced unnoticeable cytokine 
induction. Moreover, the RNA nanoparticles were delivered to macrophages specifically 
and the degree of immunostimulation greatly depended on the size, shape, and the 
number of payload per RNA nanoparticles. Stronger immune response was observed 
when the number of adjuvants per nanoparticle was increased, demonstrating the 
advantage of shape transition of the nanoparticles from triangle into pentagon which can 
carry five adjuvants. This finding suggested that RNA nanotechnology such as 
developing RNA nanoparticles based on pRNA has great potential to develop novel 
immunomodulators. To the best of my knowledge, I reported the first time the use of 
RNA nanostructures derived from bacterial phage Phi29 pRNA to deliver CpG DNA. 
 
Materials and Methods 
RNA nanoparticles design, synthesis, and self-assembly 
The 3WJ crystal structure of the pRNA molecule (PDB ID: 4KZ2) [54] was 
primarily used for designing polygon models using Swiss PDB viewer, as previously 
described [36]. RNA strands for corresponding nanoparticles were synthesized by in vitro 
T7 transcription using polymerase chain reaction (PCR) generated DNA templates. DNA 
oligo for PCR were directly ordered from Integrated DNA Technologies, Inc. (Coralville, 
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IA). For generating 2’-F modified RNA polygons, Y693F mutant T7 polymerase and 2’-
F modified cytosine (C) and uracil (U) nucleotides were used to synthesize the 
corresponding RNA strands. RNAs were further purified by denaturing 8M urea 8% 
PAGE. Cy5 whole chain labeled RNA was prepared by using Cy5 Label IT® Kit (Mirus 
Bio LLC, Madison, WI). Cy3-labeled CpG DNA was ordered from Integrated DNA 
Technologies, Inc. (Coralville, IA). In this Cy3-labeled CpG DNA, Cy3 was conjugated 
to the 5’ end of the DNA through a phosphate bond. RNA nanoparticles self-assembly 
was examined by running a 2% agarose gel. The gel was stained with ethidium bromide 
(EB) and imaged by Typhoon FLA 7000 (GE Healthcare, Marlborough, MA). 
The detailed sequence to construct the RNA triangle harboring three CpG ODNs 
are listed below: 
Sequence Name Sequence 
Triangle-A 
RNA 
5’- GGGCCGUCAAUCAUGGCAAGUGUCCGCCAUACUUUG 
UUGCACGCCCUCGGAAUGCAAUACGACUGUA -3’ 
Triangle-B 
RNA 
5’ - GGGCGUGCAAUCAUGGCAACGAUAGAGCAUACUUUG 
UUGGCUGGCCUAGUUGGAAAUGGCGGUAUG G -3’ 
Triangle-C 
RNA 
5’ - GGCCAGCCAAUCAUGGCAAUAUACACGCAUACUUUG 
UUGACGGCCCAGUUAAACAUCGCAUGUGCUU -3’ 
Triangle-D 5’- GGACACUUGUCAUGUGUAUGCGUGUAUAUUGUCAUG 
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RNA UGUAUGCUCUAUCGUUGUCAUGUGUAUGGC -3’ 
CpG-A DNA 5’- TCCATGACGTTCCTGACGTTTTTTTTACAGTCGTATT 
GCATTCCGA -3’ 
CpG-B DNA 
 
5’- TCCATGACGTTCCTGACGTTTTTTTCCATACCGCCATT 
TC CAACTA -3’ 
CpG-C DNA  5’- TCCATGACGTTCCTGACGTTTTTTTAAGCACATGCGA 
TGTTTAACT -3’ 
The detailed sequences to construct the shape transition (triangle to square to 
pentagon) nanoparticles harboring CpG ODNs are listed below: 
Sequence 
Name 
Sequence 
CPG-TRI-A 
(for triangle) 
5’- GGGAGCCGUCAAUCAUGGCAAGUGUCCGCCAUA 
CUUUGUUGCACGCUCUCUCGGAAUGCAAUACGACUGUA -3’ 
CPG-TRI-B 
(for triangle) 
5’- GGGAGCGUGCAAUCAUGGCAACGAUAGAGCAUACUUU 
GUUGGCUGGUCUCUAGUUGGAAAUGGCGGUAUGG -3’ 
CPG-TRI-C 
(for triangle) 
5’- GGGACCAGCCAAUCAUGGCAAUAUACACGCAUACUUU 
GUUGACGGCUCUCAGUUAAACAUCGCAUGUGCUU -3’ 
TRI-D 5’- GGACACUUGUCAUGUGUAUGCGUGUAUAUUGUC 
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(for triangle) AUGUGUAUGCUCUAUCGUUGUCAUGUGUAUGGC -3’ 
CPG-SQR-A 
(for square) 
5’- GGGAGCCGUCAAUCAUGGCAAGUGUCCGCCAUA 
CUUUGUUGCACGCUCUCUCGGAAUGCAAUACGACUGUA -3’ 
CPG-SQR-B 
(for square) 
5’- GGGAGCGUGCAAUCAUGGCAAGCGCAUCGCAUACUUU 
GUUGCGACCUCUCAUUGAUCUAUGAUCGUACGAU -3’ 
CPG-SQR-C 
(for square) 
5’- GGGAGGUCGCAAUCAUGGCAACGAUAGAGCAUACUUU 
GUUGGCUGGUCUCUAGUUGGAAAUGGCGGUAUGG -3’ 
CPG-SQR-D 
(for square) 
5’- GGGACCAGCCAAUCAUGGCAAUAUACACGCAUACUUU 
GUUGACGGCUCUCAGUUAAACAUCGCAUGUGCUU -3’ 
SQR-F 
(for square) 
5’- GGACACUUGUCAUGUGUAUGCGUGUAUAUUGUC 
AUGUGUAUGCUCUAUCGUUGUCAUGUGUAUGCGAUGCGC
UUGUCAUGUGUAUGGC -3’ 
CPG-PENT-A 
(for pentagon) 
5’- GGGAGCCGUCAAUCAUGGCAAGUGUCCGCCAUACUUU 
GUUGUAGGGUCUCAUGUUAAGUAACGUCUAGAAU -3’ 
CPG-PENT-B 
(for pentagon) 
5’- GGGACCCUACAAUCAUGGCAAAUAUGCGCCAUACUUU 
GUUGCACGCUCUCGAAAGCUUGUAGCUAUAGUUA -3’ 
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CPG-PENT-C 
(for pentagon) 
5’- GGGAGCGUGCAAUCAUGGCAAGCGCAUCGCAUACUUU 
GUUGCGACCUCUCAUUGAUCUAUGAUCGUACGAU-3’ 
CPG-PENT-D 
(for pentagon) 
5’- GGGAGGUCGCAAUCAUGGCAACGAUAGAGCAUACUUU 
GUUGGCUGGUCUCUAGUUGGAAAUGGCGGUAUGG -3’ 
CPG-PENT-E 
(for pentagon) 
5’- GGGACCAGCCAAUCAUGGCAAUAUACACGCAUACUUU 
GUUGACGGCUCUCAGUUAAACAUCGCAUGUGCUU -3’ 
PENT-F 
(for pentagon) 
5’- GGACACUUGUCAUGUGUAUGCGUGUAUAUUGUCAUGU 
GUAUGCUCUAUCGUUGUCAUGUGUAUGCGAUGCGCUUGU
CAUGUGUAUGGCGCAUAUUUGUCAUGUGUAUGGC -3’ 
CPG-A 5’- TCCATGACGTTCCTGACGTTTTTTTTACAGTCGTAT 
TGCATTCCGA -3’ 
CPG-B 5’- TCCATGACGTTCCTGACGTTTTTTTCCATACCGCCA 
TTTCCAACTA -3’ 
CPG-C 5’- TCCATGACGTTCCTGACGTTTTTTTAAGCACATGCG 
ATGTTTAACT -3’ 
CPG-D 5’- TCCATGACGTTCCTGACGTTTTTTTATCGTACGATC 
ATAGATCAAT -3’ 
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CPG-E 5’- TCCATGACGTTCCTGACGTTTTTTTATTCTAGACGT 
TACTTAACAT -3’ 
CPG-F 5’- TCCATGACGTTCCTGACGTTTTTTTTAACTATAGCT 
ACAAGCTTTC -3’ 
RNA polygons were assembled in one pot by mixing equimolar concentrations 
(final concentration of 1 µM) of the corresponding RNA strands in 1× TMS buffer (50 
mM TRIS pH = 8.0, 100 mM NaCl, and 10 mM MgCl2). Samples were annealed for 1 h 
by controlled slow cooling from 80 °C to 4 °C.    
 
Dynamic light scattering  
Apparent hydrodynamic sizes of RNA nanoparticles (10 µM) in 50µL 1× TMS 
buffer were measured by Zetasizer nano-ZS (Malvern Instruments, Ltd, Malvern, United 
Kingdom) at 25 °C. The laser wavelength was 633 nm. The intensity distribution was 
used to calculate the sizes of the nanoparticles. 
 
Atomic force microscopy imaging 
RNA triangles harboring CpG DNAs were imaged by AFM following previously 
reported methods [293]. Briefly, the RNA samples were diluted with 1 × TMS buffer to a 
final concentration of 3-5 nM. Then, the droplet of samples (5-10 µL) was immediately 
deposited on APS-modified mica surface. After 2 min incubation on the surface, excess 
samples were washed with DEPC-treated water and dried under a flow of Argon gas. 
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AFM images in air were acquired using MultiMode AFM NanoScope IV system 
(Veeco/Digital Instruments, Santa Barbara, CA) operating in tapping mode. 
 
Cell cultures 
Mouse macrophage-like RAW 264.7 cells were grown in Dulbecco's Modified 
Eagle's Medium supplemented with 10% fetal bovine serum, 1% penicillin–streptomycin 
at 37 °C in humidified air containing 5% CO2. Cells were then seeded on 24-well plates 
or 96-well plates at the density of 5 × 105 cells/mL and cultured overnight before use. 
 
Cytokine secretion from RAW 264.7 cells 
RAW 264.7 cells were plated into 24-well plates with the density of 2.5 × 105 
cells per well and cultured overnight. Then RNA nanoparticles harboring different 
numbers of CpG ODNs were diluted in Opti-MEM medium (Life Technologies 
Corporation, Carlsbad, CA) and then added to the cells. The cells were continually 
cultured for 8 hours at 37 °C in humidified air containing 5% CO2, and the cell culture 
supernatant were collected and stored at -80 °C until use. The concentration of TNF-α 
and IL-6 in the supernatant were determined by enzyme-linked immunosorbent assay 
(ELISA) using Mouse ELISA MAX™ Deluxe sets (BioLegend, Inc., San Diego, CA), 
following protocols provided by the manufacturer. At least three independent wells were 
tested for each nanoparticle and control samples. 
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Confocal microscopy imaging 
RAW 264.7 cells were seeded on glass coverslips in 24-well plates and cultured at 
37 °C in humidified air containing 5% CO2 overnight. The culture medium was removed 
and the cells were washed with Opti-MEM medium twice to remove dead cells. RNA 
nanoparticles harboring Cy3-labeled CpG DNA or Cy3-labled CpG DNA only were 
diluted in Opti-MEM medium and added to the cells. After 4 hour incubation at 37 °C in 
humidified air containing 5% CO2, the cells were washed twice with PBS and fixed with 
4% formaldehyde. ProLong® Gold Antifade Reagent with DAPI (Life Technologies 
Corporation, Carlsbad, CA) was used to stain the cell nucleus and mount the samples. 
Alexa Fluor® 488 phalloidin (Life Technologies Corporation, Carlsbad, CA) was used to 
stain actin. The images were obtained by using Olympus FV1000 confocal microscope or 
Olympus fluorescent microscope (Olympus Corporation, Tokyo, Japan). 
 
Flow cytometry assay 
RAW 264.7 cells were detached from the cell culture flask by using a cell scraper. 
The cells were washed with Opti-MEM medium and aliquot in 1.5 mL eppendorf tubes at 
the density of 5 × 105 cells per tube. RNA nanoparticles harboring Cy3-labled CpG DNA 
or Cy3-labled CpG DNA only were diluted in Opti-MEM medium and incubated with the 
cells at 37 °C for 1.5 hour. The cells were vertexed every 30 minutes during the 
incubation. After washing with PBS, the cells were resuspended in PBS and the intensity 
of fluorescence was determined by FACSCalibur flow cytometer (BD Biosciences, San 
Jose, CA). 
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Serum stability assay of RNA polygons harboring CpG DNA 
Preassembled complexes (1 µM) of RNA triangle, square and pentagon (2’-F 
modified) harboring DNA CpG were incubated in RPMI-1640 medium containing 10% 
fetal bovine serum. Aliquots (10 µL) were taken at 0 hr, 1 hr, 3 hr, 6 hr, 8hr and 16 hr 
time points after incubation at 37 °C, followed by analysis using 6% native PAGE gels. 
The gel was further stained with ethidium bromide (EB) and imaged by Typhoon FLA 
7000 (GE Healthcare, Marlborough, MA). 
 
Cytotoxicity assay 
The cytotoxicity of RNA nanoparticles harboring CpG ODNs was evaluated by 
the MTT assay kit (Promega, Madison, WI), according to the protocol provided by the 
manufacturer. Briefly, RAW 264.7 cells were seeded at 96 well plates and cultured at 
37 °C in humidified air containing 5% CO2 overnight. RNA nanoparticles harboring CpG 
ODNs and controls were dissolved in fresh cell culture medium at the indicated 
concentrations and added to the cells for incubation at 37 °C for 24 hours. Then 15 µL of 
the dye solution was added to each well, followed by 4 hour incubation at 37 °C, Next, 
100µl of the solubilization solution was added to each well and the plate was future 
incubated at room temperature on a plate shaker until the formazan crystals were 
completely solubilized. The absorbance was measured at 570 nm using a microplate 
reader. The cell viability was calculated relative to the absorbance of the cell only control 
(viability of cell only control = 1). At least three independent wells were tested for each 
sample.  
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For cytotoxicity assay on KB cells, RNA nanoparticles harboring CpG ODNs and 
control samples were incubated with KB cells for 16 hours (two independent wells for 
each sample). After 16 hours, cell viability was examined by the MTT assay kit (Promega, 
Madison, WI), following the previously described procedure. 
  
Cytokine secretion from mice 
Male CD-1 mice (4-5 week old) were purchased from Charles River Laboratories. 
All animal procedures were approved by the Institutional Animal Care and Use 
Committee at University of Kentucky and were performed in accordance with guidelines 
issued by the National Institutes of Health for the care of laboratory animals. For in vivo 
immunostimulation, RNA triangular nanoparticles harboring CpG ODN, RNA triangular 
nanoparticles, or CpG ODN were dissolved in PBS and administrated to the mice via tail 
vein injection at 2 mg/kg (CpG ODN per body weight). The same volume of PBS was 
injected as a control. Blood samples were collected 3 hours post-injection by cardiac 
puncture. Serum was prepared by centrifugation at 12800 g for 10 min. Serum TNF-α 
and IL-6 levels were determined by enzyme-linked immunosorbent assay (ELISA) using 
Mouse ELISA MAX™ Deluxe sets (BioLegend, Inc., San Diego, CA), following 
protocols provided by the manufacturer. Two independent measurements of the cytokine 
levels from serum aliquots of the tested mouse were performed. 
 
Statistical analysis 
The results were presented as mean ± standard deviation. Statistical differences 
were evaluated using unpaired Student’s t-test, and p<0.05 was considered significant. 
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Results 
Design of RNA triangles harboring CpG DNA 
The structural features of the recently discovered ultrastable pRNA 3WJ module 
from the bacteriophage Phi 29 DNA packaging motor [54] were utilized for in silico 
design of the RNA triangles (Figure 5.1a). The particular angle of the 3WJ formed by 
H1 and H2 is 60 °, which can be used to build a triangular shape nanoparticle [36] as the 
normal triangle also has the internal angle of 60 ° (Figure 5.1b). Each RNA triangle 
contained a pRNA 3WJ motif at each vertex. Each triangle was composed of three 
external short RNA strands and one internal long RNA strand. For the construction of 
RNA triangles harboring CpG DNA, I designed extended external short strands with 
sticky ends for RNA-DNA hybridization. I hypothesized that the RNA sticky ends will 
base pair with the CpG DNA with DNA sticky ends and form hybrid RNA-DNA 
nanoparticles. A schematic design of the RNA triangle nanoparticle harboring 3 CpG 
DNAs is shown in Figure 5.2a. In Figure 5.2a, the RNA sequence for the assembly of 
the RNA triangle is marked in blue color, and RNA sticky ends for DNA-RNA 
hybridization is marked in green color, and CpG DNA is marked in red color. I 
hypothesized that when these designed RNA and DNA strands mixed together, a 
triangular RNA nanoparticle with CpG DNA at each end will be successfully self-
assembled. 
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Construction and physicochemical characterization of RNA triangles harboring 
CpG DNA 
RNA triangles harboring CpG DNA were assembled in one pot by mixing 
equimolar concentrations (final concentration of 1 µM) of four RNA strands and three 
DNA strands in 1X TMS buffer. To evaluate the step-wise self-assembly of the designed 
RNA nanoparticles, Cy5-labeld RNA triangle D strand and a 2% agarose gel was used 
(Figure 5.2b). Specifically, the image under Cy5 channel demonstrated the participation 
of triangle D strand in all the assembly intermediates as well as the final products. The 
image under EB channel showed the successful assembly of the designed RNA 
nanoparticle. 
To further evaluate the size and shape of the resulting RNA assemblies, structural 
characterization of RNA triangles harboring CpG DNA was conducted by atomic force 
microscopy (AFM). AFM images revealed that the shapes of resulting RNA 
nanoparticles were similar to their predicted 3D models (Figure 5.2c). In addition, the 
elongated arms of each RNA nanoparticle are clearly visible, demonstrating the 
successful incorporation of the designed DNA strands into the RNA triangles. The 
estimated average size was found to be around 20 nm. However, this value does not 
reflect the true size of the designed RNA nanoparticles due to the AFM tip convolution.  
DLS was performed to determine the apparent hydrodynamic size for RNA 
triangles harboring three CpG ODNs (Figure 5.2d). The diameter was found to be 14.2 ± 
0.8 nm based on the intensity distribution, which agreed with its corresponding 3D model. 
However, there was a difference between the sizes determined by AFM and DLS. This 
could be attributed to the different mechanism in determining nanoparticle size as DLS 
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calculates the average size of nanoparticles in solution assuming that the nanoparticles 
have globular shapes, while AFM imaging can produce larger images of the nanoparticles 
because of the size of the used AFM tip. However, the sizes determined by the two 
techniques were in agreement with our designed dimension of the nanoparticles.    
 
Evaluation of the interaction between RNA triangles harboring CpG DNA and 
macrophage cells 
CpG oligonucleotide is a ligand for TLR-9 [305, 313], and previous studies have 
found that it can be used as vaccine adjuvant or immunotherapy reagent for disease 
control and treatment [307, 314, 318]. To evaluate whether the RNA triangles can 
enhance the efficacy of CpG DNA, I further studied the interaction of the designed RNA 
nanoparticles with macrophage cells. Using the mice microphage-like RAW 264.7 cells 
as the model, I evaluated the cell binding and entry by using flow cytometry (Figure 
5.3a). The flow cytometry experiment revealed that RNA triangle nanoparticles 
significantly enhance cellular binding and entry of CpG DNA. Moreover, the level of 
inflammatory cytokine TNF-α excretion by the cells when they were incubated with the 
RNA triangles and CpG DNA was measured by using the enzyme-linked immunosorbent 
assay (ELISA) (Figure 5.3b). As shown in Figure 5.3b, compared with cells treated with 
triangle only and CpG DNA only, cells treated with CpG DNA loaded triangle showed 
significantly increased TNF-α level. And this activity also shows good dosage-response 
relationship (Figure 5.3c), as higher concentration of nanoparticles induced higher level 
of TNF-α.  
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Comparison of the modulation effect of RNA triangle, square, and pentagon 
nanoparticles harboring CpG DNA 
  By increasing the number of external strands and the propagation of the central or 
internal strand, the tension on the inter-helical angle of the pRNA three-way junction 
could be increased to 90 ° and 108 °, allowing for the structural transition of RNA 
triangles to squares and pentagons. To evaluate whether the different shape of RNA 
polygons could affect the immunomodulation effect, we designed and constructed new 
RNA polygons harboring different numbers of CpG DNAs. Similar to the experiments 
described above, the immunostimulatory efficacy of different RNA polygons was 
evaluated by measuring the release of cytokines after addition to mouse macrophage-like 
RAW 264.7. The triangular RNA nanoparticle coupled with only one CpG exhibited the 
highest level of cytokine induction for both TNF-α and IL-6 comparing to square and 
pentagonal RNA nanoparticles (Figure 5.4a).  Upon increasing the number of CpG per 
nanoparticle there is opposite effect, as pentagonal RNA nanocarrier showed the highest 
level of the induction of both TNF-α and IL-6 (Figure 5.4b). The results suggest that the 
cytokine release by CpG coupled to RNA polygons with different shape remarkably 
increases the immunostimulatory activity compared to CpG alone. RNA nanoparticles 
with the size of about 10-nm such as the triangle with a single CpG induced the greatest 
amount of TNF-α and IL-6. In addition, the induction of cytokines is highly dependent on 
the number of CpG per polygon. With the increasing number of CpG per polygon, 
stronger immune response is observed, demonstrating the advantage of the transition of 
triangle into pentagon which can carry five CpG (Figure 5.4c). Moreover, I also 
evaluated the toxicity of the tested RNA nanoparticles by MTT assay. The toxicity assay 
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revealed that no significant cytotoxicity was induced on RAW 264.7 cells upon the 
incubation with the tested RNA nanoparticles (Figure 5.5). Furthermore, a similar 
cytotoxicity assay was performed one more time by using KB cells, and similar results 
were observed (Appendix 3, Supplementary Figure 3). 
 
Comparison of cellular uptake by different RNA polygons harboring CpG DNA 
Previously, it has been demonstrated that the CpG oligonucleotide can be readily 
recognized by TLR9 on the endosomal membrane of macrophages, resulting in cellular 
uptake of the CpG adjuvants [319, 320]. To investigate whether there is a difference 
between the efficiency of RNA polygons binding to the cells, I quantified the cellular 
uptake of polygons-CpG by using the flow cytometric assay [124, 125]. Figure 5.6a 
demonstrates the binding of different RNA polygons-CpG to the RAW 264.7 cells in a 
dose-dependent manner. Results demonstrate that there is an increase in binding 
efficiency from triangle to pentagon with more CpGs. Overall, RNA polygons-CpG 
complexes have significantly more binding efficiency to cells compared to CpG only.  
This observation was further confirmed by confocal microscope images (Figure 
5.6b) revealing that RNA nanoparticle harboring CpGs are localized in the cytoplasm 
exclusively and there are much higher amounts of triangular nanoparticles inside the cell 
compared to free CpG, suggesting that RNA nanoparticles could efficiently enhance the 
cellular uptake of the CpG adjuvants.  
Collectively, both flow cytometry and confocal microscope imaging results 
demonstrate that all RNA nanoparticles with different shape and harboring CpGs have 
much stronger binding and cellular entry to the macrophage-like RAW 264.7 cells 
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compared to free CpGs. In addition, cellular uptake is highly dependent on the number of 
CpG per polygon. With the increasing number of CpG per polygon, more efficient cell 
entry is observed (Figure 5.6a), demonstrating the advantage of the transition of triangle 
into pentagon which can carry five CpG. Notably, all RNA polygons-CpG complexes 
still can be detected in the gel after 16 h incubation in 10% fetal bovine serum (FBS) 
indicating robustness of the assembled complex in extracellular environment (Figure 5.7). 
 
Enhancement of modulation effect in vivo by immunological CpG DNA adjuvant 
incorporated into RNA nanoparticles 
 To examine whether RNA nanoparticles retain their immunostimulatory activity 
in vivo, CpG DNA containing triangle, free triangle and free CpG DNA were 
administered to CD-1 mice by injection into the tail vein at 2 mg/kg (CpG 
oligonucleotide per body weight), following determination of cytokine TNF-α and IL-6 
levels after 3 hour post administration in collected blood serum. Figure 5.4d shows that 
free triangle nanoparticle and free CpG did not induce any cytokine production, whereas 
the complex triangle-CpG resulted in elevated levels of both cytokines. The difference in 
immunostimulatory activity of triangle-CpG was estimated to be 10-fold comparing to 
free CpG in vivo. These data are in agreement with the in vitro stimulation of murine 
RAW 264.7 cells. Furthermore, a confirmatory follow-up animal trial was also performed 
by using square-CpG nanoparticles, and similar immunostimulatory activity were 
observed (Appendix 2, Supplementary Figure 2). 
 
 
180	
	
Discussion 
Previous studies have demonstrated that rationally designed RNA nanoparticles 
can be used as potent multifunctional nanocarriers for delivery of therapeutics [73, 124, 
125]. In this study, I demonstrated that rationally designed RNA polygons have the 
potential to serve as multivalent nanocarriers of vaccine adjuvants and particularly of 
CpG ODNs [305]. The designed RNAs self-assemble into distinct non-toxic 
homogeneous nanoparticles. I also found that size and shape of the RNA nanostructures 
are important factors for the induction of immune responses. There is a correlation 
between the RNA size and the number of CpGs that can be incorporated. The highest 
level of secretion of pro-inflammatory cytokines TNF-α, IL-6 was obtained with the 
smallest triangle nanoparticle harboring one CpG compared to square and pentagon 
nanoparticles. However, upon increasing the numbers of CpG per RNA nanoparticle the 
cytokines induction was affected more by pentagon. This study illustrates the importance 
of the size and shape of RNA nanoparticles for improvement of activity of CpG based 
vaccines targeting infectious diseases and cancer cells as well as for an increase immune-
response by the innate and adaptive immune systems. The RNA nanoparticles harboring 
CpGs are effective, versatile and easy to manufacture, offering new solutions to address 
the unmet needs in current vaccines and adjuvants development.  
In summary, the development of RNA nanoparticles for delivering CpG DNA as 
novel vaccine adjuvants can provide several advantages: (1) The RNA nanoparticle-based 
adjuvants have defined size, structure and stoichiometry. (2) Due to the multivalent 
nature of RNA nanoparticles, multiple antigen and adjuvants could be incorporated into 
one nanoparticle for achieving synergistic or enhanced immune repose such as cytokine 
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induction and antibody production. (3) Nanosize of the particles will facilitate tissue 
penetration and target to important immune tissues or organs such as lymph nodes for 
achieving targeted and enhanced immune stimulation. (4) Multiple targeting ligands 
could be incorporated into one particle for achieving better targeting to immune cells 
such as B cells, T cells, dendritic cells and macrophages. (5) RNA nanoparticles are also 
thermodynamically stable. For example, the three-way junction RNA nanoparticles are 
resistant to denaturation in 8 M urea and do not dissociate at ultra-low concentrations 
[124]. (6) The cellular uptake of the RNA nanoparticle-based adjuvants is greatly 
enhanced compared to CpG DNA only. The immune response induced by the RNA 
nanoparticle-based adjuvants is also greatly enhanced compared to CpG DNA only.  
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Figure 5.1. Structural features of the pRNA 3WJ motif. (a) Secondary structure of 3WJ 
motif with base pairs annotated using Leontis-Westhof nomenclature [321]. (b) Tertiary 
structure of 3WJ motif with indication of ∠AOB ~ 60 ° angle formed between H1 and 
H2. Angle corresponds to inner angles of polygons.  
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Figure 5.2. Design, construction and characterization of RNA triangles harboring CpG 
DNA. (a) Schematic illustration of the design and self-assembly of RNA triangles 
harboring CpG DNA. (b) 2% agarose gel showing the step-wise self-assembly of the 
designed RNA nanoparticles. Cy5 channel showing the incorporation of Cy5 Triangle D 
strands into the RNA nanoparticles. EB channel showing the step-wise self-assembly of 
the total RNA and DNA strands. Representative results from at least two independent 
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experiments are shown. (c) AFM images of RNA triangles harboring CpG DNA. 
Representative results from a total of ten raw AFM images are shown. (d) The size of 
RNA triangles harboring CpG DNA determined by DLS. Representative results from 
three independent measurements are shown. 
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Figure 5.3. Evaluation of the interaction between RNA triangles harboring CpG DNA 
and macrophage-like RAW 264.7 cells. (a) Evaluation of the cell binding and entry by 
flow cytometry. Representative results from at least two independent experiments are 
shown. (b) Determination of TNF-α level in cell culture supernatant by ELISA. The error 
bars represent standard deviations from three independent wells. ****: p < 0.0001 versus 
150 nM DNA CpG only control, unpaired Student's t-test. The induction of TNF-α by 
triangle-CpG, triangle only control and CpG DNA only control was independently 
repeated two additional times with triplicate independent wells for each sample and 
similar results were observed. (c) Concentration study of RNA triangles harboring CpG 
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DNA. The error bars represent standard deviations from three independent wells. *: p < 
0.05 versus 12.5 nM Triangle-CpG control, unpaired Student's t-test. ***: p < 0.001 
versus 12.5 nM Triangle-CpG control, unpaired Student's t-test.  
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Figure 5.4. Effect of cytokine induction in macrophage-like RAW 264.7 cells and mice 
by RNA polygons harboring CpG DNA and RNA polygons control. (a) Induction of 
188	
	
TNF-α in RAW 264.7 cells by 50 nM RNA polygons harboring one CpG or multiple 
CpGs. The error bars represent standard deviations of measurements from three 
independent wells. **: p < 0.01 versus 250 nM DNA CpG only control, unpaired 
Student's t-test. ****: p < 0.0001 versus 250 nM DNA CpG only control, unpaired 
Student's t-test. The induction of TNF-α in RAW 264.7 cells by 50 nM RNA square 
harboring 4 CpGs, 50 nM RNA square only control and 200 nM DNA CpG only control 
was independently repeated at least three additional times with triplicate independent 
wells for each sample and similar results were observed. (b) Induction of IL-6 in 
RAW264.7 cells by 50 nM RNA polygons harboring one CpG or multiple CpGs. The 
error bars represent standard deviations from three independent wells. **: p < 0.01 versus 
250 nM DNA CpG only control, unpaired Student's t-test. ***: p < 0.001 versus 250 nM 
DNA CpG only control, unpaired Student's t-test. ****: p < 0.0001 versus 250 nM DNA 
CpG only control, unpaired Student's t-test. The induction of IL-6 in RAW 264.7 cells by 
50 nM RNA square harboring 4 CpGs, 50 nM RNA square only control and 200 nM 
DNA CpG only control was independently repeated at least three additional times with 
triplicate independent wells for each sample and similar results were observed. (c) 
Increase of TNF-α induction in RAW 264.7 cells with increasing number of CpGs per 
RNA square or pentagon. The error bars represent standard deviations from three 
independent wells. For RNA square samples: ***: p < 0.001 versus 200 nM DNA CpG 
only control, unpaired Student's t-test. ****: p < 0.0001 versus 200 nM DNA CpG only 
control, unpaired Student's t-test. For RNA pentagon samples:  **: p < 0.01 versus 250 
nM DNA CpG only control, unpaired Student's t-test. ****: p < 0.0001 versus 250 nM 
DNA CpG only control, unpaired Student's t-test. (d) Immunostimulatory activity by 
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triangle-CpG nanoparticles in animal model. The error bars represent the range from two 
independent measurements of the cytokine levels from serum aliquots of the tested mouse. 
**: p < 0.01 versus 2 mg/kg DNA CpG only control, unpaired Student's t-test. ***: p < 
0.001 versus 2 mg/kg DNA CpG only control, unpaired Student's t-test. A confirmatory 
follow-up animal trial was performed by using square-CpG nanoparticles, and similar 
results were observed (Appendix 2, Supplementary Figure 2). 
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Figure 5.5. Effect of RNA triangle harboring CpG DNA, triangle control and CpG DNA 
only control on RAW 264.7 cell viability. The cells were incubated with different 
concentrations (200 nM, 100 nM, 50 nM and 25 nM) of RNA triangles only, RNA 
triangles harboring 3 CpGs and CpG only. The error bars represent standard deviations 
from three independent wells. *: p < 0.05 versus cell only control, unpaired Student's t-
test. ns: non-significant, unpaired Student's t-test. A similar cytotoxicity assay was 
performed one more time by using KB cells, and similar results were observed (Appendix 
3, Supplementary Figure 3). 
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Figure 5.6. Comparison of RNA polygon-CpG complexes binding to the RAW 264.7 
cells. (a) The plot represents the summary of the flow cytometry data showing RNA 
nanoparticles binding to the cell in a dose dependent manner. Data was from one 
experiment, and four different concentrations of each sample and CpG DNA only control 
were tested in this experiment. The cell binding of triangle-3CpGs and CpG DNA only 
control was assayed by flow cytometry for two additional times and similar results were 
observed. (b) Confocal images showing the binding comparison of the triangle-CpG and 
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CpG only control to the RAW 264.7 cells by co-localization of nucleus (blue), actin 
(green), and CpGs (red) signals. Representative results from two independent 
experiments are shown. 
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Figure 5.7. Serum stability assay of RNA polygons harboring CpG DNA. Preassembled 
complexes (1 µM) of 2’-F modified RNA triangle, square and pentagon harboring CpG 
DNA were incubated in RPMI-1640 medium containing 10% fetal bovine serum. 
Aliquots (10 µL) were taken at 0 hr, 1 hr, 3 hr, 6 hr, 8hr and 16 hr time points after 
incubation at 37 °C, followed by analysis using 6% native PAGE gels. Data was from 
one experiment. A similar serum stability assay was performed one more time for RNA 
triangle harboring CpG DNA, and similar results were observed. Moreover, similar 
serum stability assays have also been performed for other 2’F-modified RNA 
nanoparticles for numerous times, and similar results were also observed and published 
previously [124, 125, 174].  
Pentagon-CpG 
Square-CpG 
Triangle-CpG 
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Chapter 6: Conclusions and Perspectives 
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  In the final chapter of this dissertation, I review the main conclusions of this 
dissertation and discuss the directions of future work in RNA nanotechnology and RNA 
nanomedicine. 
 
Conclusions 
The emerging field of RNA nanotechnology, which is the study of RNA 
nanostructures constructed by utilizing inter-RNA interactions, has opened a new arena in 
nanotechnology and nanomedicine. Indeed, RNA can offer several advantages for 
building controllable nanostructures with diverse applications. On one hand, RNA is 
almost as simplistic as DNA in terms of base pairing. Like DNA, RNA also has four 
different bases A, C, U and G, and most interactions between these bases can be 
predicted. On the other hand, RNA also has diverse folding and functions like protein. 
For example, many bulges, loops, pseudoknots and non-canonical base pairing exist in 
RNA structures that are critical to their biological activities [12, 29-32]. Moreover, many 
new biological functions have been discovered recently with RNA especially non-coding 
RNA [322]. For example, siRNA [323] and miRNA [324, 325] can be used to silence 
specific genes. Ribozymes can catalyze specific biochemical reactions [326, 327]. 
Riboswitches [328] and long non-coding RNAs [329] play important roles in gene 
regulation. Guide RNAs (gRNAs) can direct Cas9 (CRISPR associated protein 9) 
nucleases to edit genes at specific genomic loci [330]. All of these advantages make RNA 
nanotechnology a very intriguing and promising research field. In this dissertation, I have 
presented the design and construction of several RNA nanostructures with defined shapes 
and sizes, and studied their potential applications in nanotechnology and nanomedicine: 
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• First, I reported the design and self-assembly of multifunctional 3D RNA 
tetrahedrons based on the pRNA-3WJ motif [304]. The assembled RNA 
tetrahedrons have defined 3D structures as revealed by both AFM and cryo-EM. 
The size of the RNA tetrahedrons can be easily tuned by changing the number of 
RNA base pairs per edge. Several functional modules including aptamers, 
ribozyme and siRNA were successfully incorporated into the RNA tetrahedron. In 
vitro cell binding showed that the RNA tetrahedron functionalized with EGFR-
aptamer has strong binding to EGFR-positive cells. In vivo biodistribution study 
showed that the RNA tetrahedron functionalized with EGFR-aptamer targeted to 
cancer xenografts in mouse models. These results indicated that 3D RNA 
tetrahedron nanoparticles have the potential to deliver imaging modules and 
therapeutics for cancer diagnosis and therapy. 
• Secondly, I reported the design and self-assembly of RNA cube and 
dodecahedron cages with defined shapes and sizes by using the pRNA 3WJ as the 
basic building block. The assembled RNA cages have distinct 3D structures as 
revealed by cryo-EM and AFM. In addition, the designed RNA cube cages can be 
applied to deliver immunoactive CpG DNAs to macrophage cells and elicit 
enhanced immune responses.  
• Thirdly, I reported the design and bottom-up self-assembly of the RNA nanowire 
with the length of several micrometers by using the modular multi-domain 
strategy [308]. The constructed RNA nanowire has been characterized by cryo-
EM, negative staining TEM, fluorescent microscopy and AFM. This study 
demonstrated the expanding of the toolboxes of RNA nanostructures to RNA 
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microstructures. Comparing with previously reported RNA array and RNA 
filaments, this newly designed RNA nanowire was self-assembled purely based 
on RNA base pairing and only four artificially-designed short RNA strands were 
needed to assembly the RNA nanowire. 
• Fourthly, I reported the design and construction of RNA polygons to serve as 
multivalent nanocarriers of vaccine adjuvants and particularly of CpG DNA [92]. 
The designed RNA and DNA strands self-assembled into distinct homogeneous 
nanoparticles with triangular, square or pentagonal shapes. I also found that size 
and shape of the RNA nanostructures played important roles in the induction of 
immune responses. This finding demonstrated that rationally designed RNA 
nanoparticles have great potential to be developed as novel immunomodulators or 
vaccine adjuvants. 
 
Perspectives 
RNA is not only an informational molecule that can transfer genetic information, 
but also a structural molecule that can be utilized for programmable self-assembly by 
engineering its sequence. In addition, RNA molecules can be designed to form artificial 
nanostructures with defined chemistry, structure, size and stoichiometry for applications 
in nanotechnology and nanomedicine [286]. In the future, one new direction of research 
is to expand the structural and functional diversity of 3D RNA nanostructures by 
exploring novel RNA motifs and RNA folding pathways. In addition, it is also possible to 
employ RNA-binding proteins to build artificial RNA-protein chimeric nanostructures 
that equipped with both RNA-based functionality and protein-based functionality [128]. 
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It will be also interesting to explore the possibility to incorporate classic methodologies 
in DNA nanotechnology (such as the DNA origami technique [331] and computer-aided 
design of DNA nanostructures by utilizing specialized software [332]) into RNA 
nanotechnology. It is expected that RNA mimics of DNA motifs widely used in DNA 
nanotechnology such as the DNA 4WJ [333] and DNA double-crossover molecules [334] 
will also play important roles in the construction of artificial RNA nanostructures. To 
obtain a more thorough understanding of the 3D conformation of the designed RNA 
nanostructures, high-resolution AFM, cryo-EM, X-ray diffraction and nuclear magnetic 
resonance (NMR) spectroscopy can be applied to characterize these RNA nanostructures 
with the aim to acquire atomic-level details. From an application perspective, one 
intriguing research direction is to test drug loading to these artificial RNA nanostructures. 
Particularly, 3D RNA nanoparticles may have the potential to encapsulate and protect a 
range of different therapeutics including nucleic acid therapeutics, small molecule 
therapeutics and protein therapeutics. For example, nucleic acid therapeutics such as 
siRNA and miRNA can be loaded into RNA nanoparticles via sticky end-mediated 
cohesion, while small molecule therapeutics such as paclitaxel and doxorubicin can be 
loaded via covalent conjugation or non-covalent binding to the RNA double helix. In 
addition, it will also be appealing to combine RNA nanoparticles with other 
nanotechnology approaches and investigate whether other nanotechnology approaches 
can improve the pharmacological properties of RNA nanoparticles. For instance, it will 
be interesting to encapsulate RNA nanoparticles into liposomes [335] or exosomes [336] 
and study the intracellular traffic and fate of liposome/exosome-encapsulated RNA 
nanoparticles. Furthermore, for the successful clinical application of RNA nanoparticles, 
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the production of clinical-grade RNA nanoparticles in large scale under Good 
Manufacturing Practice (GMP) regulation [337] will also be an important prerequisite. 
Currently, there are two mainstream approaches to produce RNA molecules: 1) in vitro 
transcription based on corresponding DNA templates [338]; 2) solid-phase synthesis 
based on phosphoramidite chemistry [339]. It is expected that automation of these 
synthesis procedures will greatly reduce the cost and improve the efficiency for large-
scale production of RNA molecules. Another alternative approach for RNA production is 
the expression of recombinant RNA molecules in bacterial cells such as Escherichia coli 
[331, 340]. Since recombinant protein technology has been widely used in the modern 
biotechnology industry for manufacturing protein therapeutics [341], the future 
improvements of recombinant RNA technology also has the potential to pave the way for 
producing highly pure RNA molecules for clinical applications. 
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Appendix 1 
 
Supplementary Figure 1: Schematic of the 3D structure of an A-form RNA helix [137]. 
Reprinted with permission from Ref. [137]. Copyright 2014 The American Association 
for the Advancement of Science. A-form RNA helix has 11 base pairs per helix turn, 32.7° 
helix twist per base pair and 2.9 Å rise per nucleotide. The minor groove is also named as 
shallow groove since it is wide and shallow compared to the major groove. Moreover, 
from the top view the RNA helix has a hollow central cavity, which is significantly 
different from DNA. 
 
 
 
6 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. S1. Schematic of an A-for  RNA helix.   
RNA is characterized by a steep base-pair inclination of 19° relative to the helical axis, 
and a helicity of 11 bp/turn (34). The major and minor grooves of RNA are typically 
referred to instead as the deep and shallow grooves, respectively, due to the fact that the 
minor groove is wide and shallow compared to the major groove.  Another characteristic 
of RNA is that from the top view the helix has a hollow central cavity, which is in 
contrast to DNA for which the base pairs pass through the central axis. 
 
  
2.9Å rise
Base
Inclination ~19°
~11 base pairs / turn      3.2 nm / turn
Major Groove
(Deep Groove)
Minor Groove
(Shallow Groove) 2.3 nm
helical twist
32.7°/ base pair
+
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Appendix 2 
 
 
Supplementary Figure 2: Immunostimulation by square-CpG nanoparticles in mice. 
CpG DNA containing square nanoparticles, free square nanoparticles and free CpG DNA 
were dissolved in PBS and administered to CD-1 mice by injection into the tail vein at 2 
mg/kg (CpG oligonucleotide per body weight). Blood samples were collected 3 hours 
post-injection by cardiac puncture. Serum was prepared by centrifugation at 12800 g for 
10 min. The levels of both TNF-α and IL-6 in serum were determined by ELISA. The 
error bars represent the standard error of the mean (SEM) from the measurements of six 
mice per treatment group. **: p < 0.01 versus 2 mg/kg DNA CpG only control, unpaired 
Student's t-test. Data was collected in collaboration with Sijin Guo and Mengshi Ma. 
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Appendix 3 
 
Supplementary Figure 3: Effect of RNA triangle harboring CpG DNA, triangle control 
and CpG DNA only control on KB cell viability. KB cells were incubated with 100 nM 
or 300 nM triangle, triangle-3CpGs, and CpG DNA only respectively for 16 hours. After 
16 hours, cell viability was examined by MTT assay. The error bars represent the range 
of measurement from two independent wells. ns: non-significant compared with cell only 
control, unpaired Student's t-test. 
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